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Summary 
Background / Aims:  
Maternal drug misuse in pregnancy is a significant clinical and public health 
problem. Consequences for the newborn infant include prematurity, intrauterine 
growth restriction (IUGR) and neonatal abstinence syndrome (NAS). There is 
increasing evidence that maternal drug misuse in pregnancy may have longer 
term adverse effects on infant visual and neurodevelopmental outcome. Most of 
the evidence regarding visual outcomes in particular derives from small 
uncontrolled studies with a lack of adequately powered, controlled studies to 
date. 
The visual evoked potential (VEP) can be used to assess the integrity and 
maturity of the infant visual pathway and both visual and neurodevelopmental 
abnormalities can be predicted by abnormal VEPs in infancy. Drug misuse is also 
associated with alteration of the VEP in adults and in animal models. Many drugs 
used in pregnancy can cross the placenta and enter the fetal circulation, 
including illicit drugs and prescribed methadone, which is the currently 
recommended treatment for pregnant opiate-dependent women. Hitherto few 
studies have investigated the effects of maternal drug misuse upon the newborn 
infant VEP. 
This study investigates in detail the effects of prescribed methadone and 
additional illicit drug use in pregnancy upon the infant VEP recorded at birth and 
at six months of age, and explores any association with NAS. The range and 
incidence of visual and neurodevelopmental abnormalities at six months of age is 
described, and how these relate to a history of NAS and the pattern of in utero 
drug exposure is explored. 
Pilot work: 
Pilot work demonstrated the feasibility of recording neonatal flash VEPs in a 
small group of infants exposed to methadone in utero, and showed that drug 
exposed infants had abnormal VEPs compared to unmatched controls.  
12 
A further pilot study described longer term visual outcomes, which included 
nystagmus, reduced visual acuity and strabismus, in a selected group of infants 
and children exposed to methadone in utero, thus informing clinical and 
electrophysiological assessment at six months of age. The pilot studies were 
followed by a major prospective cohort study. 
Prospective Study:  
One hundred and two term infants of mothers prescribed substitute methadone 
during pregnancy and 50 comparison infants matched for birth weight, gestation 
and socio-economic group were recruited in the neonatal period. Flash and 
flicker VEPs were recorded from the occipital scalp of infants within three days 
of birth. Drug exposure was determined by maternal history, maternal and infant 
urine and meconium toxicology. Excess alcohol exposure in utero was 
determined by elevated fatty acid ethyl esters in meconium. 
Neonatal flash VEPs were classified as mature, typical, or immature according to 
waveform morphology, and amplitude and latencies measured. Flicker VEPs 
were analysed using a fast-Fourier transformation and responses at each flicker 
frequency determined.  
The same cohort of drug-exposed and comparison infants was invited for clinical 
visual evaluation at six months of age in conjunction with pattern-onset VEPs  
and Griffiths developmental assessment.  
Results:  
Neonatal testing: 
Neonatal VEPs were successfully recorded from 100 drug-exposed infants and 50 
matched comparison infants at a median age of 24 hours (IQR 13-44). 
Gestational age, birth weight and socio-economic group did not differ between 
groups. Flash VEPs from methadone-exposed infants had fewer P1 components 
(p=0.001), and were more likely to be of immature waveform (p<0.001) 
compared to comparisons. VEPs from methadone-exposed infants were also 
smaller in overall amplitude (median 27µV vs 39.5µV, p<0.001). The relative risk 
13 
of an abnormal VEP in the methadone-exposed cohort was 5.6 with an 
attributable risk percent of 82%. The majority of infants were exposed to illicit 
drugs in addition to prescribed methadone, most commonly opiates (74%) and 
benzodiazepines (66%). VEPs did not differ between infants exposed to opiates 
only, those additionally exposed to benzodiazepines and those exposed to 
stimulants. Regression analysis confirmed that the difference in VEP parameters 
between drug-exposed and comparison infants was associated with methadone 
exposure and not other drugs of misuse.  
48% of the methadone-exposed cohort developed NAS requiring pharmacological 
treatment; there was no association between neonatal VEPs and subsequent 
onset or severity of NAS.  
Flicker VEP analysis demonstrated an optimal flicker frequency of 4.6 Hz in both 
groups, but there were few differences in the proportion of responses between 
groups. 
Six month follow-up: 
Retention rate to six month follow-up was 79% for the methadone-exposed 
cohort and 52% for comparison infants. Age at assessment (median 27 weeks, 
range 26-30 wk), weight and OFC did not differ between groups. The 
demographic characteristics of comparison infants who were followed up were 
compared to those of comparison infants who were not followed up. There were 
no significant differences in birth weight (2 sample t-test p=0.445), OFC (2 
sample t-test p=0.712), gestation (Mann-Whitney test p=0.984), 5-minute Apgar 
score (Mann-Whitney test p=0.263) or DEPCAT score (Mann-Whitney test 
p=0.258) between groups. 
Methadone-exposed infants were more likely to have visual abnormalities than 
comparison infants, even after correcting for excess in utero alcohol exposure 
(40% vs 8%; adjusted p=0.007). Abnormalities in the methadone-exposed cohort 
included nystagmus (11%), strabismus (25%) and reduced visual acuity (22%). The 
relative risk of an abnormal visual outcome in the methadone-exposed cohort 
was 5.1 with an attributable risk percent of 80%. 
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Electrophysiological abnormalities persisted at six months of age: methadone- 
exposed infants had smaller amplitude pattern VEPs (25 μV vs 34 μV; p=0.005) 
with delayed peak latencies (115ms vs 99ms; p=0.019) and fewer responses at 
the small check size (p=0.003), compared to controls. 
Methadone-exposed infants had significantly lower neurodevelopmental scores 
compared to comparison infants (GQ 97 for cases vs 105 for controls; p<0.001), 
even after correcting for maternal smoking, antidepressant treatment and 
excess alcohol consumption during pregnancy. Infants exposed to poly-drug 
misuse and treated for NAS in the newborn period performed particularly poorly 
on their neurodevelopmental scores. Visual impairment was an independent 
predictor of poor neurodevelopmental outcome and most infants scoring <85 on 
neurodevelopmental assessment had co-existing visual problems. 
Conclusions:  
In utero exposure to prescribed methadone and other substances of misuse is 
associated with an alteration in visual electrophysiology in the newborn period 
suggestive of immature visual maturation.  These changes are independent of 
additional benzodiazepine or stimulant exposure, and appear to be associated 
with prescribed substitute methadone.  
At six months of age, there is a high incidence of clinical visual abnormalities in 
infants exposed to methadone and other drugs of misuse in utero. Persistence of 
electrophysiological abnormalities beyond the neonatal period suggests that 
opiates may have a longer term effect on the developing visual system. Drug-
exposed infants also have poorer neurodevelopmental scores than matched 
comparison infants after correcting for maternal smoking and excess alcohol 
intake. The bias of loss to follow-up was minimised by the high retention rate of 
drug-exposed infants. Although there was a higher loss of comparison infants, 
there were no differences in demographic characteristics between comparison 
infants followed up and those not followed up, suggesting the groups were 
similar. In addition, published data suggest the incidence of visual abnormalities 
described in the comparison population to be representative of the larger 
population. Infants born to drug-misusing mothers are highly vulnerable and 
warrant early comprehensive visual assessment. 
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1 Chapter 1 Introduction 
1.1 Drug misuse in pregnancy 
1.1.1 Incidence 
The use of illicit non-prescribed drugs by pregnant women is unfortunately a 
common problem in some parts of the United Kingdom (UK) (1-5). There are 
thought to be between 250,000 and 350,000 children of known problem drug 
users in the UK - about one child for every problem drug user (6). In Scotland it 
is estimated that 4-6% of all children under the age of 16 years have a drug-using 
parent, representing between 41,000 and 59,000 children.  The incidence of 
maternal drug misuse is increasing with anonymous screening suggesting that 11-
16% of expectant women use at least one illicit substance during pregnancy (7).  
It is also well recognised that a high percentage of women misuse more than one 
drug in pregnancy - studies have shown that the majority of mothers prescribed 
methadone in pregnancy misuse other substances, with up to 66% taking 
additional benzodiazepines and heroin (8,9).  
1.1.2 Pregnancy outcomes 
Among the drug misusing population the incidence of unplanned pregnancy is 
high and antenatal care is often erratic. Substance misuse in pregnancy is 
associated with increased risk of pregnancy complications including premature 
rupture of the membranes, placental abruption, antepartum haemorrhage, 
stillbirth and neonatal death (1,2). Infants born to drug misusing mothers 
represent a very high risk group, with increased rates of preterm birth and intra-
uterine growth restriction (IUGR) (1,5,10-12). Substance misusing mothers as a 
group tend to suffer from the consequences of poverty including physical and 
mental ill health and poor nutritional status. They are likely to smoke cigarettes, 
and may experience domestic violence and drink excessive amounts of alcohol 
(1,13). Such unfavourable circumstances pose a threat to the health of the 
newborn, not least to neurological and visual development. 
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1.1.3 Management in pregnancy 
Management of maternal opiate misuse during pregnancy includes substitute 
prescribing of methadone, a synthetic opioid which stabilises lifestyle, reduces 
the incidence of preterm birth and IUGR and reduces risk-taking behaviour 
(2,5,10-12). Several studies have reported an increase in birth weight and 
reduction in neonatal mortality rate associated with prescribed methadone use 
compared to illicit opiates. Meta-analysis found the mean reduction in birth 
weight below normal with maternal methadone use to be 279 grams, compared 
to a reduction of 489 grams with illicit heroin use (14). The use of methadone in 
pregnancy is associated with better compliance with antenatal obstetric care 
and better preparation for parenting responsibilities (11).  Regular prescription 
of methadone engages patients and facilitates attendance for both antenatal 
care and social service support. Methadone is also more pharmacologically stable 
than heroin: it is more slowly absorbed and longer acting and leads to stable 
blood concentrations when taken daily.  Maintenance methadone abolishes most 
of the symptoms of heroin intoxication and withdrawal, which are harmful to the 
fetus.  Attempted withdrawal from illicit opiates and methadone treatment 
during pregnancy has poor outcomes and guidelines recommend that opiates 
should not be withdrawn after 32 weeks‟ gestation (13). 
Despite the potential benefits, substitute prescribing of methadone in pregnancy 
remains an emotive topic, which has attracted political and media debate and 
led to some health professionals‟ refusal to prescribe (15). One significant 
disadvantage of methadone is the high incidence of neonatal abstinence 
syndrome (NAS) which is seen in infants who have been exposed to methadone in 
utero.  
1.1.4 Identification of drug exposure 
1.1.4.1 Techniques 
Maternal reporting of drug misuse is often inaccurate due to guilt, 
embarrassment and/or fear of legal or custodial repercussions. Maternal 
interview has been found to have a low sensitivity for detecting opiate and 
cocaine exposure (67% and 65% sensitivity respectively) (16). As a result of this, 
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various techniques to determine more accurately in utero drug exposure have 
been established. In clinical practice drug screening is performed as infrequently 
as possible to foster a sense of trust and responsibility and to keep women 
engaged with health services (8). In research practice, however, additional 
toxicology analysis is often employed to determine a more comprehensive 
pattern of drug exposure. Techniques for detecting gestational exposure to drugs 
of misuse include maternal and infant urine or blood analysis, meconium and 
neonatal hair analysis.  
1.1.4.2 Blood/urine 
Blood samples for methadone levels can be taken from the umbilical cord after 
delivery or by either venesection or capillary blood sampling of the infant. Urine 
toxicology can detect the vast majority of drugs of misuse and is easily 
performed on both mother and infant postnatally. The main limitation of both 
blood and urine analyses is that due to the short half-life of many drugs of 
misuse, these methods can only be used to detect drug exposure late in 
pregnancy. Cocaine in particular has a very short half-life and can only be 
detected in blood or urine for up to one week following exposure. Cannabis and 
opiates have longer half-lives but will still only be detected for a maximum of 
three to four weeks following exposure. These limitations have led to the 
development of other biological markers, which reflect longer term exposure to 
illicit drugs and alcohol.  
1.1.4.3 Meconium/hair 
Meconium and neonatal hair analysis have become established methods for 
defining in utero exposure to drugs of misuse (17,18). Deposition of drugs into 
meconium begins at approximately 12 to 16 weeks of gestation when fetal 
swallowing commences, and therefore meconium analysis examines drug 
exposure in the second two trimesters of pregnancy. Neonatal hair grows during 
the third trimester and will reflect exposure to illicit drugs during this time. Bar-
Oz et al (2003) investigated the sensitivity of meconium analysis and neonatal 
hair analysis in 185 paired samples collected from infants with a history of in 
utero drug exposure (17). They found that meconium analysis was more sensitive 
at detecting cocaine and cannabis compared to neonatal hair analysis and, since 
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meconium is a discarded material, had the added advantage of being more 
acceptable to parents. All drugs of misuse commonly screened for in infant urine 
can be detected by meconium analysis including opiates, methadone, 
benzodiazepines, cocaine, cannabinoid and amphetamine.  
Meconium analysis can also be used to detect prenatal ethanol exposure (19,20). 
As prenatal ethanol exposure may be a confounding factor for abnormal visual 
and neurological development, it is important to measure co-exposure in studies 
of drug-exposed infants. In a similar manner to under-reporting of illicit drug 
use, pregnant women will often deny excessive alcohol use during pregnancy and 
a biological marker of exposure would therefore be useful.   
Ethanol conjugates to a number of fatty acid species collectively named fatty 
acid ethyl esters (FAEEs). Ethanol can cross the placenta in pregnancy due to its 
small molecular size and high water solubility and enter the fetal circulation. 
Fetal ethanol metabolism leads to the formation of FAEEs, which are deposited 
in fetal meconium. Studies have shown that meconium FAEE analysis is fivefold 
more sensitive than self-reported screening for detection of ethanol-exposed 
pregnancies (19).  
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1.2 Effects of maternal drug misuse on the infant 
1.2.1 Neonatal abstinence syndrome 
Illicit substances used by mothers in pregnancy can cross from the maternal 
circulation, via the placenta to enter the fetal circulation, resulting in a physical 
drug dependency in the newborn. At birth division of the umbilical cord leads to 
abrupt discontinuation of the supply of illicit drug to the infant, which can result 
in neonatal drug withdrawal commonly referred to as neonatal abstinence 
syndrome (NAS). Signs of NAS include irritability, jitteriness, increased muscle 
tone, poor feeding, tachypnoea, diarrhoea, sweating, sneezing, yawning, skin 
excoriation and, in extreme cases, convulsions.  
Methadone, morphine and heroin activate opiate receptors in the brain, which 
decrease the activity of adenylate cyclase, resulting in reduced cAMP production 
and release of noradrenaline. During chronic exposure, noradrenaline release 
gradually increases towards its normal level as tolerance to the drug develops. If 
opiates are withdrawn, their inhibitory effect is lost, resulting in symptoms of 
withdrawal. 
Signs of NAS may develop within 12 hours of birth or they may not be apparent 
until the second week of life or even later. This is due to differences in the 
pharmacological properties of addictive substances and/or differences in 
metabolism. Approximately 40-60% of infants who have been exposed to 
methadone in utero will develop symptoms of NAS (8,12,21,22).  
Factors that may influence the development of NAS include maternal methadone 
dose, the use of other illicit drugs, maternal cigarette smoking, rate of placental 
transfer of methadone, inter-individual variation in metabolism of methadone 
between mother and baby, and breast-feeding (8,9,23-25).  
Prescribed maternal methadone dose has not consistently been found to 
correlate with the development of NAS. Some of the studies investigating this 
did not, however, correct for confounding factors such as additional illicit drug 
use (12,22). A large recent retrospective audit of 450 singleton infants born to 
mothers prescribed methadone in pregnancy showed a strong correlation 
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between prescribed maternal methadone dose and the risk of the infant 
developing NAS, even when corrected for additional illicit drug use (8). Heavy 
cigarette smoking concurrent with methadone use is associated with higher NAS 
scores (23), and use of illicit drugs in addition to methadone may increase the 
requirement for treatment (9). Breast-feeding appears to reduce the 
requirement for pharmacological treatment of NAS (8,26):  Dryden et al found 
that breast-feeding for greater than 72 hours was independently associated with 
a halving of the odds of the infant requiring pharmacological treatment for NAS. 
The mechanism of this is unclear, as studies have demonstrated that transfer of 
methadone into maternal milk is minimal (25). It may partly be due to the 
soothing effect that breast-feeding has on newborn infants (27).  
Several objective scoring systems exist to guide initiation and intensification of 
treatment; the most commonly utilised of these are the Finnegan and Lipsitz 
scores (28,29). Treatment options for infants developing NAS secondary to 
maternal opiate use in pregnancy include opiates, sedatives (phenobarbital or 
diazepam) and supportive treatments (swaddling, pacifiers, massage, relaxation 
baths, and waterbeds) (30-33). Cochrane meta-analysis of available studies 
found a reduction in treatment failure with opiate use compared to the other 
interventions (30). A combination of opiate and phenobarbital may reduce the 
severity of withdrawal and duration of hospitalisation as well as improving 
neurobehavioural scores, and is often required to treat NAS following polydrug 
misuse (32,33).  
Due to the many different factors involved in the development of NAS, it is 
impossible to predict the likelihood of onset in individual cases and so the 
management of infants born to drug-misusing mothers is expectant, usually 
involving prolonged postnatal hospital stay to observe for signs of NAS. One study 
reported that the median postnatal stay for healthy maternal drug-exposed 
infants who did not require pharmacological treatment was seven days, more 
than three times longer than the median stay for healthy non-maternal drug-
exposed babies (8). This extended postnatal stay does however have some 
advantage in allowing for social work assessment prior to discharge and 
organisation of a comprehensive post-discharge care plan.  
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Infants born to drug misusing mothers constitute a significant workload to health 
and social services and are a resource burden: Dryden et al found that infants 
born to mothers prescribed methadone in pregnancy accounted for 2.9% of all 
hospital births but 18.2% of neonatal cot days. Better understanding of the 
patho-physiology of NAS would be helpful in managing drug misuse in pregnancy 
and guiding treatment of infants.  
1.2.2 Neurodevelopmental outcomes 
There are numerous data linking maternal opiate misuse with developmental 
delay (34-50). Fifteen studies have followed up a total of 770 drug-exposed 
infants and reported on their neurodevelopmental outcome at ages ranging from 
two months to 12 years. Various different scales of infant and child development 
were used and, due to heterogeneity of the studies, meta-analysis is not 
possible. Furthermore, retention to follow-up was often low (a mean of 66% in 
infants followed up after one year of age). Motor developmental delay was 
demonstrated in several of the studies (34,38,49) and a low mental development 
index or low intelligence quotient (IQ) was found by many authors 
(34,35,38,43,47). Several papers report behavioural problems in children who 
had been exposed to drug-misuse in utero, including aggression, poor 
concentration, social inhibition and, in particular, attention deficit hyperactivity 
disorder (44-46,48,50). Small head circumference is commonly reported at birth, 
usually associated with low birth weight, although catch-up growth does occur. 
Other reported neurological anomalies include cerebral palsy and abnormalities 
of muscle tone and posture (34,45,47).  
Environmental factors and poor parenting skills may in part account for some of 
these findings. Attempts have been made to correct for confounding factors by 
examining the differences in outcome in children raised by their parents 
compared to those who had been adopted (45). One study found that children in 
adoptive homes had better psychomotor scores than those living with their 
parents, suggesting that the environment plays a significant role in outcome. 
The children in adoptive homes, however, still had significantly lower scores on 
one of their performance scales compared to non-drug exposed controls (45). 
Bunikowski et al (1998) found no difference in developmental outcome between 
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infants in foster care versus those living with their biological parents, and 
described significantly lower development quotients in drug-exposed infants 
compared to controls (34). These studies are not necessarily contradictory as 
children in foster care are commonly moved between accommodations including 
those of their natural parents. Topley et al (2008) described an optimistic 
outcome in children of drug-misusing parents who were in full-time schooling, 
with no child having a statement of special educational need and a similar 
number (17%) requiring a low level of additional support in school compared to 
the corresponding local population (48). None of the children in this latter study 
had a formal developmental assessment performed however, and a high 
proportion had behavioural or concentration difficulties.  
The high loss of study subjects to follow-up is a criticism of many of these 
studies and is a reflection of the social disruption that is associated with the 
drug culture. It is unlikely, however, that infants whose family life is so chaotic 
that they are untraceable at follow-up will perform better than those infants for 
whom data are obtainable (38). The retention of infants in longitudinal or 
follow-up studies from socially deprived backgrounds is recognised to be 
challenging. However various techniques can be employed to maximise study 
retention rates including reimbursement of transport costs and diligent tracking 
of participants (51).   
1.2.3 Visual outcomes  
Prenatal exposure to various harmful substances can have adverse effects on 
infant visual development (52). Strabismus, nystagmus, hypoplastic optic discs, 
delayed visual maturation and prolonged eyelid oedema have been reported 
following in utero cocaine exposure, as well as both superficial and deep retinal 
haemorrhages (53-55). It is postulated that these findings may be due in part to 
retinal vascular changes caused by the vasoconstrictive effects of cocaine on 
placental blood vessels.  
Ocular abnormalities are also seen in infants with fetal alcohol syndrome, and 
include short horizontal palpebral fissures, epicanthus, telecanthus, 
microphthalmia, refractive errors, strabismus and retinal vessel tortuosity (56-
58). Up to half of infants born to alcoholic mothers demonstrate optic nerve 
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hypoplasia. This is consistent with animal studies: in utero alcohol exposure in 
rats is associated with ultra structural damage to the macroglial cells and myelin 
sheaths and hypoplasia of the optic nerve (59,60). Animal models demonstrate 
that ethanol exposure during a critical period of early development has an 
adverse effect on neurotransmitter systems, resulting in apoptosis of developing 
neurons. A similar pattern of apoptotic neurodegeneration may lead to many of 
the ophthalmic manifestations and other central nervous system features of 
fetal alcohol syndrome. 
There are fewer data regarding visual outcome in infants exposed to opiates 
and/or benzodiazepines in utero. Gill et al (2003) undertook ophthalmology 
assessment in 49 infants born to opiate-dependent mothers, the majority of 
whom (77%) were exposed to opiates alone (61). Twenty-nine infants had a full 
examination and 20 completed a telephone questionnaire only. Seven of the 
infants examined had confirmed strabismus and a further six of the telephone-
surveyed children had a history of intermittent strabismus. This equates to an 
incidence of strabismus of over ten times that of the general population. The 
authors found no differences in the incidence of strabismus between those 
infants treated for NAS and those not (61). Similarly, Nelson et al (1987) found 
an incidence of strabismus of 24% in their cohort of 29 infants assessed up to two 
years of age (62). The majority of infants in this study were however exposed to 
polydrug misuse including cocaine and amphetamines. A recent Scottish study 
found that 26% of infants born to opiate-using mothers failed health visitor vision 
screening tests in the community on at least one occasion within the first six 
months of life: 42% of the referred group had abnormalities confirmed by formal 
ophthalmology assessment including nystagmus and squint (4).  
The presence of nystagmus in five children born to drug-addicted mothers was 
reported first in 2002 (63). Three children presented with congenital horizontal 
pendular nystagmus and two children with a transient horizontal nystagmus in 
association with NAS. More recently nystagmus, strabismus and delayed visual 
development were described in 14 infants exposed to methadone and/or 
benzodiazepine in utero (64). The nystagmus was horizontal in all cases and in 
most cases was noted in the first six months of life. Recent follow-up of this 
cohort has suggested the nystagmus and reduced visual acuity may be 
permanent in children exposed to opiates and benzodiazepines in utero (65). 
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1.3 Assessing the infant visual system: clinical 
assessment 
The most common visual abnormalities reported in infants who have been 
exposed to opiate misuse in utero are reduced visual acuity, nystagmus, delayed 
visual maturation, strabismus and refractive errors (61,62,64,65). 
Visual acuity can be assessed in infancy using Cardiff or Teller acuity cards (66). 
Cardiff cards contain simple picture images and Teller cards contain black and 
white grating patterns. Cardiff picture images are drawn with a white band 
bordered by two narrow black bands, all on a neutral grey background. If the 
visual target lies beyond the subject‟s acuity limit it merges with the background 
and becomes invisible. The picture targets are of the same overall size but with 
decreasing width of black and white bands: acuity is defined by the narrowest 
white band for which the target is visible. The principle of the test is 
preferential looking – an infant will choose to look towards a visible target rather 
than a plain stimulus. 
Nystagmus described in association with maternal drug misuse is usually 
horizontal in nature and will be detected by observation (64,65). Manifest 
nystagmus is apparent on observation of the child with both eyes open, and is 
usually best observed with the child fixating on a small toy. Latent nystagmus is 
a type of congenital nystagmus that is only present with monocular viewing, and 
manifest latent nystagmus is that which is present with both eyes open but beats 
in a different direction depending on which eye is viewing (i.e. always towards 
the viewing eye). 
Delayed visual maturation (DVM) is the condition whereby infants appear 
behaviourally visually delayed at a young age with no corresponding ocular or 
central nervous system abnormalities, but then recover vision over a period of 
time (usually by six months of age) (67,68). Such infants usually present in the 
first few months of life with a failure to fix and follow and will demonstrate 
reduced visual acuity on testing. The diagnosis is made retrospectively when the 
infant recovers normal vision. 
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Strabismus (squint) can be detected using the Hirschberg test in infancy (equal 
pupillary light reaction) (69). The presence of strabismus in an infant over six 
months of age warrants ophthalmology assessment. Timely detection can lead to 
early intervention with correction of refractive errors, selective patching and 
occasionally surgery (69). Unattended strabismus can lead to amblyopia, 
susceptibility to which is greatest in the first three years of life. In addition, the 
cosmetic disorder associated with strabismus can interfere with social and 
psychological development: children with uncorrected strabismus are at 
significantly greater risk of displaying conduct and externalising problems (70).  
Refractive errors require retinoscopy for diagnosis and include hypermetropia 
(long sightedness), myopia (short sightedness) and astigmatism. Accurate 
assessment of refractive errors in infancy usually requires pupil dilatation as 
young infants will not fixate on a static object for assessment. The technique of 
rapid retinoscopy through undilated pupils has been described as an efficient 
method of detecting high refractive errors and candidates for nonstrabismic 
amblyopia in childhood (71).  
Cerebral visual impairment (CVI) involves disordered higher visual processing and 
may also involve reduced visual acuity and visual fields (72-74). CVI can be 
diagnosed by structured history taking and validated by observation of behaviour 
and testing. Two higher visual processing pathways have been described: the 
dorsal stream and the ventral stream. The dorsal stream passes between the 
occipital lobes and the posterior parietal lobes and allows appraisal of the whole 
visual scene and visual guidance of movement through the scene. Dorsal stream 
dysfunction causes problems with the processing of complex visual scenes such 
as finding a toy in a toy-box or on a patterned background, finding clothes in a 
drawer and seeing objects at a distance (as there is more to see). It also causes 
problems with visual guidance of movement such as inaccurate reach and grasp, 
difficulty with curbs and steps, and difficulty crossing floor boundaries. The 
ventral stream passes between the occipital lobes and the temporal lobes and is 
responsible for visual recognition, orientation and visual memory. Ventral stream 
dysfunction causes problems with recognising faces, understanding facial 
expression, navigation and copying. Children with CVI will often develop coping 
strategies to help them adapt to everyday life, such as coding and recognising by 
colour. Problems interpreting the visual world and the compensatory strategies 
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required can affect behaviour; some children demonstrate hyperactivity, 
withdrawal and aggression. The implementation of a developmental programme 
and strategies to modify behaviour can result in significant improvement in 
visual function (72-74). 
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1.4 Assessing the infant visual system: visual evoked 
potentials 
The visual evoked potential (VEP) is an electrical signal generated in the visual 
cortex of the brain in response to a visual stimulus (75,76). A normal VEP 
depends upon an intact visual pathway from the retina via the optic nerves and 
optic chiasm to the lateral geniculate nuclei and visual cortex (Figure 1-1).  
VEPs reflect visual and cortical integrity and are a useful measure of visual 
development. They can be used to detect, quantify and monitor abnormalities of 
the visual system (76). In clinical paediatric practice, VEPs are used in the 
detection and management of optic nerve hypoplasia or atrophy, amblyopia, 
congenital cataract, delayed visual maturation and cortical visual impairment 
(76). An abnormal VEP is strongly predictive of visual abnormalities and adverse 
neurological outcome in selected preterm and term infants (77-81). 
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Figure 1-1 Visual pathways in the brain  
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1.4.1 Types of VEPs 
The visual stimuli used to elicit VEPs can be luminance or pattern (75). 
Luminance stimulation involves either a flashing or flickering light source. The 
flash VEP is elicited by a light source with a relatively long inter-stimulus 
interval and is classified as a transient VEP. The flicker VEP is elicited by rapid 
repeated visual stimulations that overlap in time producing a continuous 
oscillating waveform and these are classified as steady-state VEPs. The pattern 
stimulus is commonly a black and white checkerboard or black and white 
grating, usually presented on a high resolution computer monitor.                                               
1.4.2 The infant VEP 
1.4.2.1 Flash VEP 
The flash VEP is most commonly used in the newborn period, as it does not 
require visual fixation. The flash VEP waveform is characterised by a series of 
deflections designated as negative and positive in a numerical sequence (N1, P1, 
N2, P2, N3, P3) (Figure 1-2). Each negative and positive deflection can be 
described in terms of its latency (time from the stimulus onset to the 
corresponding deflection in milliseconds (ms)) and its amplitude. The amplitude 
of each deflection is measured in microvolts (µV) and may be described either 
from baseline or between peaks and troughs.  
All healthy term newborns should demonstrate a flash visual evoked response. A 
positive waveform at approximately 200ms (P2) has been found to be the most 
consistently present component, found in 100% of newborns by Benavente et al 
(2005) and 94% by Shepherd et al (1999) (78,82). A negative component at 
approximately 300ms (N3) was present in 82% of term infants tested by Shepherd 
and in 42% of infants tested by Benavente. Both these studies measured flash 
VEPs in healthy term newborn infants within the first five days of life. 
Over the first few months of life the VEP waveform becomes more complex and 
a positivity emerges at approximately 100ms (P1) (Figure 1-3). The latencies of 
P1 and P2 components decrease with increasing postnatal age so that by six 
months of age the mean latency of P1 has reduced from 102ms to 81ms and the 
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mean latency of P2 has reduced from 200ms to 147ms. The amplitude of both P1 
and P2 increases significantly with increasing postnatal age and by six months of 
age the flash VEP has matured significantly and starts to resemble that of an 
adult (82,83).  
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Figure 1-2 Adult flash VEP 
Six components are present (N1, P1, N2, P2, N3, P3). The major component, P2 has a 
latency of approximately 120ms in healthy adults. 
 
Figure 1-3 Infant flash VEP  
Components present include positivity at 100ms (P1), positivity at 200ms (P2) and negativity 
at 300ms (N3). 
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1.4.2.2 Flicker VEP 
An alternative and novel luminance electrophysiology technique is the flicker 
VEP. A flickering light stimulus will elicit VEPs that overlap in time to produce a 
continuous oscillating waveform. A mathematical technique, the Fourier 
analysis, is used to interpret the data (84,85).   
As with the flash VEP, the flicker response does not require infant visual fixation 
and can therefore be recorded in the newborn period. Early data suggest that 
the flicker response may provide an alternative practical and objective indicator 
of visual pathway integrity (86-88). The flicker VEP involves presenting a 
flickering light stimulus at various frequencies usually ranging from 4 to 40 Hz. 
This flickering light stimulus has the potential to evoke cortical activity at the 
stimulation frequency. Mathematical analysis of the VEP by Fourier 
transformation will determine whether a response is present at the frequency 
under investigation (Figure 1-4). A cortical response detected at the exact 
stimulus frequency being applied is designated the fundamental response (F1). A 
cortical response present at an exact multiple of the stimulus frequency is 
designated the harmonic response (F2 at double the stimulus frequency, F3 at 
triple the stimulus frequency). The optimal stimulus frequency is the frequency 
which generates the largest amplitude response. Limited data available in the 
literature suggest the optimal flicker frequency is approximately 4Hz at one 
week of age, increasing to 7Hz at six months of age, still considerably below the 
optimal flicker frequency of approximately 18Hz in adult subjects (87,88). 
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Figure 1-4 Infant flicker VEP 
A 4.7 Hz flickering light stimulus produces a continuous oscillating waveform, which is 
shown in (1). Fourier analysis is applied to the data to convert it from the time domain (1: 
time on x axis in milliseconds) into the frequency domain (2: frequency on x axis in Hz). 
This demonstrates a response at 4.7 Hz (large amplitude spike at a frequency of 4.7Hz on 
graph (2)). The second large spike at approx 10 Hz is the harmonic response (2). A harmonic 
response is commonly seen in analysis of the flicker VEP although its aetiology is unclear. 
It is signified by a response at an exact multiple of the primary response – in this case the 
harmonic response in graph (2) is shown by the large spike at 9.4Hz.  
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1.4.2.3 Pattern VEP 
The recommended pattern stimulus is a black and white checkerboard (75). The 
stimulus is described by the visual angle subtended by the side of a single check 
and measured in degrees and minutes of arc subtended at the eye. One minute 
of arc (1‟) is a unit of angular measurement equal to one sixtieth (1/60) of a 
degree. 
Table 1-1 Pattern VEP check sizes 
 
 
Minutes of 
arc 
 
Degree 
Size of 
check 
 
15‟ 
 
0.25 Small 
 
60‟ 
 
1 Medium 
 
120‟ 
 
2 Large 
 
All checks should be square with an equal number of light and dark checks. Two 
forms of pattern VEP testing have been established – pattern reversal and 
pattern onset. Pattern reversal involves a pattern that abruptly reverses (i.e. 
black to white and white to black) at a specified number of reversals per 
second. In the pattern onset VEP, the pattern is abruptly exchanged with a 
diffuse grey background. Overall screen luminance must remain equal during 
pattern reversal or pattern onset/offset. 
Visual stimulation with an alternating pattern produces a VEP waveform that in 
healthy adult subjects consists of a negative deflection at 75ms (N75), a positive 
deflection at 100ms (P100) and a negative deflection at 135ms (N135) (Figure 1-
5). The pattern reversal VEP has relatively low intrasubject and intersubject 
variability and it is therefore the preferred method of testing in most 
circumstances. A pattern onset stimulus produces a similar negative-positive 
deflection designated C1 and C2 (Figure 1-6). 
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Figure 1-5 Adult pattern reversal VEP  
The pattern reversal VEP typically consists of three components: a negativity at 75ms, a 
positivity at 100ms and a negativity at 135ms. 
 
 
 
 
 
 
Figure 1-6 Adult pattern onset VEP  
The pattern onset VEP is more variable in appearance than pattern reversal. The response 
consists of two major components in adults: a C1 component at approximately 75ms and a 
C2 component at approximately 125ms.  
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An assessment of cortical acuity can be made by reducing the spatial frequency 
of the pattern stimuli (i.e. the checks on the checkerboard get smaller and 
smaller) until no reproducible VEP can be recorded.  
The pattern VEP is generally thought to have limited applicability in the newborn 
period, as it requires an awake and attentive baby. Harding et al (1989), 
however, have documented a positive component at 280 ms in response to a 
pattern reversal stimulus in infants between 33 and 37 weeks gestational age 
(89).  
The pattern reversal VEP in healthy infants in the first year of life is well 
described; the main component being a simple positivity at approximately 200 
ms, commonly referred to as P100 (Figure 1-7) (90-92). The VEP response to 
small checks is absent at birth but develops between two to four months of age. 
The latency of the P100 component reduces with increasing postnatal age, from 
approximately 200 ms at six weeks of age, to 150 ms at six months of age and 
100ms at 12 months (92). Pattern VEP latencies are longer for smaller check 
sizes and therefore normative data specific for the check size under 
investigation must always be used. A study of pattern VEPs in 161 infants 
between three weeks and two years of age demonstrated rapid visual 
development in the first six months of life as shown by the development of 
reproducible VEPs to smaller check sizes and a rapid decrease in the latency of 
the first reproducible positive peak (92).  
Infant fixation on the visual display should be monitored during pattern VEP 
testing and the recording interrupted during periods of loss of fixation. Various 
strategies may be used to direct the infant‟s visual attention to the pattern 
screen and include dangling small objects in front of the screen and 
superimposing interesting pictures upon the pattern. 
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Figure 1-7 Infant pattern reversal VEP 
Black and white reversing checkerboards produce a negative-positive-negative waveform, 
conventionally labelled N75-P100-N145: however, in infants, it is normal for the P100 peak to 
be as late as 200ms, depending on their age and the size of the checkerboard. 
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Summary: Characteristic features of a maturing VEP in infancy 
Flash VEP: 
Emergence of P2 component 
Emergence of P1 component 
Increased amplitude of components 
Reduced latency of components 
Flicker VEP: 
Increase in optimal flicker frequency 
Pattern VEP: 
Reduced latency of components 
Response detected at smaller check sizes 
 
 
 
 
 
 
 
Chapter 1  39 
1.4.3 VEPs in preterm and sick infants  
The flash VEP can be recorded from the occipital scalp as early as 24 weeks 
gestation. The dominant feature of the preterm flash VEP is a broad negativity 
at about 300 ms, commonly referred to as N3 (78,93). By around 35 weeks 
gestation the P2 component emerges and the VEP starts to resemble that of 
term infants (Figure 1-8).  
 
 
 
Figure 1-8 Maturation of the infant flash VEP  
The predominant characteristic of the preterm infant VEP is a broad negativity at 300ms 
(N3). Taylor JM, McCulloch DL. Journal of Clinical Neurophysiology 1992; 9(3): 357-72. 
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Several studies have investigated the predictive value of the flash VEP in 
determining clinical outcome for preterm infants (78,94-97,77). Shepherd et al 
(1999) recorded the flash VEP in 81 preterm infants and found the sensitivity and 
specificity with regards to survival to be 86% and 89% respectively, and with 
respect to development of cerebral palsy to be 60% and 92%. Pike et al (2000) 
found the flash VEP could predict cerebral palsy with a sensitivity of 71% and 
specificity of 90% and Kato et al (2000) found corresponding values of 78% and 
94% in their study of 60 preterm infants. Poor prognostic factors for outcome 
include an absent VEP at any age, a delayed N3 latency before term age and an 
absent P2 component at term. In their study of 62 preterm infants, Beverley et 
al (1990) found that an abnormal VEP correlated with intraventricular 
haemorrhage but was not predictive of neurodevelopmental outcome. Similarly, 
Ekert et al (1997) found that the flash VEP correlated with the development of 
periventricular leukomalacia but not with neurodevelopmental outcome. 
The flash VEP has also been investigated as a tool to predict prognosis in term 
infants with perinatal asphyxia (79,98-100). The largest study by Taylor et al 
(1992) examined serial flash VEPs in 92 term infants with birth asphyxia. They 
found that death or severe neurological impairment could be predicted if an 
absent VEP was documented at any time or if abnormalities of the waveform 
persisted beyond day four of life. These findings were similar to other papers 
which have found VEPs to have a high predictive value for death or 
neurodevelopmental impairment (79,98,99).  
Pattern orientation reversal VEPs have been described in term and preterm 
infants using rapid orientation reversal of sine wave gratings at 4 Hz and 8 Hz 
(101).  The authors found that very low birth weight infants with normal 
neonatal ultrasound scans and neurological outcome had similar VEPs to term 
infants. Four infants in this study with abnormal cranial ultrasounds had absent 
VEPs and a subsequent abnormal neurological outcome (101). A further study by 
the same authors found the orientation reversal VEP to be predictive of a low 
neurodevelopmental score in preterm infants with a sensitivity of 86% and 
specificity of 65% (102). Mercuri et al (1999) found that the orientation reversal 
VEP also correlated with cerebral damage as assessed by MRI in term infants 
with perinatal brain insults (103). The use of VEPs in predicting outcome in 
preterm and term infants is summarised in Table 1-2. 
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Table 1-2 Predictive value of the VEP in infancy 
 
Reference VEP type Subjects Outcome 
Sensitivity/specificity 
(where given) 
Taylor, 
McCulloch 
(81) 
Flash / 
pattern 
 
32 children 
4mth-5yr, 
cortical 
blindness 
 
Predictive of long-term 
visual outcome 
100% / 94 % 
McCulloch  
et al (80) 
Flash / 
pattern 
 
 
25 term infants, 
birth asphyxia 
 
 
Predictive of long-term 
visual outcome 
- 
Shepherd  
et al (78) 
Flash 
 
81 preterm 
infants 
 
Predictive of death and 
CP 
Death 86% / 89%, 
CP 60% / 92% 
Pike, Marlow 
(97) 
Flash 
 
92 preterm 
infants 
 
Predictive of CP and 
transient dystonia 
71% / 90% 
Kato et al 
(77) 
Flash 
 
60 preterm 
infants 
 
Predictive of CP 78% / 94% 
Taylor 
et al (100) 
Flash 
92 term infants, 
birth asphyxia 
 
Predictive of death or 
severe neurological 
impairment 
 
78% / 100% 
Whyte 
et al (79) 
Flash 
25 term infants, 
birth asphyxia 
 
Predictive of 
neurodevelopmental 
outcome 
 
- 
Muttitt 
et al (99) 
Flash 
36 term infants, 
birth asphyxia 
 
Predictive of 
neurodevelopmental 
outcome 
 
91% / 100% 
Whyte (98) Flash 
93 term infants, 
birth asphyxia 
 
Predictive of 
neurodevelopmental 
outcome 
 
89% / 100% 
Atkinson 
et al (102) 
OR-VEP 
26 preterm 
infants 
 
Predictive of Griffiths 
development quotient 
< 80 
 
86% / 65% 
Mercuri 
et al (103) 
OR-VEP 
 
29 term infants, 
HIE or brain 
lesions on MRI 
 
Predictive of 
neuromotor outcome 
90% / 87% 
CP: cerebral palsy, HIE: hypoxic ischaemic encephalopathy, MRI: magnetic resonance imaging 
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1.4.4 Clinical applications of the VEP  
Visual acuity estimation: 
VEP estimates of visual acuity are useful in infants who cannot co-operate with 
standard visual acuity tests (76,104). Visual acuity can be estimated by 
determining the smallest pattern size that elicits an identifiable VEP. With 
adequate co-operation reproducible VEPs should be obtained to check sizes 
down to 15 minutes of arc or smaller in children over three months of age.  
Lesions of the eye and ocular media: 
Although diagnoses of ocular abnormalities are usually apparent from clinical 
examination, the VEP can be used to provide presurgical information about the 
integrity of the afferent visual pathways in conditions such as congenital 
cataracts. The VEP can also be used to assess visual acuity and guide 
management in conditions such as congenital glaucoma and retinal dystrophies. 
Lesions of the afferent visual pathway: 
In conditions such as optic nerve hypoplasia, optic nerve atrophy or glioma of 
the optic nerve or chiasm, the VEP can be used to assess the degree of 
functional visual loss and monitor disease progression and / or recovery. 
Delayed visual maturation: 
VEPs can be useful in infants with delayed visual maturation (DVM) to 
differentiate between DVM and more serious aetiologies of permanent visual 
impairment. Flash and pattern VEPs are usually present in DVM although they 
may have prolonged latencies, small amplitude or abnormal waveforms (105). 
The VEPs normalise as vision recovers spontaneously in these patients. 
Amblyopia: 
Amblyopia is subnormal visual acuity in one or both eyes despite correction of 
any significant refractive error. The word is used to denote a specific 
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developmental disorder of visual function arising from sensory stimulation 
deprivation. Amblyopia is usually asymptomatic and is detected only by 
screening programmes. Monocular pattern VEPs are sensitive for early detection 
of amblyopia and can be used to monitor treatment. The typical findings in 
amblyopia are small amplitude VEPs and absent VEPs to small check sizes in the 
amblyopic eye. During occlusion therapy, VEPs become equal and symmetrical as 
acuity equalises in the two eyes. 
Cortical blindness: 
Chronic cortical blindness is usually due to prenatal or perinatal events whereas 
acute-onset cortical blindness results from an insult to the posterior visual 
pathways. The pattern VEP is useful in determining the level of visual function in 
infants with chronic cortical blindness. In children with acute-onset cortical 
blindness, the flash VEP is a useful prognostic test for visual recovery (81). 
Special circumstances: infants with nystagmus 
In adult subjects, pattern onset and pattern reversal VEPs were compared 
between subjects with nystagmus and those with normal vision using 
checkerboard stimuli of two sizes (120‟ and 60‟). In the presence of nystagmus, 
pattern reversal VEPs were significantly smaller and of poorer quality than those 
obtained by pattern-onset stimuli (106).  This study confirmed similar findings 
from other authors suggesting that pattern-reversal stimulation is not reliable in 
patients with horizontal nystagmus (107,108). Therefore, in the presence of 
nystagmus, the recommended method of pattern VEP testing is pattern onset.  
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1.4.5 Subject variables and the VEP 
Sleep state: In young infants sleep state and eye opening state may influence 
the flash and flicker VEP (82,109-111). Sleeping infants have longer latency 
components compared to alert infants and the VEP amplitude is significantly 
smaller during quiet sleep compared to awake in both term and preterm infants. 
Documentation of sleep and eye opening state is therefore important during VEP 
recording. Sleep state can be defined using a behavioural scoring system 
assessing eye opening state, body movements, facial movements and 
vocalisations (112). This can be simplified to four sleep states: quiet sleep, 
active sleep, quiet wakefulness and active wakefulness.  
Intrauterine growth restriction: Infants with IUGR were found to have smaller 
amplitude flash VEPs compared to normally grown controls by Stanley et al 
(113). However, all these IUGR infants had detectable VEPs of comparable 
waveform to normally grown control infants.  
Head size: The relationship between VEP latency and both sex and head size was 
investigated by Gregori et al (2006) who recorded pattern-reversal VEPs in 
healthy adult subjects (114). They found the P100 latency to be shorter in 
female subjects with smaller head circumference although there was no 
difference in the subgroup of the two sexes with a comparable range of head 
sizes. They concluded that the difference in VEP latency between groups was 
attributable to head size and not to sex. Malcolm et al have investigated gender 
and OFC differences in healthy term infants undergoing pattern-reversal VEPs 
(91): they found shorter peak latencies in infants with smaller head 
circumference but also found an independent effect of gender on P1 latency, 
with females demonstrating shorter peak latencies than males. Accurate 
recording of growth parameters, including occipito-frontal circumference, and 
sex is therefore important when comparing VEPs.  
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1.4.6 Drug misuse and the VEP 
Drug and alcohol misuse are associated with alterations in visual 
electrophysiology in adults and in animal subjects (115-118). Rat pups born to 
methadone-exposed mothers demonstrated delayed latency flash VEPs and 
reduced amplitude flicker VEPs compared to controls at the peak of the 
abstinence syndrome (119). There were no long term effects and all VEPs were 
normal 21 days after birth.  
Methamphetamine misuse causes a delay in P100 peak latency of pattern VEPs in 
adult subjects compared to controls. It is suggested this may be due to dopamine 
depletion during long term drug misuse (117). Pattern VEPs in adult subjects 
exposed to methadone demonstrate a delay in N75 and P100 compared to 
normal controls (115). Proposed mechanisms for these alterations in visual 
sensitivity include increased turnover of dopamine in the retina and an adverse 
effect on neural transmission within primary visual areas of the brain. Pattern 
VEPs in adult subjects with previous cocaine use demonstrate a significantly 
delayed P100 latency, conceivably due to the vasoconstrictive affect of cocaine 
on the retinal, optic nerve and occipital vasculature (116). Chronic alcoholism 
has also been shown to have an effect on the pattern VEP with reported 
abnormalities including delayed P100 and abnormal VEP waveform (118,120). 
Whitham et al (2010) have recently described pattern-reversal VEPs recorded at 
four months of age in infants who had been exposed to methadone in utero and 
buprenorphine in utero compared to control infants (121). They recruited 30 
buprenorphine-maintained women, 22 methadone-maintained women and 33 
non-opioid dependent controls. They found that the methadone exposed infants 
had significantly delayed P1 latencies in response to 48‟ and 69‟ check sizes 
compared to the buprenorphine exposed infants and controls. No neonatal 
testing was undertaken in this study and the results were not correlated with 
longer term visual outcomes. 
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1.5 Conclusion 
Maternal drug misuse is a significant problem in pregnancy and can seriously 
affect the health of not only the mother, but also the fetus and newborn infant. 
The currently recommended treatment for pregnant opiate-dependent women is 
prescribed substitute methadone, but in common with other illicit drugs used in 
pregnancy this crosses the placenta and enters the fetal circulation.  
The association of maternal drug misuse with prematurity, IUGR and NAS is well 
recognised and there is increasing evidence of longer term impact on infant 
visual and neurodevelopmental outcome. Most of the evidence regarding longer 
term visual outcomes in particular derives from small uncontrolled studies, with 
no adequately powered controlled studies published to date. 
The VEP can be used to assess the integrity and maturity of the infant visual 
pathway. Testing is non-invasive and can be easily performed in the neonatal 
period. Both visual and neurodevelopmental abnormalities can be predicted by 
abnormal VEPs in infancy, with abnormalities including absent responses, 
delayed latencies and immature morphology. Drug misuse is associated with 
alteration of the VEP in adult humans and in animal models. To date, however, 
few studies have investigated the effects of maternal drug misuse upon the 
newborn infant VEP. 
This study investigates in detail the effects of prescribed methadone and 
additional illicit drug use in pregnancy upon the newborn infant VEP. It aims to 
define abnormalities of the newborn VEP by comparison with matched  infants 
and, by repeating VEPs in these cohorts at six months of age, to assess whether 
in utero drug exposure has a longer-term effect on visual electrophysiology. 
Extensive data will be collected regarding drug exposure, including history and 
toxicology analyses, allowing investigation of the effects of individual drugs of 
misuse on the VEP, both at birth and at six months of age.  
The study also aims to determine visual and neurodevelopmental outcomes in 
later infancy in this cohort. By performing a combined clinical visual and 
neurodevelopmental assessment at six months of age, it describes the incidence 
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and scope of abnormalities and assesses how these relate to a history of NAS and 
the pattern of in utero drug exposure. 
The study seeks to determine the predictive role of the VEP in the early 
detection of visual and neurodevelopmental abnormalities secondary to 
maternal drug misuse in the knowledge that, if the VEP correlates with longer 
term visual and/or developmental outcome, this relatively simple and 
inexpensive investigation could trigger earlier referral to appropriate specialists 
and result in improved outcome in this vulnerable group of infants. 
The study also seeks to investigate the potential value of the VEP in predicting 
the onset and severity of NAS. This condition has significant health implications 
for the infant, family unit and health care resources but its pathophysiology is 
poorly understood.  If the VEP were found to be predictive of NAS, this 
technique could be used to improve management of these infants by allowing 
earlier targeted treatment of NAS and earlier hospital discharge of infants 
unlikely to be affected. 
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Figure 1-9 Drug misuse flowchart 
Relations between maternal drug misuse, NAS, visual abnormalities, neurodevelopmental 
abnormalities and VEPs. 
49 
2 Chapter 2 Pilot studies 
2.1 Flash Visual Evoked Potentials in newborn infants 
exposed to methadone in utero  
2.1.1 Introduction 
Drug misuse has been demonstrated to cause an alteration of the VEP in human 
adults as well as in animal studies, and maternal drug misuse has been 
associated with impaired infant visual development (61,62,64,115,119). A pilot 
study was undertaken to test the hypothesis that maternal drug misuse in 
pregnancy is associated with an alteration of the VEP in the neonatal period.   
2.1.2 Aims  
 To assess the feasibility of measuring flash VEPs in newborn infants 
exposed to methadone in utero. 
 To compare flash VEPs recorded in the first few days after birth from 
infants exposed to methadone in utero and from non-maternal drug 
exposed control infants. 
 To describe the short term maturation of VEPs in drug-exposed infants.  
2.1.3 Subjects and Methods 
This was a prospective case-control pilot study.  Eligible infants were born at 
term (>37 completed weeks gestation) to drug-misusing mothers who had been 
prescribed substitute methadone during pregnancy. Exclusion criteria were 
ocular abnormalities, other major congenital abnormalities and significant 
neonatal illness. Infants were recruited from the postnatal ward of the Women‟s 
Reproductive Health Service in the Princess Royal Maternity, Glasgow. Control 
subjects were healthy term infants born in the study hospital, using identical 
exclusion criteria. The multidisciplinary care package offered to drug misusing 
women included a postpartum stay of up to ten days to monitor for signs of NAS 
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and to provide parenting support. Infants were assessed for significant NAS using 
a modified Lipsitz score undertaken twice daily by experienced midwifery staff.  
Significant NAS was diagnosed if two modified Lipsitz scores at 12 hourly 
intervals were >5, and the infant was unusually difficult to console and/or 
feeding poorly.  Pharmacological treatment was then commenced, with oral 
morphine solution as first line therapy. 
Drug exposure in utero was determined from maternal history and infant urine 
toxicology.  Infant bag urine samples were obtained after consent and before 
administration of any medication to the baby. Samples were stored at -20oC until 
analysis in a single batch on an Abbott Architect c8200 analyser (Abbott, Abbott 
Park, IL, USA), using Abbott Multigent reagents (EMIT immunoassays) according 
to manufacturer‟s instructions.  Assays included opiates, methadone, 
benzodiazepines, amphetamines, cannabinoids and cocaine metabolites. 
The first VEP recording was performed within four days of birth, and a second 
recording was undertaken after one week if the infant remained in hospital.  
VEPs were recorded from the occipital scalp using three silver-silver chloride 
electrodes in the midline occipital (recording), midline frontal (reference) and 
mastoid (ground) positions. Electrode positions were determined using the 
standard 10:20 clinical montage (75). Scalp-electrode impedance was measured 
before each recording and electrodes repositioned if necessary to ensure that 
impedance was below 10 kohms. A hand-held integrating sphere (Colorburst®, 
Diagnosys  LLC, Lowell, MA 01854) was presented 5 cm from the infant‟s eyes in 
the midline and delivered bright white flashes (50 cd s/m2) at 1 Hz.  All 
stimulation was binocular. A minimum of two averaged VEPs of 30 flashes each 
were collected to ensure reproducibility.  Awake/sleep state and degree of eye 
opening were documented. VEPs were stored and subsequently assessed by two 
independent observers, blinded to the infant‟s clinical course.  VEPs were 
classified as typical (predominant positivity near 200 ms, P2), atypical (more 
complex response with unusual peak latencies), immature (predominant 
negativity near 300 ms, N3), or non-detectable (Figure 2-1).  The largest peak to 
trough amplitude was measured for all detectable VEPs and the total sum 
amplitude of all peaks and troughs was calculated. When present, peaks and 
troughs were labelled in order of increasing latency as P1, P2, N3, P3 and 
Chapter 2  51 
amplitude from baseline and latency noted. Each outcome was compared 
between methadone-exposed and control infants. 
The study was approved by Glasgow Royal Infirmary research ethics committee 
(REC reference: 06/S0704/5) and written informed parental consent obtained for 
all infants. 
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Figure 2-1 VEP classification 
 
A. Typical VEP response: Predominant positivity at ~ 200ms (P2).                                            
B. Immature response: Predominant negativity at ~ 300 ms (N3). 
C. Atypical response: Complex response with unusual peak and trough latencies.  
D. Non-detectable: No reproducible VEP present. 
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2.1.4 Results 
Twenty-one methadone-exposed infants and 20 control infants were recruited. 
The characteristics of the two groups are described in Table 2-1. The maternal 
methadone-exposed group differed from the control group with respect to birth 
weight (2818 gm vs 3486 gm; p<0.001) and head circumference (32.9 cm vs 34.9 
cm; p<0.001). The methadone-exposed infants were also of earlier gestation 
(38.6±1.4 vs 39.8±0.95 weeks; p=0.002).   
The first VEP was recorded at a median age of 30 hours – this age did not differ 
significantly between the groups. VEPs were repeated after one week in 14 of 
the maternal methadone-exposed infants, seven of whom developed significant 
NAS. Eight methadone-exposed infants in total developed NAS requiring 
pharmacological treatment. Interpretable data were obtained in 54/55 VEP 
sessions; in one session the infant was too unsettled to allow a successful 
recording (VEP was successfully recorded two days later). 
Toxicology: Eleven of the 13 infant urine samples obtained were positive for 
methadone. For both negative infant samples, maternal urine testing confirmed 
methadone use during late pregnancy. Other substances detected in infant urine 
included benzodiazepines (8/13), cocaine (2/13) and cannabinoids (1/13). 
VEPs: At 1-4 days of age, maternal methadone-exposed infants had an abnormal 
distribution of VEP waveforms compared to controls infants (Chi2 =12.0, p< 
0.01), with fewer typical VEPs and more immature waveforms. VEPs were non-
detectable in five cases (Figure 2-2).  
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Table 2-1 Pilot patient demographics 
 
  
Methadone (n=21) 
 
 
Control (n=20) 
 
p value 
 
Gestation (weeks) 
 
 
38.6 (1.4) 
 
39.8 (0.95) 
 
0.002 
 
Male: Female 
 
 
         10:11 
 
10:10 
 
0.879 
 
Birth weight (grams) 
 
 
2818 (533) 
 
3486 (535) 
 
<0.001 
 
OFC (cm) 
 
 
32.9 (1.38 ) 
 
34.9 ( 1.45) 
 
<0.001 
Data are means (standard deviations). 
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Figure 2-2 Distribution of VEP waveforms.  
White: control group (n=20). Black: drug-exposed infants at a median age of one day (n=21). 
Grey: drug-exposed infants at a median age of eight days (n=14). Data are expressed as a 
percentage of each group. 
 
 
 
 
 
 
 
 
 
 
Chapter 2  56 
Median total sum amplitude was significantly different between groups:  17μV 
for the methadone-exposed group and 30μV for the control group (Mann-Whitney 
test, 95% CI of difference 5–25μV, p=0.002). All measured peaks and troughs for 
methadone-exposed infants tended to have longer mean implicit times than 
controls and the difference was significant for P2: P1, 132ms versus 117ms 
(p=0.4); P2, 240ms versus 189ms (p=0.004); N3, 315ms versus 302ms (p=0.6); P3, 
394ms versus 334ms (p=0.2). Amplitudes of P1, P2 and N3 were smaller for 
methadone-exposed infants than controls: P1, 3μV versus 5μV (p=0.02); P2, 14μV 
versus 18μV (p=0.009); N3, 10μV versus 16μV (p=0.045). P3 amplitude did not 
differ between groups.  
Sleep and eyelid closure had no significant effect on the amplitudes of these 
bright flash VEPs but P2 was prolonged in sleep (215±28 ms) compared with P2 of 
awake infants (194±16 ms; p=0.03).  
After one week VEPs in the methadone-exposed infants had an increased 
proportion of typical, and fewer non-detectable VEPs (Figure 2-2) but amplitude 
remained low (median 11.3; range 0-21). There were no significant differences 
in any of the measured VEP parameters between the seven infants who did and 
the seven infants who did not develop NAS.  
2.1.5 Conclusions 
These pilot data showed significant differences in the neonatal flash VEP of 
infants exposed to methadone in utero compared with non-drug-exposed control 
infants. VEPs in drug-exposed infants were more likely to be absent and, if 
present, to show delayed peak and trough latencies, smaller amplitudes and 
immature waveform. 
These pilot data suggested a need for a further study of VEPs in infants exposed 
to drug misuse in utero. Questions raised included whether the VEP could be of 
use in predicting the onset of NAS and/or predicting visual and 
neurodevelopmental abnormalities secondary to maternal drug misuse. Longer 
term follow up of a larger number of maternal drug-exposed infants, along with 
comprehensive toxicology was required to address these questions, and to 
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determine any relationship between the neonatal VEP and the pattern of 
maternal drug misuse in pregnancy. 
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2.2 Flicker Visual Evoked Potentials in healthy term 
newborn infants 
2.2.1 Introduction 
An alternative method of assessing visual pathway function in the newborn 
period uses steady state luminance stimuli, otherwise described as the flicker 
VEP. Infants show maturation of the optimal stimulus frequency in the first year 
of life, reaching typical adult values of 12 to 15Hz by approximately 15 months 
of age. An optimal stimulus frequency of 4-5Hz has been reported in infants 
during the first few months of life (86,88) but very few studies have reported 
flicker VEPs in newborn infants. 
2.2.2 Aims 
 To describe flicker VEPs in a cohort of healthy term newborn infants. 
 To determine optimal flicker frequencies and luminance, to guide the 
testing protocol for subsequent studies of maternal drug-exposed infants. 
2.2.3 Subjects and Methods 
Subjects: 
This was a prospective observational study carried out at the PRM, Glasgow. All 
healthy, term (≥37 completed weeks gestation) infants born in the study hospital 
were eligible for inclusion. Exclusion criteria were significant neonatal illness, 
congenital ocular abnormality or a history of in utero exposure to drug misuse. 
All infants were ≤48 hrs of age at the time of testing. Informed parental consent 
was obtained for all participants and Research Ethics Committee approval was 
obtained prior to study commencement. 
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Recording: 
VEPs were recorded in a dimly illuminated room with the infant placed supine in 
a cot. Recording sessions were timed to suit the infant‟s feeding schedule in 
order to maximise co-operation. VEPs were recorded using three silver-silver 
chloride electrodes in the midline occipital (recording), midline frontal 
(reference) and mastoid (ground) positions. Electrode positions were determined 
using the standard 10:20 clinical montage. Scalp-electrode impedance was 
measured before each recording and was below 5 kohms.  Awake/sleep state 
and degrees of eye opening were documented. The VEP signals were amplified 
and band-pass filtered (0.6-100Hz). 
Stimuli: 
A hand held LED-based stimulator (Colorburst®, Diagnosys  LLC, Lowell, MA 
01854) was used to present the flickering light 5cm from the infant‟s eyes in the 
midline. Frequencies of 2.9 Hz, 4.64 Hz, 7.3 Hz, 12.7 Hz, 18.55 Hz and 38.1 Hz 
were presented at two different luminances (80 cds/m2 and 500 cds/m2), 
subsequently referred to as dim and bright flicker respectively. All stimulation 
was binocular. The stimulus was a white square waveform. A sample frequency 
of 1000Hz was used and the time window varied according to the frequency 
under investigation (4096ms for 2.9Hz and 4.64 Hz, 2048ms for 7.3 Hz, 1024ms 
for 12.7 Hz, 18.5 Hz and 38.1 Hz).  
Data processing and analysis: 
Each averaged VEP was subjected to resampling and Fourier analysis (84). Noise 
was estimated as the average of the two neighbouring spectral lines (one below 
and one above the response frequency). A significant response was defined as a 
signal to noise ratio (SNR) of > 2.82 which corresponds to a p value < 0.05 (85). A 
significant response at each flicker frequency was sought for both the 
fundamental response (F1) and its first harmonic (F2) (Figure 2-3, Figure 2-4). 
The optimal stimulus frequency was described for each recording, defined as the 
frequency that elicited the highest amplitude response at F1. 
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Figure 2-3 Flicker F1 response 
Flicker VEP recorded on day 1 of life using a bright flicker light stimulus with a frequency of 
4.6Hz. A significant response is shown at F1 (signal magnitude 4.8, Signal to Noise Ratio 
11.6, p < 0.001) as demonstrated by the spike at 4.6Hz. No response is seen at F2. 
 
 
 
Figure 2-4 Flicker F1 and F2 response 
Flicker VEP recorded on day 2 of life using a bright flicker light stimulus at a frequency of 
4.6Hz. A significant fundamental response is seen at F1 (signal magnitude 7.4, Signal to 
Noise Ratio 7.15, p = 0.002) and a significant harmonic response is seen at F2 (signal 
magnitude 2.5, Signal to Noise Ratio 4.1, p = 0.013). 
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2.2.4 Results 
Flicker VEP recordings were obtained in 34 healthy term newborn infants within 
the first two days of life. Gestation ranged from 37-41 weeks (median 39.5). The 
mean birth weight was 3468 grams (standard deviation 531 grams). Flash VEPs 
were recordable from all infants. 
Unlike the flash VEP, not all infants demonstrated a flicker response. The 
proportions of infants with flicker responses at the dim and bright light stimuli 
are shown in Figure 2-5. The bright light stimulus more often produced a VEP 
response than the dim light stimulus. This was statistically significant at 4.6 Hz 
(66% response with bright stimulus vs 23% response with dim stimulus; Chi 2 = 13, 
p<0.001), 12 Hz (23% response with bright stimulus vs 9% response with dim 
stimulus; Chi 2= 2.7, p=0.090) and 18 Hz (31% response with bright stimulus vs 6% 
response with dim stimulus; Chi 2= 7.7, p=0.004). Overall, the greatest number 
of responses was obtained using the bright 4.6 Hz stimulus (66% response rate). 
Only a minority of infants demonstrated a response above 18 Hz. 
Flicker F1 amplitude data were not normally distributed using Anderson-Darling 
tests for normality: data were therefore described as medians and inter-quartile 
ranges and statistical analysis done with Mann-Whitney tests. The bright light 
stimulus consistently produced larger amplitude F1 flicker responses at all 
frequencies. This was statistically significant at 4.64 Hz, 7.3 Hz and 18.5 Hz 
(Table 2-2) (Figure 2-6). The largest amplitude responses were produced using 
the 4.64 Hz bright light stimulus and the magnitude of response declined with 
increasing stimulus frequency.  
An association was investigated between the flash VEP amplitude and flicker VEP 
amplitude. Both flash P2 amplitude data and flicker F1 amplitude data were of 
skewed distribution and were therefore logarithm transformed to a normal 
distribution for investigation of any linear relationship between the variables. A 
fitted-line scatter plot and regression analysis were undertaken (Figure 2-7). 
There was a positive linear correlation between flash and flicker VEP amplitude: 
R2 17.8%, p=0.023. 
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Figure 2-5 Flicker VEP response 
The graph demonstrates the proportion of infants with a flicker VEP response at 
frequencies ranging from 2.9 Hz to 38.1 Hz. Responses to dim and bright light stimuli are 
shown and both the fundamental response (F1) and the first harmonic are shown (F2). The 
greatest proportion of responses was obtained using the 4.6 Hz bright flicker stimulus. 
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Table 2-2 Flicker F1 VEP amplitudes 
 
Freq Dim stimulus Bright stimulus p-value 
2.9 Hz 2.79 (1.50-5.03) 2.98 (1.85-4.66) 0.946 (-0.87,0.86) 
4.64 Hz 1.09 (0.66-1.75) 3.41 (2.60-4.59) <0.001 (-2.82,-1.68) 
7.3 Hz 0.85 (0.46-1.13) 1.16 (0.61-1.56) 0.048 (-0.53,0.007) 
12.7 Hz 0.47 (0.33-0.71) 0.58 (0.42-0.95) 0.057 (-0.30,0.003) 
18.5 Hz 0.25 (0.16-0.34) 0.46 (0.31-0.71) <0.001 (-0.32,-0.10) 
38.1 Hz 0.08 (0.04-0.12) 0.09 (0.05-0.15) 0.300 (-0.05,0.01) 
Data are medians (inter-quartile ranges). Statistical analysis was done using Mann-Whitney tests. 
The 95% confidence interval for difference is given in brackets after the p-value. The bright flicker 
stimulus produced larger amplitude F1 responses at all frequencies which was statistically 
significant at 4.64 Hz, 7.3 Hz and 18.5 Hz. The optimal stimulus frequency was 4.64 Hz. 
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Figure 2-6 Boxplot of flicker amplitude 
The bright flickering 4.64 Hz stimulus produced larger amplitude responses compared to 
the dim stimulus; Mann-Whitney test: p<0.001. 
 
 
Figure 2-7 Scatterplot of flash and flicker amplitude 
There was a positive linear association between the flash and flicker VEP amplitude data (R
2
 
17.8%, p=0.023). 
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2.2.5 Conclusion 
This study provides normative data for flicker VEPs in healthy term newborn 
infants and allows comparison between the flicker stimuli of two different 
luminances. 
In common with other electrophysiological tests of visual function in the 
newborn, a bright flicker stimulus more reliably produced significant responses 
than a dim stimulus. The optimal stimulus flicker frequency demonstrated in this 
study was 4.6Hz which is in keeping with previous reports from older infants 
(87,88). Very few infants demonstrated responses above 18Hz. This study 
suggests that optimal flicker VEPs are achieved using a bright (500cds/m2) 
flickering light stimulus at approximately 5Hz in the newborn infant. 
Modification of future protocols for testing in newborn infants should include an 
additional testing frequency at approximately 5 Hz and removal of the 38Hz 
frequency. 
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2.3 Visual Evoked Potentials in preterm infants 
2.3.1 Introduction 
Immature flash VEPs, similar to those of moderately preterm infants, have been 
described in newborn infants exposed to methadone in utero in pilot study 
1(122). Since flicker VEP recording is a more objective method applicable in the 
newborn period there is a requirement for established normative values for 
flicker VEPs in healthy moderately preterm infants.  
2.3.2 Aims 
To describe flash and flicker VEPs in a group of moderately preterm infants. 
2.3.3 Subjects and Methods 
This was a prospective observational study. Inclusion criteria were moderately 
preterm infants (33 – 35+6 weeks‟ gestation) born at the PRM who were clinically 
stable and appropriately grown (birth weight >10th centile and <90th centile).  
Exclusion criteria were congenital ocular abnormality, other significant 
congenital abnormality, significant neonatal illness and/or a history of maternal 
drug misuse in pregnancy. To provide a comparative group 14 healthy term 
infants were matched to the preterm infants for sex, DEPCAT score (123) and 
maternal smoking status.    
2.3.3.1 Recording  
VEPs were recorded within 12 to 72 hours of birth. VEPs were recorded in a 
dimly illuminated room with the infant placed supine in their cot or incubator. 
Each recording session was timed according to the infant‟s feeds, to maximise 
co-operation. VEPs were recorded using three silver-silver chloride electrodes in 
the midline occipital (recording), midline frontal (reference) and mastoid 
(ground) positions. Scalp-electrode impedance was measured before each 
recording and was below 5 kohms.  Awake/sleep state and degrees of eye 
opening were documented. The VEP signals were amplified and band-pass 
filtered (0.6-100Hz). 
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2.3.3.2 Stimuli 
A hand held LED-based stimulator (Colorburst®, Diagnosys  LLC, Lowell, MA 
01854) was used to present the flash and flicker light 5cm from the infant‟s eyes 
in the midline. Bright (50 cds/m2) and dim (5 cds/m2) white flashes were 
delivered at 1 Hz and a minimum of two averaged VEPs of 30 flashes each were 
collected to ensure reproducibility. A bright flickering light stimulus was then 
presented at frequencies of 4.64 Hz, 5.86 Hz, 7.32 Hz, 12.7 Hz and 18.55 Hz. 
These flicker frequencies were modified from those used in the pilot study of 
term newborn infants: an additional frequency was added at 5.86 Hz as the pilot 
study had demonstrated an optimal response at 4.6 Hz, and the 38 Hz frequency 
was removed as few term infants had demonstrated a response at this level. Two 
different flicker stimuli were used at each frequency – a pulse wave and a sine 
wave. All stimulation was binocular. A sample frequency of 1000Hz was used and 
the time window varied according to the frequency under investigation (4096ms 
for 4.64 Hz, 2048ms for 5.86 Hz and 7.32 Hz, 1024ms for 12.7 Hz and 18.55 Hz).  
2.3.3.3 Data processing and analysis 
Flash VEPs  
VEPs were classified as present or absent. When present, peaks and troughs 
were labelled in order of increasing latency as P1, P2, N3, P3 and amplitude 
from baseline and latency noted. Total sum amplitude of all peaks and troughs 
was calculated. The morphology of the preterm waveform was described relative 
to term controls infants. 
Flicker VEPs 
Each VEP was subjected to resampling and Fourier analysis (85). Noise was 
estimated as the average of the two neighbouring spectral lines (one below and 
one above the response frequency) and a significant response was defined as a 
signal to noise ratio (SNR) of >2.82 which corresponds to a p value <0.05 (85). A 
significant response at each flicker frequency was sought for both the 
fundamental response (F1) and the first harmonic (F2). The optimal stimulus 
Chapter 2  68 
frequency was also described, defined as the frequency which elicited the 
highest amplitude response at F1. 
The study was approved by the Glasgow Royal Infirmary research ethics 
committee (REC reference number 09/S0704/2) and informed parental consent 
was obtained for all participants. 
2.3.4 Results 
2.3.4.1 Demographics 
Fourteen preterm infants and 14 term infants matched for sex, DEPCAT score 
and smoking status were recruited to the study. The median gestation of the 
preterm group was 35 weeks (IQR 34-35) and of the term group was 39 weeks 
(IQR 38-41). Mean birth weight and head circumference of the preterm infants 
were significantly lower than that of the term infants (mean birth weight 2219 
grams vs 3219 grams, p<0.001; mean OFC 31.4 cm vs 35.1 cm, p<0.001). 
2.3.4.2 Flash VEPs 
Significantly fewer preterm infants had a VEP response with the dim light 
stimulus compared to term infants. When a response was present it was of 
reduced amplitude and delayed P2 latency (Table 2-3). 
All preterm and term infants had a VEP response to the bright light stimulus. 
Significantly fewer preterm infants had a P1 response compared to term infants. 
Mean P2 latency with the bright light stimulus was again delayed in the preterm 
group; however this was not statistically significant. Total VEP amplitude was 
similarly reduced with the bright light stimulus (Table 2-3, Figure 2-8). 
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Table 2-3 Flash VEPs in preterm and term infants 
 
 DIM FLASH BRIGHT FLASH 
 Preterm Term p-value Preterm Term p-value 
VEP present 50% 100% 0.006 100% 100% 1.000 
P1 present 0% 7% 1.000 0% 50% 0.006 
P2 present 29% 93% 0.001 100% 100% 1.000 
P2 latency (ms) 
260 
(13.3) 
218 
(32.7) 
0.028 250 
(44.6) 
224 
(37.1) 
0.104 
Total amp (µV) 
1.15 
(0-7.8) 
25.45 
(9.7-43.3) 
<0.001     22.6 
(17.4-31.2) 
48.6 
(27.9-69.7) 
0.006 
Data are percentage response (%), mean (standard deviation) for P2 latency and median (inter-
quartile range) for amplitude. 
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Figure 2-8 Boxplot of flash VEP amplitude in preterm infants.  
Preterm infants had significantly smaller amplitude responses compared to term infants 
with both the bright flash stimulus (p=0.006) and dim flash stimulus (p<0.001).  
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The flash preterm infant VEP waveforms were also used to better define an 
immature VEP morphology for future studies. On review of the waveforms it was 
found that no preterm VEPs had P1 components and all had P2 and N3 
components. In 13/14 preterm waveforms, the amplitude of N3 was greater than 
three times the amplitude of P2 (Figure 2-9). 
 
 
 
Figure 2-9 Preterm VEP waveform 
A bright flash VEP waveform recorded from an infant born at 34 weeks gestation on day 2 of 
life. No P1 component was present. The waveform was a predominant negativity with N3 
amplitude greater than three times P2 amplitude. 
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2.3.4.3 Flicker VEPs 
Twelve preterm infants underwent flicker VEP analysis (two sets of data were 
lost due to a computer system failure). Results were compared to those of 14 
term infants matched as described above. Similar to term infants, preterm 
infants had an optimal flicker response at 4.6 Hz. On statistical analysis the 
preterm group had a greater proportion of responses at 5.86Hz compared to 
controls but had fewer responses at 18.55Hz (Table 2-4). However, using a 
Bonferonni correction to account for the number of statistical tests performed, 
these differences were not significant.  
Flicker F1 amplitudes were compared between the 12 preterm infants and the 
14 matched term infants. There were few differences in amplitude between 
groups (Table 2-5). At 18.55 Hz the term infants had larger amplitude flicker F1 
responses, but after using a Bonferroni correction for the number of statistical 
test performed this was no longer significant and may have been due to chance. 
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Table 2-4 Flicker responses in term and preterm infants 
 
 Pulse wave Sine wave 
Freq (Hz) Preterm Term p-value Preterm Term p-value 
4.64 83% 64% 0.391 92% 79% 0.598 
5.86 75% 29% 0.047 50% 79% 1.000 
7.32 25% 43% 0.429 50% 57% 1.000 
12.7 17% 21% 1.000 17% 14% 1.000 
18.55 0% 36% 0.042 0% 14% 0.483 
Statistical analysis was undertaken to investigate the flicker VEP response between preterm and 
term infants. Using a Bonferroni correction to account for the number of statistical tests performed, 
a p-value of <0.005 was considered significant. 
 
Table 2-5 Flicker amplitude in term and preterm infants 
 
  Pulse wave   Sine wave  
Freq (Hz) Preterm Term p-value Preterm Term p-value 
4.64 2.74 2.77 0.777 3.67 1.96 0.095 
5.86 1.51 0.89 0.269 1.44 1.88 0.857 
7.32 0.94 1.43 0.129 1.36 1.67 0.341 
12.7 0.78 0.59 0.487 0.84 0.85 0.699 
18.55 0.42 0.61 0.033 0.49 0.47 0.738 
Data are median values. Mann-Whitney tests were used for comparisons between groups. 
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2.3.5 Conclusion 
Preterm infants had fewer flash VEP responses compared to term infants and in 
particular fewer P1 responses. The total VEP amplitude was reduced and P2 
latency delayed. A reasonable definition for the preterm infant flash VEP 
waveform was: no P1 component present, predominant N3 waveform with N3 
amplitude greater than three times the P2 amplitude. Preterm infants 
demonstrated similar flicker responses to term infants with 4 Hz to 18 Hz 
stimuli. However, the numbers studied may have been too small to detect 
significant differences between groups. Optimal stimulus frequency for both 
groups was 4.64 Hz. 
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2.4 Ocular and electrophysiology abnormalities in 
children exposed to methadone in utero 
2.4.1 Introduction 
There is increasing evidence to suggest that in utero opiate and benzodiazepine 
exposure has an adverse effect on infant visual development (61,64). Within the 
local ophthalmology and visual electrophysiology service, it was recognised that 
an increasing number of children were being referred with a history of maternal 
methadone use (personal communication – Drs R Hamilton and J MacKinnon).  
2.4.2 Aims 
 To describe the combined ophthalmology and visual electrophysiology 
findings in infants and children who had been exposed to methadone and 
other drugs of misuse in utero and referred to a regional visual 
electrophysiology service. 
 To use this information to inform the testing protocol for the follow-up 
phase of the study. 
2.4.3 Subjects and Methods 
This was a retrospective descriptive case series of children referred to paediatric 
ophthalmology services because of concerns regarding visual function and who 
were known to have been exposed in utero to methadone. Ophthalmic and 
orthoptic examination included visual acuity, cover tests, ocular motility, 
cycloplegic refraction and dilated fundoscopy. Visual acuity was assessed using 
age-appropriate tests; some subjects were unable to cooperate with behavioural 
acuity tests and step VEP acuity assessment was used instead. Delayed visual 
maturation was a retrospective diagnosis in babies with visual behaviour which 
was poorer than expected for their postnatal age but which improved by six 
months of age. Structured history taking was used to seek evidence of cerebral 
visual impairment (CVI) in older children (72). 
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Following ophthalmology and orthoptic review, all infants were assessed in a 
specialist visual electrophysiology clinic where appropriate investigations were 
undertaken depending on the age of the child and presenting symptoms. VEPs 
and electroretinograms (ERGs) were recorded according to international 
standards, but with methods modified to suit the age of the child (75). Pattern-
reversal VEPs to a black-and-white checkerboard at 100% contrast, subtending 
30°×24° and reversing at 1.1Hz were recorded. Pattern-onset VEPs were 
recorded to a black-and-white checkerboard at 100% contrast, interleaved with 
an isoluminant grey screen, subtending 30°×24° and reversing at 1.1Hz. Flash 
VEPs were recorded to a hand-held diffuse flash with a time-integrated 
luminance of 11.7 cds /m2. In order to estimate acuity, step VEPs were recorded 
to black-and-white reversing checks using real-time analysis and a successive 
approximation algorithm to find spatial thresholds (124).  
Paediatric and neonatal case notes were reviewed, and details obtained 
regarding maternal antenatal urine toxicology when available. Subjects were 
excluded from the case series if they had been born before 32 weeks gestation 
or had another diagnosis which could potentially account for their visual 
abnormalities such as fetal alcohol syndrome or birth asphyxia. 
2.4.4 Results 
Twenty children underwent comprehensive ophthalmology and visual 
electrophysiology assessment. All children had been exposed to prescribed 
substitute methadone in utero and a majority had also been exposed to illicit 
drugs in utero, most commonly benzodiazepines (11/20, 55%) and heroin (8/20, 
40%). Drug exposure as determined from case notes and maternal urine 
toxicology is shown in Table 2-6. Twelve infants (60%) had received 
pharmacological treatment for NAS.  
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Table 2-6 Drug exposure and systemic findings 
 
Patient 
number 
Gestation 
(wks) 
MDN Heroin BDZ Other drugs Alcohol Treatment 
for NAS 
1 38       
2 32       
3 39       
4 40    Cannabis   
5 38       
6 39       
7 40       
8 38    Cocaine   
9 36    Cocaine   
10 34    Cannabis   
11 40    Cannabis   
12 35    Cannabis   
13 40       
14 38       
15 36       
16 38    Antidepressant   
17 41       
18 40    Cannabis   
19 37       
20 39    DF118   
MDN: methadone, BDZ: benzodiazepines, NAS: neonatal abstinence syndrome, DF118: 
dihydrocodeine. 
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Ocular and electrophysiology findings are shown in Table 2-7.  The most common 
abnormalities demonstrated were reduced visual acuity (19/20, 95%), nystagmus 
(14/20, 70%), delayed visual maturation (10/20, 50%), strabismus (6/20, 30%) 
and refractive errors (6/20, 30%).  
Significantly more infants with a history of treated NAS developed nystagmus 
than those without NAS: 11/12 (92%) versus 3/8 (38%); Fisher‟s exact test, 
p=0.017. Nystagmus was horizontal in nature with the majority having a 
pendular wave-form although one patient exhibited a jerk type pattern. The 
observed characteristics of the nystagmus varied in being manifest, latent, or 
manifest with a latent component. Interestingly, patient 13 initially had 
manifest latent nystagmus which developed with time into latent nystagmus 
alone. Fundal examination was abnormal in two cases – one case had bilateral 
abnormal blood vessels crossing the macula which showed regression at five 
months of age, and the other had slight pallor of both optic discs.  
Twelve patients (60%) had abnormal visual electrophysiology. One of these 
(patient 11) had a reduced amplitude cone and flicker ERG, but normal fundus 
and normal pattern-onset VEP to 60‟ checks. All other ERGs recorded were 
normal (n=13). Flash VEPs were recorded from 11 patients and were normal in 
eight (73%) and delayed in three cases (patients 5, 10 and 12). Pattern-reversal 
VEPs were recorded from six patients and were normal in two cases but delayed 
or absent in four cases (patients 5, 9, 17 and 20). Pattern-onset VEPs were 
recorded in six cases and were normal in five but delayed in one (patient 5). 
Eleven subjects had their visual acuity estimated using the step VEP; in nine 
cases (82%), acuity was abnormal for age. Step VEP acuity estimates agreed with 
contemporary behavioural acuity assessments in all of the nine cases where both 
were available. 
Five children (25%) had significant neurodevelopmental problems 
(developmental delay in four, cerebral palsy in one), three of whom (patients 2, 
13 and 19) had CVI and one of whom (patient 12) had a delayed flash VEP. 
Cerebral visual impairment (CVI), causing functional visual processing problems 
including dorsal and ventral stream abnormalities, was screened for in the older 
children by structured history taking and was found in five cases (25%).  
Chapter 2  79 
Table 2-7 Ocular and electrophysiology findings 
 
Patient 
 
DVM Nystagmus Strabismus Refractive 
error 
CVI Flash 
VEP 
P-R VEP P-O VEP VEP 
acuity 
1   XT   Normal   Raised 
2       Normal  Raised 
3      Normal    
4        Normal Raised 
5      Delayed Abnormal Delayed  
6      Normal   Normal 
7   ET     Normal  
8      Normal   Raised 
9    HA  Normal Absent  Raised 
10      Delayed  Normal Raised 
11        Normal  
12   XT MA (rt eye)  Delayed   Raised 
13   MT    Normal   
14   XT H     Raised 
15      Normal    
16    HA  Normal   Raised 
17       Absent Normal  
18          
19   ET HA  Normal    
20    A   Delayed  Raised 
DVM: delayed visual maturation, ET: esotropia, XT: exotropia, MT: microtropia. For refraction M: 
myopia, H: hypermetropia, A: astigmatism. CVI: cerebral visual impairment, VEP: visual evoked 
potential, P-O: pattern onset, P-R: pattern reversal. 
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2.4.5 Conclusion 
Ocular abnormalities detected in infants and children exposed to methadone and 
other substances of misuse in utero included reduced visual acuity, nystagmus, 
delayed visual maturation, refractive errors and strabismus (125). There was also 
a high incidence of VEP abnormalities. Infants who have received treatment for 
NAS may be at particular risk of visual abnormalities, especially nystagmus. 
Visual assessment of infants exposed to drug misuse in utero should include an 
assessment of visual acuity, observation for nystagmus, corneal reflexes to 
assess for strabismus and assessment for refractive errors; as well as 
measurement of VEPs. Due to the high incidence of nystagmus in this cohort, the 
preferred method of pattern VEP testing should be pattern-onset (106). 
81 
3 Chapter 3 Methods 
Maternal drug misuse can seriously affect the health of the fetus and newborn 
infant. The association of maternal drug misuse with prematurity, IUGR and NAS 
is well recognised, and there is growing concern about infant visual and 
developmental outcome. Drug misuse is associated with changes in the visual 
system as measured by VEPs in adults and in animal models. Since visual 
abnormalities and neurodevelopmental abnormalities can be predicted by 
abnormal VEPs in infancy, it is postulated that the VEP may be a valuable tool in 
the detection of adverse effects of maternal drug misuse upon the infant.  
Pilot work demonstrated the feasibility of recording VEPs in the neonatal period 
and showed abnormal VEPs in infants exposed to drug misuse in utero compared 
to unmatched controls (Chapter 2.1). Further pilot work described the scope of 
clinical visual abnormalities in a selected group of infants and children exposed 
to methadone in utero (Chapter 2.4). Further study was required to validate and 
investigate these pilot data and would require recruitment of a large number of 
methadone exposed infants, along with comprehensive toxicology collection and 
longer term follow up. 
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3.1 Objectives 
There were two parts to the study: 
Part 1: Neonatal visual evoked potentials  
In the first part of the study, neonatal VEPs were measured in infants who had 
been exposed in utero to methadone and other drugs of misuse. These VEPs 
were compared to VEPs from matched non-maternal drug-exposed infants. 
Associations were sought between neonatal VEPs and the pattern of in utero 
drug exposure. Investigations were also undertaken to determine whether 
neonatal VEPs were predictive of the development of NAS. 
Part 2: Early visual and neurological development 
In the second part of the study the same cohort of maternal drug-exposed and 
comparison infants was followed-up at six months of age with clinical visual and 
electrophysiology assessment as well as assessment of overall 
neurodevelopmental progress. An association was sought between the neonatal 
VEP and both visual and developmental outcome at six months of age. 
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3.2 Hypothesis and aims 
Hypothesis (1): 
The neonatal VEP is altered in infants exposed in utero to methadone compared 
to non-exposed infants. 
Aims (1): 
To describe neonatal VEPs in infants exposed in utero to methadone. 
To compare these data with data obtained from non-maternal drug-exposed 
infants. 
Hypothesis (2): 
The neonatal VEP can be used to predict which infants will develop NAS. 
Aim (2): 
To assess whether the neonatal VEP is predictive of NAS. 
Hypothesis (3): 
Clinical visual abnormalities are more common in infants exposed in utero to 
methadone than non-exposed infants. 
Aims (3): 
To compare visual development at six months of age in infants exposed in utero 
to methadone with that of non-maternal drug-exposed infants.  
To define the incidence of visual abnormalities in infants exposed in utero to 
methadone compared to non-exposed infants. 
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Hypothesis (4): 
Developmental abnormalities are more common in infants exposed in utero to 
methadone than non-exposed infants. 
Aim (4): 
To compare developmental outcomes at six months of age in infants exposed in 
utero to methadone with that of non-exposed infants. 
Hypothesis (5): 
The neonatal VEP can be used to predict which infants will develop visual and/or 
developmental abnormalities. 
Aim (5): 
To assess if visual and/or developmental outcome at six months of age 
correlates with the neonatal VEP. 
Hypothesis (6): 
At six months of age the VEPs differ between infants who had been exposed to 
methadone in utero and non-exposed infants. 
Aim (6): 
To describe and compare VEPs in infants who had been exposed to methadone in 
utero and non-exposed infants at six months of age. 
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3.3 Subjects and setting 
The study was conducted at the Princess Royal Maternity (PRM), the largest 
maternity unit in Glasgow, which provides obstetric care to the majority of drug-
misusing women in the city.  
Eligible infants were born to drug-misusing mothers prescribed substitute 
methadone in pregnancy and delivered at or admitted within 48 hours of birth to 
the PRM. Exclusion criteria were prematurity (defined as <36 completed weeks 
of gestation), congenital ocular abnormality, other significant congenital 
abnormalities and significant neonatal illness.  
For comparative purposes, 50 non-maternal drug-exposed infants were recruited 
with exclusion criteria identical to the cases. To correct for any potential 
confounding effect of birth weight, gestation or socio-economic status on the 
newborn infant VEP, the infants were matched as follows: completed week of 
gestation, birth weight ± 250 grams, DEPCAT socio-economic group ± 1(123). 
The study was approved by Glasgow Royal Infirmary Research Ethics Committee 
prior to study commencement (REC reference number 08/S0704/40). The study 
was also granted overall management approval for Greater Glasgow and Clyde 
Health Board prior to commencement (Research and Development Project 
number YN08NN325). All aspects of the study were conducted in accordance 
with Good Clinical Practice guidelines. 
Neonatal recruitment commenced on 15th October 2008 and ended on 30th March 
2010. Six month follow-up commenced on 21st April 2009 and ended on 28th 
September 2010. 
Design: Prospective cohort study. 
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3.4 Sample size calculation 
Pilot study 1 demonstrated a significant difference in flash VEP latency, 
amplitude and morphology between 21 methadone-exposed infants and 20 
control infants (122). These infants were however exposed to poly-drug misuse. 
The aim was to recruit enough patients to determine the independent effects of 
different drugs of misuse as well as substitute methadone on the neonatal VEP. 
From local audit and research data it was estimated that approximately 20% of 
pregnant women prescribed substitute methadone would use no additional illicit 
substances (126). It was therefore calculated that 100 maternal drug-exposed 
infants would require to be recruited to identify a sub-group of 20 who had been 
exposed to methadone alone, thereby permitting study of the isolated effect of 
methadone on the neonatal VEP. In addition, to minimise the confidence 
intervals of parameters such as VEP amplitude and latency the largest feasible 
number of infants was recruited within the two year duration of the study. From 
local audit, it was predicted that approximately 150 babies per year would be 
delivered at PRM to mothers prescribed substitute methadone, of whom around 
120 would be delivered at >36 weeks gestation. Based on previous studies, a 65% 
recruitment rate predicted around 70 eligible infants recruited each year. This 
was a conservative estimate as recruitment rate in the pilot study was 84%. To 
allow sufficient time for completion of the six month follow-up an eighteen 
month recruitment period was planned, anticipating recruitment of 100 
maternal drug-exposed infants to the study. Drop-out was predicted to be 
minimal for Part 1 of the study since all intervention was neonatal. 
From this cohort, a sub-group of around 50 (50%) infants was expected to 
develop significant NAS requiring pharmacological treatment (4,126). A group of 
this size was likely to demonstrate 95% confidence intervals for averages of 
neonatal flash VEP parameters of around ±2.3μV and ±10.7ms for P2 amplitude 
and latency (78), which is adequately narrow for clinical purposes. To match this 
study group in size, it was proposed to recruit the same number of non-maternal 
drug-exposed infants (n=50).  
Follow-up: Local audit demonstrated that approximately half of all methadone-
exposed infants offered follow-up clinic appointments failed to attend on two or 
Chapter 3  87 
more occasions (126). Follow-up studies of developmental outcome in infants 
exposed to opiates in utero report drop-out rates varying from 10-60% 
(38,45,47).  A 40% drop-out by six months was therefore assumed, giving 60 
drug-exposed infants and 30 comparison infants for visual and 
neurodevelopmental assessment at this age. A well-accepted test battery of 
child development for examining functional vision (127) used a sample size of 28 
to define normal results at around six months: these data gave confidence to 
describe adequately both groups with the predicted study numbers. 
3.5 Recruitment 
Eligible mothers and babies were identified by daily communication with the 
midwifery and medical staff on the postnatal wards of the PRM. All mothers 
were approached in person after discussion with the attending midwife. Mothers 
were given verbal and written details of the study and time to consider 
participation and to discuss the study with their partner (Appendix 1 - Parent 
Information Sheet). If verbal consent was given, the mother was asked to sign a 
consent form and was given a copy of both the consent form and Parent 
Information Sheet to keep. A copy of the consent form was inserted in the 
baby‟s notes and a record kept for the study document folder. Consent for the 
six month follow-up was also obtained at this time, and maternal contact details 
recorded. A letter was subsequently sent to the General Practitioner to inform 
them of the infant‟s participation in the study (Appendix 2 - Letter to GP). 
3.6 Data collection 
3.6.1 Maternal data 
Information regarding the pattern of drug misuse in pregnancy was obtained 
from mothers of both drug-exposed and comparison infants by confidential 
interview and by review of maternal case notes. Mothers were also asked about 
their smoking habit and alcohol use in pregnancy. The interview was conducted 
with the mother alone, and it was stressed that information disclosed would not 
affect the care that either the mother or her baby would receive. 
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Further maternal data collected included age, body mass index (BMI), 
prescription of antidepressants or antipsychotics during pregnancy and 
socioeconomic group. Socioeconomic group was defined using the Carstairs 
DEPCAT scoring system (123). This scoring system uses information from the 2001 
Census to place geographical areas into socioeconomic groups based on the 
following: presence of overcrowding, unemployment, social class (based on 
occupation) and car ownership. The report provides a DEPCAT score for each 
postcode in Scotland with a score of one representing the most affluent areas 
and a score of seven representing the most socially deprived areas. 
3.6.2 Neonatal data 
Data collected included birth weight, sex, gestation, method of delivery, Apgar 
scores at birth, occipito-frontal circumference (OFC) and method of feeding. 
Most of these data were collected from maternal and neonatal case notes. The 
OFC was measured with a disposable measuring tape three times in succession 
by the researcher and the largest value plotted on an appropriate growth chart 
(Four-in-one decimal growth charts, Designed and published by Child Growth 
Foundation, Harlow Printing Limited). The closest centile line for both birth 
weight and OFC was documented. Low birth weight (LBW) was defined as birth 
weight < 2500g, and small for gestational age (SGA) was defined for infants 
whose birth weight was < 3rd centile for gestational age.  
The presence and severity of NAS was recorded throughout the infant‟s hospital 
stay, including requirement for and duration of pharmacological treatment.  NAS 
severity was assessed as per routine practice at PRM, using a modified version of 
the Lipstiz scoring tool (Appendix 3 - PRM neonatal abstinence syndrome 
guidelines) (28). Infants underwent twice daily NAS scoring by trained midwifery 
staff on the postnatal ward. Treatment was commenced if infants had two NAS 
scores ≥5 and they were unable to be settled between feeds. Treatment was 
commenced as per protocol with oral morphine solution at a dose of 60 
micrograms/kg/dose four hourly and increased if necessary in increments of 10 
micrograms/kg/dose to a total of 80 micrograms/kg/dose four hourly. Infants 
whose symptoms remained significant on the maximum dose of oral morphine 
solution, or whose symptoms worsened after weaning of oral morphine solution, 
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were commenced on oral phenobarbital solution. Length of hospital stay and 
need for admission to the Neonatal Unit were recorded.   
3.6.3 Confidentiality and data protection 
All patient related information was stored on a password protected study 
database. At study entry, each participant was allocated a unique study 
identification number and all personal data were stored anonymously on the 
study database under this number. A list matching study number to patient 
identification was stored separately on a password protected computer. 
3.7 Toxicology 
3.7.1 Toxicology samples 
Most methadone-prescribed mothers had routine urinalysis performed at their 
booking hospital visit and at approximately 36 weeks gestation. Additional urine 
toxicology samples were obtained in some mothers during their pregnancy, on   
clinical grounds. A specimen of the infant‟s urine and a sample of meconium 
were obtained as soon as possible after delivery (but after informed consent had 
been obtained), to facilitate accurate assessment of the pattern of drug 
exposure in utero.  Urine was obtained via a urine bag applied to the infant‟s 
perineum, and was sent to the laboratory in a universal container. Meconium 
was obtained directly from the infant‟s nappy and collected into a universal 
container. Samples of each were frozen at -20°C prior to being analysed in 
batches. Meconium samples were also obtained from comparison infants after 
study recruitment and screened for alcohol metabolites. 
3.7.2 Toxicology analysis 
Maternal and infant urine samples were analysed by the regional toxicology 
laboratory at Gartnavel General hospital using Abbott enzyme multiplied 
immunoassay technique (EMIT) assays run to Substance Abuse and Mental Health 
Services Administration guidelines on an Abbott Architect Analyser. Assays 
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included methadone, opiates, benzodiazepines, amphetamines, cannabinoids 
and cocaine metabolites.  
Meconium samples were analysed in the Department of Forensic Medicine and 
Science at the University of Glasgow.  Established methods for drug testing in 
meconium involved enzyme-linked immunosorbent assay screening plus solid 
phase and liquid-liquid extraction followed by gas chromatography-mass 
spectrometry.  These procedures allowed detection of the major drug groups, 
including methadone and detected elevated fatty acid ethyl esters as a 
biomarker for prenatal alcohol exposure (17,128). A cut-off level of ≥ 10,000 
nanograms/gram was used to signify excessive alcohol consumption in pregnancy 
(19). 
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Figure 3-1 Infant drug exposure 
A comprehensive assessment of drug exposure was undertaken in infants exposed to 
methadone in utero using the methods summarised above. 
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3.8 Neonatal VEP recording 
VEPs were recorded within 72 hrs of birth in accordance with a Standard 
Operating Procedure (Appendix 4 – Standard Operating Procedure for recording 
VEPs). They were recorded from the occipital scalp using three silver-silver-
chloride electrodes placed according to international 10:20 classification. VEPs 
were recorded to single flashes of light and then to flicker stimuli. All 
stimulation was binocular. Light stimuli were delivered using a hand held LED 
stimulator. Stimulus generation, recording and data storage were carried out 
using the Espion® evoked potential system (Photograph 1). Impedance was 
recorded at the start and end of the recording and aimed to be < 10 kOhms. 
3.8.1 Flash VEPs 
A white pulse flash light stimulus was delivered at a frequency of 1 Hz, at two 
different luminance: three candelas seconds per meter squared (cds/m2) 
(standard flash) and 28 cds/m2 (bright flash) (Photograph 2). A minimum of 30 
and up to 100 trials were undertaken and repeated to ensure reproducibility. All 
VEPs which were described as non-detectable had 100 trials repeated twice. The 
sample frequency was 1000 Hz. The standard flash (subsequently referred to as 
dim flash) was chosen as it represented International Society for Clinical 
Electrophysiology of Vision (ISCEV) standards for flash VEPs in adults (75). The 
bright flash was selected based on data from Pilot study 1 which demonstrated 
significant differences between groups when a bright flash stimulus was used 
(Chapter 2.1).  
3.8.2 Flicker VEPs 
Pulse and sine wave flicker stimuli were presented at 4.64 Hz, 5.86 Hz, 7.32 Hz, 
12.7 Hz and 18.55 Hz. These frequencies were chosen based on pilot normative 
control data which demonstrated an optimal flicker response at a frequency of 
4.64 Hz in newborn infants (Chapter 2.2). A bright luminance flicker stimuli was 
used (500 cd/m2), also based on the pilot study. Each neonatal VEP recording 
took approximately 45 minutes. Sleep state and eye-opening during recordings 
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were noted. Sleep state was defined as awake, drowsy or asleep and eye 
opening state as open, intermittent or closed.  
3.9 Follow up assessment 
All infants were invited to participate in assessment at six months of age. 
Contact details were recorded at recruitment. When the infant was 
approximately five months old an initial invitation to attend for follow up was 
issued: if the parent was not contactable at this stage via the recorded details, 
contact tracing was undertaken by contacting the general practitioner and/or 
patient services. If the infant was no longer in the care of the biological parents, 
social work was contacted to trace the infant‟s whereabouts. An appointment 
was made over the telephone for follow-up attendance, with every effort made 
to ensure that the timing suited the parents/carers‟ schedules and the child‟s 
routine. Where applicable, follow-up was co-ordinated with existing scheduled 
hospital out patient clinic appointments. A letter was sent as confirmation of the 
agreed appointment date (Appendix 5 – Letter to parent/carer) and a reminder 
telephone call was undertaken on the day prior to the appointment. 
To facilitate attendance, a taxi was made available to transport the 
parent/carer and child to the hospital. Follow-up was performed at the PRM and 
included: 1) repeat VEP testing, 2) clinical visual assessment, 3) developmental 
assessment and 4) growth parameter measurement.  
3.9.1 VEP testing 
VEP testing at six months of age was undertaken using pattern-onset stimuli 
(Photograph 3). Pattern onset stimuli produce larger and clearer VEPs in patients 
with nystagmus compared to pattern reversal stimuli (106) and pilot data 
(Chapter 2.4) had demonstrated a high incidence of nystagmus in a drug-exposed 
study group. VEPs were recorded using the standard clinical montage of three 
electrodes as described in the SOP. Pattern-onset VEPs were recorded to the 
appearance of 60‟ (one degree of arc) black and white checks alternating 
between a diffuse grey background with equal overall luminance presented at 
one reversal per second. The 60‟ check size was chosen to comply with ISCEV 
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standards for clinical recordings of transient pattern VEPs (75). Depending on 
response to the 60‟ check size, further responses were investigated at 15‟ (0.25 
degree of arc) and 120‟ (2 degree of arc) checks (Figure 3-2). Six month old 
infants with normal vision were expected to demonstrate a VEP response at the 
small (15‟) check size (92). The infant‟s attention was maintained on the 
computer screen by tapping the fixation screen and dangling rattles and bells; 
the recording was paused if the infant lost fixation. As with flash VEPs, a 
minimum of 30 and up to 100 trials were recorded and repeated to ensure 
reproducibility for each check size.   
As the follow up study progressed it became apparent that only a minority of 
infants were presenting with nystagmus, and a publication subsequent to 
determination of the study protocol demonstrated that the pattern-reversal VEP 
was delayed in four month old infants who had been exposed to methadone in 
utero (121). It was therefore decided to add pattern-reversal VEPs to the visual 
electrophysiology testing protocol for infants who had not yet undergone follow 
up. Pattern-reversal VEPs were recorded to a black and white checkerboard at 
100% contrast with 60‟ check sizes (one minute of arc) and presented at one 
reversal per second. 
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Figure 3-2 Pattern VEP testing 
All 6 month old infants were tested with a 60’ check size. Infants with a VEP response were 
then tested with a smaller (15’) check size. Infants with no response at 60’ were tested with a 
larger (120’) check size. Infants who remained compliant and attentive had all three check 
size VEPs recorded. 
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3.9.2 Clinical visual assessment 
Clinical visual assessment used a modification of the Atkinson test battery of 
child development for examining functional vision (Appendix 6 – Standard 
Operating Procedure for visual assessment) (127). This test battery provides 
normal data for basic visual capacities as well as specific visual functions in 
perceptual, visuo-motor and spatio-cognitive domains. Vision tests used 
included: pupil responses, diffuse light reaction, lateral tracking, corneal 
reflexes, lateral field testing by peripheral refixation, convergence of eyes to an 
approaching object, defensive blink to an approaching object, visual following of 
a falling toy, batting and reaching, screening retinoscopy and Cardiff acuity 
cards for preferential looking. The test battery provided criteria for a pass or fail 
in each test and recommendations for ophthalmology referral.  
Pilot work demonstrated that the most commonly identified visual abnormalities 
in infants exposed to methadone and other drugs of misuse in utero were 
reduced visual acuity, nystagmus, delayed visual maturation, strabismus and 
refractive errors (Chapter 2.4) (125). These were all covered by the visual 
screening test as follows: 
 Cardiff acuity test cards to assess acuity and screen for DVM (Photograph 
4),  
 Observation (including covering each eye in turn) and lateral tracking to 
observe for nystagmus,  
 Corneal reflexes to observe for strabismus,  
 Screening retinoscopy to screen for significant refractive errors. 
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3.9.3 Neurodevelopmental assessment 
Neurodevelopmental assessment was undertaken using the Griffiths Mental 
Development Scales for babies from 0 to 2 years (1996 revision) (Appendix 7 - 
Standard Operating Procedure for neurodevelopmental assessment). This 
provided a general developmental quotient (GQ) plus five subscales (locomotor; 
personal/social; hearing and language; eye and hand co-ordination; 
performance) (Photographs 5 and 6). A fail was defined as a GQ <85. 
3.9.4 Growth parameters 
Infants who attended follow-up were weighed using professional paediatric 
scales (BD-815 MA paediatric weighing scales, Tanita Corporation) and their OFC 
was measured. Growth parameters were plotted on sex-appropriate growth 
charts. Further data collected included infant feeding and details of any 
illnesses and/or hospital visits.  
All assessments had to be co-ordinated with the child‟s nap, feeding times and 
limited periods of co-operation. Full assessment took approximately one to one 
and a half hours. Priority was given to the clinical visual assessment and pattern 
onset VEP testing in infants with limited co-operation. 
Any babies who failed to reach required standards for visual or 
neurodevelopmental progress were referred to an appropriate specialist 
(consultant paediatric ophthalmologist or consultant neonatologist) for further 
assessment. 
All drug-exposed infants seen at the six month follow-up were offered a formal 
ophthalmology out-patient clinic appointment irrespective of whether visual 
concerns were identified (Appendix 8 - Letter to ophthalmology). This was done 
at the request of the consultant ophthalmologist involved in the study who 
judged that sufficient concern existed regarding long-term visual outcome in 
these infants to warrant the offer of formal follow-up. It also offered 
independent verification of findings at the six-month study visit. Since the 
ophthalmology service was offered on clinical grounds, it was not offered to 
comparison infants. Assessment at the ophthalmology clinic included cover tests, 
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ocular motility, visual acuity, cycloplegic refraction and dilated fundoscopy and 
was undertaken at the Royal Hospital for Sick Children, Glasgow. 
3.10 Data analysis 
3.10.1 VEPs 
3.10.1.1 Flash VEPs 
Flash VEPs were categorised as present or absent. When present, the amplitude 
and latency of peaks and troughs were measured. Peaks and troughs were 
defined as: P1= any positive component prior to P2, N2= any negative component 
prior to P2, P2= positive component between 126-300ms and preceding N3 if 
present, N3= negative component between 200-400ms following the P2 if 
present, P3= positive component following the N3. Amplitudes were recorded 
between peaks and troughs or from baseline if there was no preceding peak or 
trough. The total sum amplitude was calculated as the sum of all recordable 
peaks and troughs.  
Each flash VEP was also placed into a descriptive category of waveform 
morphology as defined in the pilot study of methadone exposed infants (Chapter 
2.1) (122) and the pilot study of VEPs in moderately preterm infants (Chapter 
2.3). A new category was included as it was recognised that many of the infants 
had a more mature response with a P1 component in addition to a P2 
component. Descriptive categories were: typical (predominant positivity near 
200ms (P2), no P1 present), mature (P1 and P2 present), immature 
(predominant negativity near 300ms (N3): either no P2 present or N3 amplitude 
> 3 times P2 amplitude) and atypical (response present but unusual waveform 
which did not meet criteria of other categories). Examples of VEPs from each 
category are shown in Figures 3-3 to 3-7. 
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Figure 3-3 Typical flash VEP response 
Predominant positivity (P2) 
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Figure 3-4 Mature flash VEP response 
P1 and P2 components present 
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Figure 3-5 Immature flash VEP response  
The waveforms were predominantly negative. When a P2 response was present, the N3 
amplitude was greater than three times the amplitude of P2. 
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Figure 3-6 Atypical flash VEP response 
Unusual waveform with a late positive response at 356ms (P3) and no preceding P1 or P2 
component. 
 
 
Figure 3-7 Non-detectable flash VEP response 
No reproducible VEP present 
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3.10.1.2 Flicker VEPs 
Each averaged flicker VEP was subjected to resampling and Fourier analysis. The 
Meigan and Bach technique was employed to relate the statistical significance of 
a response to the signal-to-noise ratio (84,85). This technique involved making 
an estimation of the surrounding noise from the two neighbouring frequencies of 
the stimulus frequency (one above and one below the response frequency). 
Using this technique, the statistical significance of the response signal is related 
to a specific signal-to-noise ratio (SNR): SNR= 2.82, p= 0.05; SNR= 4.55, p= 0.01; 
SNR= 8.40, p= 0.001 (i.e. the response signal must be 2.82 times the surrounding 
noise signal to be significant).  
A significant response was defined as a signal to noise ratio (SNR) of > 2.82 which 
corresponds to a p value < 0.05 (85). A significant response at each flicker 
frequency was sought for the fundamental response (F1) and the F2 and F3 
harmonic. When a response was present, its magnitude and SNR were measured. 
The optimal stimulus frequency was described for each recording, defined as the 
frequency that elicited the highest amplitude response at F1. 
3.10.1.3 Pattern VEPs 
Pattern onset VEPs were categorised as present or absent at each of the check 
sizes tested (15‟, 60‟, 120‟). When present, the amplitude and latencies of C1 
and C2 were recorded. It was recognised that most infants had a C2 peak 
response but that the morphology of the peak varied in being a) single peak, b) 
plateau, or c) bifid peak. For consistency, the latencies of the C2 response were 
defined as follows: a) single peak response: C2 latency at highest point of peak, 
b) plateau response: C2 latency at start of plateau, and c) bifid response: split 
into C2a latency, first peak or shoulder and C2b latency, second peak or 
shoulder (Figure 3-8).  
Pattern reversal VEPs were categorised as present or absent at the 60‟ check 
size. When present the latencies of N75 and P100 were recorded. Examples of 
pattern VEPs in each category are shown in Figures 3-8 and 3-9. 
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All VEPs were analysed by myself and independently by a second assessor (Dr R 
Hamilton) with extensive experience in paediatric visual electrophysiology. The 
second assessor was blinded to the infant‟s group and clinical progress. If there 
was any discrepancy in analysis of the VEP a third independent assessor 
(Professor DL McCulloch) reviewed the VEP, blinded to both infant group and 
clinical progress. 
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Figure 3-8 Infant pattern onset responses 
a) single peak, b) plateau, c) bifid peak 
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Figure 3-9 Infant pattern reversal response 
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3.10.2 Drug exposure 
The dose of methadone prescribed to the mother at delivery was noted. For 
other drugs of misuse, positive exposure was defined if either toxicology samples 
or maternal history were positive. It was assumed for the purpose of the study 
that toxicology samples could provide a false negative but not a false positive 
result and therefore if any sample tested positive this confirmed exposure to the 
drug under study. For example, if a mother denied cocaine use and mother and 
infant urines were negative for cocaine but meconium was positive, this counted 
as a positive exposure to cocaine. If a mother admitted amphetamine use but all 
toxicology samples were negative for amphetamine, this counted as a positive 
exposure to amphetamine. Drug exposure was then divided into the following 
categories: group 1) opiate exposure alone, group 2) opiate and cannabinoid 
exposure, group 3) opiate and benzodiazepine exposure (methadone + opiates + 
benzodiazepines or methadone + benzodiazepines), group 4) opiate, 
benzodiazepine and cannabis exposure, and group 5) other poly-drug exposure 
which included stimulants (cocaine and/or amphetamines).  
Excessive alcohol consumption during pregnancy was defined as a total FAEE 
concentration in neonatal meconium greater than 10,000 nanograms/gram. The 
group of infants who had been exposed to excessive alcohol during pregnancy 
was compared to those infants not exposed, and excess alcohol exposure was 
included in multivariate regression analysis. 
3.10.3 NAS 
NAS was categorised into four groups: 1) no NAS: infants with NAS scores ≤ 3 in 
the first week of life and who did not require pharmacological treatment, 2) 
mild NAS: infants with NAS scores > 3 in the first week of life and who did not 
require pharmacological treatment, 3) moderate NAS: infants who required 
standard treatment for NAS as per unit policy (maximum dose of 60 
microgram/kg/dose oral morphine solution only) and 4) severe NAS: infants 
requiring second line treatment for NAS (either increased dose of oral morphine 
solution or addition of phenobarbital). 
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3.11 Statistical analysis 
Numerical data were described as means and standard deviations (SD) for 
normally distributed data and medians and interquartile ranges (IQR: Q1, Q3) for 
non-normally distributed data. Distribution of numerical data was determined 
using Anderson-Darling tests for normality and data were also plotted on 
histograms and boxplots.  
Demographics: 
Between group comparisons for normally distributed numerical data (birth 
weight, OFC, maternal BMI) were analysed using 2 sample t-tests. Between 
group comparisons for ordinal or ordered nominal categorical data (Apgar scores, 
DEPCAT score, gestation) were analysed using Mann-Whitney tests. Between 
group comparisons for nominal and binary categorical data (gender, method of 
delivery, method of feeding, maternal smoking) were analysed using Chi-squared 
tests. 
VEPs: 
VEP latencies and amplitudes were compared between drug-exposed and control 
groups using 2 sample t-tests / Mann-Whitney tests depending on distribution of 
data. VEP analysis involving proportions, such as presence of a response or 
presence of individual components were undertaken using Z test for two 
proportions or Chi-squared tests. 
VEP morphology (mature, typical, immature) was compared between groups 
using Chi-squared tests for nominal data.  
Flicker VEP responses were compared between groups using Z tests for two 
proportions. Flicker amplitudes were compared using Mann-Whitney tests. As 
multiple flicker analysis was undertaken, a multivariate, repeated measures, 
logistic regression model was applied to the flicker response data to compare 
cases and controls. 
Sub-group analysis: 
Chapter 3  109 
Data were divided into sub-groups depending on drug exposure (group 1-5 
outlined above). Kruskal-Wallis tests were used for sub-group analysis of 
numerical variables and Chi-squared tests were used to compare VEP morphology 
between groups. 
NAS: 
VEP latencies and amplitudes were compared between infants who developed 
NAS requiring pharmaceutical treatment and those who did not using 2 sample t-
tests / Mann-Whitney tests depending on distribution of data. VEP morphology 
was compared between infants who developed NAS and those who did not using 
Chi-squared tests. 
NAS was further sub grouped into four categories as outlined above and Kruskal-
Wallis tests were used to investigate differences between sub groups. 
Morphology between the four sub groups was compared using Chi-squared tests. 
Potential confounders: 
To assess for potential confounders, demographics were compared between 
drug-exposed and control infants. Where there was any significant difference 
identified between groups this predictor variable was entered into a multivariate 
regression analysis model with each response variable. 
Follow-up neurodevelopment: 
Griffiths general quotient scores (GQ) were compared between drug-exposed 
and control infants using Mann-Whitney tests for ordinal data. The sub-quotients 
for each of the five sub-scales were also compared between groups. A GQ score 
of <85 was classified as abnormal and the proportion of infants with abnormal 
neurodevelopment was compared between groups using Z test for two 
proportions. Linear regression models were used to correct for potential 
confounders on developmental outcome. 
Follow-up visual assessment: 
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The proportion of infants who failed visual assessment in each group was 
compared using Chi-squared tests (or Fisher‟s exact tests where group numbers 
were small). Neonatal VEP amplitudes and latencies were compared between 
drug-exposed infants with normal and abnormal visual screening using 2 sample 
t-tests or Mann-Whitney tests depending on distribution of data. Neonatal VEP 
morphology was compared between drug-exposed infants with normal and 
abnormal visual screening using Chi-squared tests.  
In addition, relative risk and attributable-risk percent were calculated for the 
outcomes of abnormal VEP and abnormal clinical visual outcome. 
All analyses were done using Minitab (versions 15 and 16) with a significance 
level of 5%. Where available, 95% confidence intervals were quoted. 
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Photograph 1: Espion evoked potential system (1= Espion recording system, 2= 
hand held light stimulus for neonatal testing, 3= computer monitor for pattern 
VEP testing) 
 
 
Photograph 2: Neonatal flash VEP recording using hand held light stimulus 
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Photograph 3: Pattern VEP recording in six month old infant (120‟ check size) 
 
 
Photograph 4: Cardiff card visual acuity testing 
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Photograph 5: Griffiths developmental assessment: eye and hand co-ordination 
 
 
Photograph 6: Griffiths developmental assessment: locomotor skills 
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4 Chapter 4 Results: Neonatal data 
One hundred and fifty four mothers were approached regarding the study, of 
whom 152 consented to participation (102 drug-exposed infants; 50 comparison 
infants), giving a 98% recruitment rate. In all the following graphs and tables, 
drug-exposed infants are referred to as cases and non-drug-exposed comparison 
infants are referred to as controls. 
4.1 Demographics 
Infant and maternal demographic data are shown in Table 4-1. There was no 
difference in sex or mode of delivery between the groups. The median gestation 
of both groups was 39 weeks and median 5-minute Apgar score of both groups 
was nine.  
The vast majority of infants in both groups were formula fed (87% of cases and 
90% of controls); mode of feeding did not differ between groups. 
Although the drug-exposed infants had a marginally lower mean birth weight 
than comparison infants, this difference was not significant (2892 grams vs 3005 
grams, 2-sample t test, p=0.209). There was no difference in the proportion of 
infants in each group who were either LBW or SGA. 
Despite similar birth weights, the drug-exposed infants had smaller head 
circumferences compared to comparison infants. The proportion of infants with 
microcephaly (OFC < 3rd centile) did not however differ between groups.  
A higher proportion of mothers of drug-exposed infants smoked compared to 
mothers of comparison infants (95% vs 60%, p< 0.001). The mean OFC of infants 
born to smoking mothers was significantly smaller than that of infants born to 
non-smoking mothers (33.49cm vs 34.66cm, p=0.001). After correcting for 
smoking status using a linear regression model, there was no longer a significant 
difference in the OFC between groups (p=0.280). 
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Socioeconomic class tended to be marginally lower in the drug-exposed infants  
(median DEPCAT 7) compared to the comparisons (median DEPCAT 6), but this 
was not statistically significant. Maternal BMI did not differ between groups. 
Fourteen of the methadone prescribed mothers were on antidepressant or 
antipsychotic medication during pregnancy (ten on antidepressants alone, two 
on antipsychotics alone, two on combined treatment), compared to none of the 
comparison mothers (14/102 vs 0/50; Fisher‟s exact test p=0.005).  
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Table 4-1 Infant and maternal demographics 
 
 Cases (n=102) Controls (n=50) p-value 
 
Sex (Male) 
 
 
46% 
 
44% 
 
0.809 
Mode of delivery 
     SVD 
     LUSCS 
 
72% 
21% 
 
70% 
20% 
 
 
0.797 
     Instrumental 
 
7% 10%  
Gestation (wks) 
 
39.3 (38.2-40.1) 39.7 (38.1-41.6) 0.419 
5-min APGAR 
 
9 (9-10) 9 (9-10) 0.862 
Birth weight (gm) 
 
2892 (505) 3005 (539) 0.209 
SGA 
 
18% 20% 0.727 
LBW 
 
20% 18% 0.812 
OFC (cm) 
 
33.5 (1.56) 34.1 (1.6) 0.015 
Microcephaly 
 
8% 8% 0.973 
Feeding at D/C    
     Formula 87% 90%  
     Breast 7% 8% 0.507 
     Mixed 
 
6% 2%  
Maternal smoking 95% 60% <0.001 
 
Maternal BMI 
 
Maternal DEPCAT 
23 (21-26) 
 
7 (5-7) 
23.5 (21-30) 
 
6 (4-7) 
0.293 
 
0.058 
 
Maternal 
antidepressants 
/antipsychotics 
 
14% 0% 0.005 
 
Data are given as percentage responses. Gestation, Apgar scores, DEPCAT scores and BMI are 
medians (inter-quartile range). Birth weight and OFC are means (standard deviation). Percentage 
responses were compared using Chi-squared tests, birth weight and OFC using 2 sample t-tests 
and gestation, Apgar, DEPCAT and BMI using Mann-Whitney tests. SVD: spontaneous vertex 
delivery, LUSCS: lower uterine segment caesarean section, SGA: small for gestational age, LBW: 
low birth weight, OFC: occipito-frontal circumference, D/C: discharge, BMI: body mass index, 
DEPCAT: Carstairs deprivation index score. 
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4.2 Neonatal Abstinence Syndrome 
Just under half of all drug-exposed infants developed NAS sufficiently severe as 
to require pharmacological treatment (49/102, 48%). The proportion of infants in 
each NAS severity group (no NAS, mild NAS, moderate NAS and severe NAS) is 
shown in Table 4-2.  
The median duration of oromorph treatment of the 49 infants treated with oral 
morphine solution was nine days. 18 of these infants required additional 
treatment with phenobarbital and the median duration of treatment of this 
subgroup was 43 days. The median total treatment days were ten days (Table 4-
2). All babies treated with phenobarbital were discharged home on the drug with 
weekly hospital follow-up.  
The median hospital stay for the drug-exposed group (n=102) was 9.5 days. 
Infants requiring pharmacological treatment had a significantly longer hospital 
stay than infants not requiring treatment (median 13 days vs median 6 days, 
p<0.001). 
38/102 babies were admitted to NNU (37%). The median length of NNU stay was 
ten days. The most common reason for NNU admission was ongoing or escalating 
treatment for NAS (17 infants), however infants were also admitted for 
respiratory distress (9 infants), poor weight gain or feeding (8 infants) and due 
to social circumstances (4 infants). 47% of infants were offered a hospital out 
patient clinic appointment following discharge. 
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Table 4-2 NAS and admission details for drug-exposed infants 
 
 Cases (n=102) 
 
Treated for NAS 
 
48% 
 
NAS severity 
 
 
     no NAS 
 
24% 
 
     mild NAS 
 
28% 
 
     moderate NAS 
 
26% 
 
     severe NAS 
 
22% 
 
Oromorph days 
 
9 (8-13) 
 
Phenobarbital days 
 
43 (38-57) 
Total treatment days 10 (8-49) 
 
Total hospital stay (days) 
 
9.5 (6-13) 
 
     hosp stay with NAS (days) 
 
13 (11-19) 
 
     hosp stay no NAS (days) 
 
6 (6-8) 
 
NNU admission 
 
37% 
 
NNU days 
 
 
10 (5-17) 
 
Data are given as percentage responses or medians (inter-quartile ranges). NAS: neonatal 
abstinence syndrome, NNU: neonatal unit. NNU days do not include days in post-natal wards. 
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4.3 Neonatal flash VEPs 
Neonatal flash VEP recording was undertaken in 152 infants (102 drug-exposed 
infants, 50 comparison infants). Two sets of data were lost due to a computer 
system failure, which left 150 sets of analysable data (100 cases, 50 controls). 
Age at recording differed by a median of six hours between the drug-exposed 
and comparison infants (median age of cases = 26 hr, median age of controls = 
20.5 hr; p=0.006). 
Both sleep state and eye opening state were compared between groups. The 
sleep state did not differ significantly between groups (cases: 11% asleep, 49% 
drowsy, 40% awake; controls: 6% asleep, 48% drowsy, 46% awake; Chi 2 =1.42, 
p=0.470). There was also no significant difference in eye opening state between 
groups with most infants in both groups having their eyes closed during recording 
(cases: 10% open, 13% intermittent, 77% closed; controls: 14% open, 26% 
intermittent, 60% closed; Chi 2 = 4.97, p=0.090). 
 
 
 
 
 
 
 
 
 
 
Chapter 4  120 
4.3.1 Normative control data 
Neonatal flash VEPs were recorded in 50 comparison infants. Normative values 
for these infants are shown in Table 4-3. 
 
Table 4-3 Normative comparison flash VEP data 
 Dim Bright 
P1 latency (ms) 117 (108-146) 137 (115-157) 
P2 latency (ms) 215 (205-252) 206 (192-229) 
N3 latency (ms) 335 (310-353) 321 (250-356) 
Total amplitude (µV) 20.4 (11-31) 39.6 (28-67) 
Data are medians (inter-quartile ranges). 
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Associations were sought between VEP latency and amplitude and: gestation, 
birth weight, OFC, sex and DEPCAT score in the comparison infants. 
There was a significant negative correlation between both P1 and P2 latency and 
gestation (P1 latency: Pearson‟s correlation coefficient= -0.61, p=0.001; P2 
latency: Pearson‟s correlation coefficient= -0.45, p=0.001) (Figure 4-1). There 
was no correlation between VEP amplitude and gestational age (Pearson‟s 
correlation coefficient= 0.22, p=0.124). 
There was no association between VEP latency or amplitude and sex, birth 
weight, OFC or DEPCAT score. 
 
 
Figure 4-1 Scatterplot of VEP latency and gestational age 
There was a significant negative correlation between flash VEP P2 latency and gestational 
age. R
2
 = 20.3%, p=0.001. 
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4.3.2 Data description and luminance comparison 
One hundred and fifty infants underwent both dim and bright flash VEP recording 
resulting in 300 VEPs for analysis. Prior to statistical analysis the VEP amplitude 
and latency data were investigated for their distribution using histograms and 
Anderson-Darling tests for normality. Both types of data appeared to have a 
skewed distribution (Figure 4-2) and were therefore described as medians and 
inter-quartile ranges.  
The bright flash stimulus consistently produced more VEP components than the 
dim stimulus. The median latencies were shorter with the bright stimulus 
compared to the dim and this was statistically significant for the P2, N3 and P3 
components (Table 4-4). The bright flash stimulus also produced larger 
amplitude responses compared to dim: median dim flash amplitude 14.5 (IQR 
6.4-28.6) vs median bright flash amplitude 31.2 (IQR 19.4-50.3); Mann-Whitney 
test: 95% CI -20.4 to -12.7; p<0.001 (Figure 4-3). The morphology of the VEP 
waveform differed between the dim and bright flash (Chi 2 = 50.4, p < 0.001) 
(Figure 4-4) with the bright flash stimulus producing more mature responses and 
fewer absent responses. 
In summary, a bright flash stimulus produced larger amplitude VEP responses 
with more components and shorter latencies compared to a dim light stimulus. 
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Figure 4-2 Histograms of VEP latency and amplitude 
Both VEP latency and amplitude data were of a skewed distribution. 
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Table 4-4 VEP data description and luminance comparison 
 DIM stimulus 
(n=150) 
BRIGHT stimulus 
(n=150) 
p-value 
 
P1 responses 
 
10 
 
45 
 
<0.001 
P1 latency (ms) 138.5 136 0.458 
IQR 117-194 115-202  
N2 responses 20 68 <0.001 
N2 latency (ms) 170.5 167.5 0.640 
IQR 157-200 149-193  
P2 responses 96 138 <0.001 
P2 latency (ms) 213.5 207 0.019 
IQR 198-243 192-224  
N3 responses 90 129 <0.001 
N3 latency (ms) 325 305 0.004 
IQR 298-354 249-339  
P3 responses 28 60 <0.001 
P3 latency (ms) 385 323 0.028 
IQR 312-425 279-387  
Data given are number of responses, medians for latencies and inter-quartile ranges (IQR). The 
data represents all babies in the study (cases and controls, n=150). Latencies were compared 
using Mann-Whitney tests and proportion of responses compared using Z test for 2-proportions. 
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Figure 4-3 Boxplot of VEP amplitude with dim and bright flash 
Denotes total sum flash VEP amplitudes using the dim and bright flash stimuli. Horizontal 
line within the box represents median, upper and lower borders of box represent Q1 and Q3, 
whiskers represent upper and lower limits and * represent outliers. 
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Figure 4-4 VEP morphology with dim and bright flash 
The graph demonstrates the VEP morphology with dim and bright flash stimuli. The bright 
stimuli produced fewer absent responses and more mature responses compared to the dim 
stimuli: Chi 
2
=50.4, p<0.001. 
 
   p<0.001 
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4.3.3 Drug-exposed and comparison VEPs 
VEP components and latency 
The drug-exposed infants had fewer P1 and P2 components present with both 
the dim and bright flash. Only 53% of cases had a P2 present with the dim flash 
compared to 86% of the controls (p<0.001). In addition, only 21% of the cases 
demonstrated a P1 response with the bright flash compared to almost half of the 
controls (48%) (p=0.001) (Table 4-5). Significantly fewer drug-exposed infants 
had a N2 response present than comparisons with the bright flash stimulus: 38% 
cases vs 60% controls, Chi2=6.523; p=0.011. Median latencies of the P1, P2, N2 
and N3 components did not significantly differ between groups. To further 
investigate any possible differences in VEP flash latency between groups, the P1 
and P2 latency data were logarithm transformed to a normal distribution and 
subjected to 2-sample t-tests. There was no significant difference in the mean 
log P1 latency between groups (log P1 latency cases: 4.93 (SD 0.25), log P1 
latency controls: 4.91 (SD 0.23), 95% confidence interval -0.119 to 0.168; 
p=0.731). Similarly there was no difference in mean log P2 latencies (log P2 
latency cases: 5.34 (SD 0.15), log P2 latency controls 5.33 (SD 0.16), 95% 
confidence interval -0.052 to 0.054; p=0.960). 
VEP amplitude 
The drug-exposed infants had significantly smaller amplitude responses with 
both the dim and bright flash compared to the comparisons. The median VEP 
amplitude with the dim flash for the cases was 11.4 V (IQR 0-20.5) compared to 
20.4 V (IQR 11.4-31.1) for the controls; Mann-Whitney p<0.001 (95% CI –14 to -
4.8). With the bright flash stimulus, the median amplitude was 27 V (IQR 17.1-
41.7) for the cases versus 39.5 V (IQR 28.1-66.6) for the controls; p<0.001 (95% 
CI –20.2 to -6.4) (Figure 4-5).  
Flash morphology 
Dim flash: VEPs were classified as absent, atypical, immature, typical or mature 
as defined in the methods section. 27% of drug-exposed infants had an absent 
VEP compared to 6% of comparisons. For the purpose of statistical analysis, 
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infants in the atypical group were combined with infants in the immature group. 
There was a significant difference in the VEP morphology between groups with 
the drug-exposed infants having more absent and immature/atypical responses, 
and fewer typical and mature responses (Chi 2 19.1, p<0.001) (Figure 4-6). 
Bright flash: VEPs were classified in a similar manner to the dim flash, however 
only 1% of cases had an absent VEP with the bright flash and no comparisons had 
an absent response. Therefore for the purpose of statistical analysis the absent, 
atypical and immature groups were combined to form one immature/abnormal 
group. Again there was a significant difference in VEP morphology between 
groups with the drug-exposed infants having more immature/abnormal responses 
and fewer mature responses (Chi 2 13.6, p=0.001) (Figure 4-7).  
Abnormal neonatal flash VEP characteristics 
The comparison infant data were used to define normal flash VEP 
characteristics. For VEP latency and amplitude, the upper and lower limits 
respectively of the comparison VEPs were used to define limits of normality. 
Using these cut off values an abnormal flash VEP was defined as: P2 latency > 
276 ms (dim flash) or > 301 ms (bright flash), total amplitude < 5 µV (both 
flashes), an absent VEP response to either flash or an immature VEP response to 
the bright flash. Each flash VEP was classified as normal or abnormal using these 
categories and these data were used to assess the predictive value of the flash 
VEP in the follow up assessments (Chapter 5 Results: Follow up data). 
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Relative risk of VEP abnormalities 
VEP abnormalities in methadone-exposed and non-exposed infants can be 
summarised as follows: 
 Abnormal VEP Normal VEP 
Methadone-exposed 56 44 
Non-exposed 5 45 
 
Relative risk= 56/(56+44) / 5/(5+45) = 5.6. 
Therefore, methadone-exposed infants were over five times more likely to have 
an abnormal VEP than non-exposed infants.  
The attributable risk percent was also calculated to estimate the proportion of 
VEP abnormalities amongst the exposed group which was attributable to 
methadone exposure. 
% AR = incidence in exposed group-incidence in non exposed group/ incidence in 
exposed group x 100 = 82%. 
Therefore 82% of the VEP abnormalities demonstrated in the drug-exposed group 
were attributable to methadone exposure. A population attributable risk percent 
was not calculated as it is unlikely the comparison group recruited for this study 
were representative of the general population. In summary, drug-exposed 
infants had smaller amplitude VEP responses with fewer P1 components and 
abnormal / immature waveform morphology compared to matched comparison 
infants. Drug-exposed infants were over five times more likely to have an 
abnormal neonatal VEP compared to non-exposed infants. 
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Figure 4-5 Boxplot of VEP amplitude in drug-exposed and comparison infants 
The sum VEP amplitudes were significantly smaller in the drug-exposed infants compared 
to controls. This was statistically significant with both the dim and bright light stimuli.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p<0.001 
p<0.001 
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Table 4-5 Neonatal flash VEPs for drug-exposed and comparison infants 
 
 
DIM FLASH BRIGHT FLASH 
 Cases Controls p-value Cases Controls p-value 
P1 response 5% 10% 0.302 21% 48% 0.001 
N2 response 11% 9% 0.244 38% 60% 0.011 
P2 response 53% 86% <0.001 89% 98% 0.033 
N3 response 60% 60% 1.000 87% 84% 0.621 
       
P1 latency (ms) 192 
(137-211) 
117 
(107-145) 
0.095 133 
(118-175) 
137 
(114-157) 
0.936 
P2 latency (ms) 213 
(198-239) 
215 
(205-215) 
0.403 207 
(191-221) 
206 
(191-228) 
0.690 
N3 latency(ms) 321 
(285-358) 
334 
(310-353) 
0.389 296 
(247-329) 
321 
(250-357) 
0.262 
 
Data are given as percentage response (%) and median (inter-quartile range) for latencies. 
Percentage responses were compared using Chi-square tests and latencies compared using Mann-
Whitney tests. 
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Morphology Absent Immature/atypical Typical Mature 
Cases  
(n=100) 
 
27% 32% 36% 5% 
Controls 
(n=50) 
6% 16% 68% 10% 
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Figure 4-6 VEP morphology with dim flash stimulus.  
The cases had more absent and immature responses and fewer typical and mature 
responses compared to controls: Chi 
2
=19.1, p<0.001. 
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Morphology Immature/abnormal Typical Mature 
Cases 
(n=100) 
 
28% 51% 21% 
Controls 
(n=50) 
10% 42% 48% 
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Figure 4-7 VEP morphology with bright flash stimulus  
The cases had more immature/abnormal and fewer mature responses compared to controls: 
Chi 
2
 =13.6, p=0.001. 
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4.3.4 Investigation of potential confounders 
Potential confounders were considered as variables which differed between the 
drug-exposed and comparison groups and which could have an independent 
effect on the newborn flash VEP. From the comparison demographics (Table 4-
1), the infant OFC, maternal smoking status and proportion of mothers on 
prescribed antidepressants differed significantly between groups.  Associations 
were therefore investigated between these variables and both VEP amplitude 
and latency. 
There did not appear to be any association between VEP amplitude or latency 
and the infant OFC (VEP amplitude and OFC: Pearson‟s correlation coefficient= 
0.11; p=0.193; VEP P2 latency and OFC: Pearson‟s correlation coefficient=-0.049; 
p=0.570). This was further illustrated by a scatter plot and linear regression 
analysis of the data (Figure 4-8). 
The drug-exposed infants also had a higher proportion of mothers on prescribed 
antidepressant and/or antipsychotic medication compared to the control infants. 
To investigate any potential confounding effect of these maternal prescribed 
drugs on the newborn infant VEP, VEP parameters were compared between 
infants whose mothers were on medication and those not. The bright flash 
amplitude did not differ significantly between groups: median amplitude 23 µV 
antidepressant group vs 27.2 µV; Mann-Whitney test p = 0.345 (95% CI -5.2 to 
13.6). There was no difference in bright flash P2 latency between groups: 
median P2 latency 205.5 ms antidepressant group vs 207 ms; Mann-Whitney test 
p=0.648. VEP morphology also did not differ (Chi 2 =0.56; p=0.761) between 
groups. 
Mann-Whitney tests were also used to compare the VEP amplitudes and latencies 
of infants born to smoking mothers with infants born to non-smoking mothers. 
Infants of smoking mothers were found to have significantly smaller amplitude 
VEP responses compared to those of infants whose mothers did not smoke 
(median amplitude non-smokers 37.2µV vs median amplitude smokers 29.8µV; 
p=0.017; 95% CI 2.2 to 19.5) (Figure 4-9). The P2 latency did not significantly 
differ between groups (non-smokers 209ms vs smokers 207ms; p=0.363; 95% CI    
-7.01 to 20.00). 
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Figure 4-8 Scatterplot of VEP amplitude and OFC 
There did not appear to be any significant correlation between VEP amplitude and infant 
OFC. Linear regression analysis: R
2
 = 1.1%, p=0.19. 
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Figure 4-9 Boxplot of VEP amplitude and smoking status 
VEP amplitudes were compared between infants born to smoking mothers and those born 
to non-smoking mothers. Infants born to smoking mothers had significantly smaller 
amplitude VEPs compared to non-smokers (Mann-Whitney test; p=0.017). 
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It was therefore necessary to use a linear regression model to assess if maternal 
smoking status was a potential confounder in the analysis of VEP amplitude and 
drug-exposure status. Both status group (case/control) and smoking status 
(smoker/non-smoker) were entered as predictor variables with VEP amplitude as 
the response variable as follows: 
Linear Regression model: VEP amplitude with status group and smoking group 
 
Predictor               Coef         SE Coef          T          P 
Constant               48.519       4.574         10.61     0.000 
Status gp             -14.714       4.337        -3.39       0.001 
Smoking gp          -2.111         5.486        -0.38       0.701 
 
 
 
Using this model, only status group was independently associated with VEP 
bright flash amplitude (p=0.001). Similarly, cases had significantly reduced VEP 
amplitude with the dim flash after correcting for maternal smoking (p=0.002). 
Previous analysis had also demonstrated that the drug-exposed infants had 
significantly fewer P2 responses with the dim flash stimulus and fewer P1 and N2 
responses with the bright flash stimulus compared to controls. Logistic 
regression analysis was used to correct for the potential confounding effect of 
smoking status on these binary outcomes.  
Logistic Regression model: Bright P1 response with status group and smoking group 
 
                                                                                            
Predictor               Coef             SE Coef          Z           P          
Constant           -0.024855        0.417291      -0.06       0.953 
Status gp          -1.21275          0.414955      -2.92       0.003      
Smoking gp       -0.092042        0.511556      -0.18       0.857      
 
 
Using a logistic regression model, after correcting for smoking status, the drug-
exposed infants were still significantly less likely to have a P1 response 
compared to control infants: p=0.003. Drug-exposed infants were also 
significantly less likely to have a bright flash N2 response than controls: p=0.008. 
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Logistic Regression model: Dim P2 response with status group and smoking group 
 
                                                                                             
Predictor                Coef            SE Coef         Z             P         
Constant               2.42099        0.661865     3.66         0.000 
Status gp             -1.44482        0.481440    -3.00         0.003     
Smoking gp          -0.897456      0.694675    -1.29         0.196     
 
After correcting for smoking status, the drug-exposed infants were significantly 
less likely to have a P2 response compared with control infants: p=0.003. 
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4.3.5 Relationship with NAS 
A relationship between the neonatal flash VEP and NAS was investigated in two 
ways. Initially drug-exposed infants were classified as having NAS or not based 
on a requirement for pharmacological treatment. VEP parameters were then 
compared between the two groups. To further investigate possible differences 
between infants with varying severity of NAS, NAS was classified into four 
severity groups (1-4) as defined in the methods section (Chapter 3.10.3). 
Statistical tests were undertaken to compare any differences between these four 
groups.  
Neonatal flash VEP parameters and their relationships to the presence of NAS are 
illustrated in Table 4-6. There was no difference in the presence of VEP 
components between infants who developed NAS and those who did not. 
Similarly, the latency of the VEP components did not differ between groups and 
the amplitude of the VEP responses did not significantly differ between those 
infants developing NAS and those not. The VEP morphology also did not differ 
between groups (dim flash stimulus: Chi 2 = 1.18, p=0.875; bright flash stimulus: 
Chi 2 = 0.44, p=0.804).  
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Table 4-6 Flash VEPs and NAS 
 DIM BRIGHT 
           No NAS NAS p-value No NAS NAS p-value 
P1 response 6% 4% 1.000 19% 23% 0.579 
P2 response 55% 51% 0.715 89% 89% 0.913 
N3 response 58% 62% 0.743 92% 81% 0.083 
P1 latency (ms) 198 165 0.773 141 130 0.259 
IQR 136-224 -  124-189 102-173  
P2 latency (ms) 216 208.5 0.837 208 203 0.122 
IQR 198-240 195-242  192-240 190-217  
N3 latency (ms) 322 314 0.437 307 293 0.614 
IQR 283-345 288-378  246-331 250-324  
Amplitude (µV) 10 12.4 0.653 27 28.8 0.771 
IQR 0-20.4 0-27.8  17.1-38 17.1-44.5  
Data are percentage response (%), medians and inter-quartile ranges (IQR) for latencies and 
amplitude. Data are compared using Chi 
2
 tests for percentage responses (Fisher’s exact test for 
dim P1 responses due to small numbers) and Mann-Whitney tests for latencies and amplitudes. 
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Kruskal-Wallis tests were used to investigate associations between the bright 
flash VEP parameters and the four NAS severity groups. There was no evidence 
of a difference between groups for VEP amplitude, P1 latency or P2 latency 
(Table 4-7). In addition the VEP morphology did not differ significantly between 
the four NAS groups (Chi 2 = 2.79, p=0.815). 
In summary, there did not appear to be any evidence of a relationship between 
the neonatal flash VEP and the subsequent development or severity of NAS. 
 
 
Table 4-7 Flash VEPs and NAS severity 
Group Amplitude (µV) P1 latency (ms) P2 latency (ms) 
1) no NAS 29.8 (23.3-50.5) 133 (114-140) 206 (185-220) 
2) mild NAS 23.2(13.9-35.4) 175 (127-191) 210 (195-254) 
3) mod NAS 31.8 (16.1-47.2) 130 (100-173) 199 (190-216) 
4) severe NAS 26.0 (18.2-44.5) 122 (107-177) 204 (187-223) 
p-value 0.229 0.460 0.168 
Data are median values (inter-quartile ranges). Kruskal-Wallis tests were used to compare data 
between groups. 
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4.3.6 Relationship with drug and alcohol exposure 
A review of the case notes of all mothers and babies and a confidential maternal 
interview were undertaken. One hundred and thirty maternal urine samples 
were collected during pregnancy from 84 drug misusing women. Seventy infant 
urine samples were collected and 110 infant meconium samples (74 samples 
from drug exposed infants, 36 samples from controls). The results were collated 
as described in the methods section to provide a drug exposure status for each 
study infant. 
Drug exposure was compared between the different techniques of detection 
(maternal history, maternal urine toxicology, infant urine toxicology, infant 
meconium toxicology). Data from each of these four techniques were combined 
to provide a pattern of overall exposure for each infant and these data were 
used for classification into a drug exposure group. Drug exposure status is shown 
in Table 4-8. Meconium was more sensitive at detecting in utero drug exposure 
than postnatal infant urine for all the drugs of misuse investigated, and was also 
more sensitive than maternal history and maternal urine for most drugs.  
Most infants were exposed to poly-drug misuse as illustrated in Figure 4-10. Only 
nine infants were exposed to methadone alone. A further eight infants were 
exposed to other opiates in addition to methadone, giving a subgroup of 17 
neonates exposed to opiates alone. The most commonly misused drugs in 
addition to methadone were opiates (74%), benzodiazepines (66%) and cannabis 
(62%). Twenty six infants were exposed to stimulants (cocaine and/or 
amphetamines) in addition to other drugs. For the purpose of statistical analysis 
babies were classified into one of five drug exposure groups: group 1 = opiates 
alone (n=17), group 2 = opiates + cannabis (n=15), group 3 = opiates + 
benzodiazepines (n=14), group 4 = opiates + benzodiazepines + cannabis (n=30) 
and group 5 = other drug exposure including stimulants (n=26) (Figure 4-10). 
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Table 4-8 Drug exposure status 
 
Drug 
Mat History 
(n=102) 
Maternal urine 
(n=84) 
Infant urine 
(n=70) 
Infant meconium 
(n=74) 
Overall 
(n=102) 
Methadone 100% 92% 61% 96% 100% 
Opiate 54% 56% 36% 81% 74% 
BDZ 51% 58% 33% 53% 66% 
Amphetamine 2% 1% 0% 14% 13% 
Cannabis 19% 39% 9% 65% 62% 
Cocaine 5% 5% 3% 15% 14% 
BDZ: benzodiazepine. Data are the percentage of positive results for each technique. The overall 
column combines the history and toxicology results to give a pattern of overall drug exposure. 
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Drug exposure group Number of babies 
1. Opiates only 17 
2. Opiates + Cannabis 15 
3. Opiates + Benzodiazepines 14 
4. Opiates + Benzodiazepines + Cannabis 30 
5. Other (stimulants) 26 
 
Figure 4-10 Pattern of drug exposure in cases 
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Infants who had been exposed to stimulants in utero had significantly lower birth 
weights than those infants not exposed to stimulants: mean 2742 gm (SD 564) vs 
mean 2971 gm (SD 449), 2 sample t-test p=0.039. They also had smaller head 
circumferences but this was not statistically significant: mean 33.04 cm (SD 
1.67) vs 33.67 cm (SD 1.47), 2 sample t-test p=0.072.  
There was a positive correlation between NAS group and drug exposure group, 
suggesting that increased in utero drug exposure was associated with increased 
NAS severity (Pearson‟s correlation=0.243, p=0.014). 
VEP amplitudes and latencies were compared between the five different drug 
exposure groups using Kruskal-Wallis tests as the amplitude and latency data 
were of skewed distribution. There were no significant differences in the VEP 
parameters between groups (Table 4-9, Figure 4-11). VEP morphology was also 
compared between groups using Chi-squared tests. For the purpose of statistical 
analysis, the typical and mature responses were classified together as normal 
responses and the absent, immature and atypical responses were classified 
together as abnormal responses. There were no differences in morphology 
between the five drug exposure groups (dim flash: Chi 2= 1.019, p= 0.907; bright 
flash: Chi 2= 4.150, p=0.386).  
VEP parameters were also compared between the nine infants who had been 
exposed to methadone alone and the rest of the drug exposed cohort (n=91). 
VEP amplitude did not differ between groups: dim flash 12.6 µV vs 10.6 µV, 
Mann-Whitney test p=0.715; bright flash 23.7 µV vs 29.0 µV, Mann-Whitney test 
p=0.142. Neither did the proportion of P1 and P2 responses (Fisher‟s exact tests 
p=0.198 and p=0.167 respectively) and VEP morphology (Fisher‟s exact test 
p=0.707) differ between groups. 
To further investigate the effects of different drugs of misuse on the neonatal 
VEP, regression analysis was undertaken. Drug exposure status for each of the 
drugs of misuse was entered as a predictor variable and VEP parameters entered 
as response variables (VEP amplitude in a linear regression model and P1 and P2 
responses in binary logistic regression models). This allowed assessment of 
methadone exposure alone on VEP parameters after correcting for additional 
illicit drug use. Methadone exposed infants had significantly reduced amplitude 
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neonatal flash VEPs after correcting for other drug use (dim flash: p=0.009; 
bright flash: p=0.012). Methadone exposed infants were also significantly less 
likely to have a bright flash P1 response compared to control infants (p=0.001), 
less likely to have a bright flash N2 response (p=0.024) and less likely to have a 
dim flash P2 response (p=0.008) after correcting for additional illicit drug use. 
Methadone dose 
Associations were investigated between parameters of the neonatal flash VEP 
and the dose of prescribed maternal methadone prior to delivery. There were no 
significant correlations between maternal methadone dose and either VEP 
amplitude (Pearson correlation 0.060; p=0.561) or VEP P2 latency (Pearson 
correlation 0.108; p=0.327). In addition the VEP morphology did not differ 
between infants exposed to a high methadone dose in utero (>50mg) and those 
exposed to a lower dose (≤50mg): Chi2=1.125; p=0.569. Similarly, the proportion 
of P1 and P2 responses did not differ between infants exposed to high versus 
lower methadone dose: P1 response Chi2=0.549; p=0.460 and P2 response 
Chi2=0.711; p=0.402. 
In summary, there did not appear to be any differences in the VEPs between 
infants in different drug exposure groups and regression analysis suggested the 
difference in VEP parameters between drug-exposed and control infants was 
associated with methadone exposure and not the other drugs of misuse. 
Excess alcohol exposure 
Excess alcohol exposure in utero was defined as infants who had elevated FAEEs 
in meconium ≥ 10,000 nanograms/gram. Meconium samples from 84 infants were 
analysed for the presence of FAEEs (63 cases and 21 controls); the remainder of 
the samples were insufficient for analysis. Twenty six drug exposed infants 
(26/63 tested, 41%) and five comparison infants (5/21 tested, 23%) were exposed 
to excess alcohol in utero. None of these infants had a clinical diagnosis of fetal 
alcohol syndrome. 
VEP parameters were compared between infants who had been exposed to 
excess alcohol in utero and those who had not. There was no difference in 
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median VEP amplitude (excess alcohol group = 30.6 µV vs no excess alcohol 
group = 31.7 µV, Mann-Whitney test p = 0.827) or VEP morphology (Chi 2 = 0.195, 
p = 0.907) between groups. The proportion of P1 and P2 components also did not 
differ between groups (Chi 2 = 0.094, p = 0.759 and Chi 2 = 0.124, p = 0.725 
respectively). 
Regression models were used to correct for the effect of excess alcohol exposure 
in utero on the neonatal flash VEP. Excess alcohol exposure was entered as a 
predictor variable along with drug exposure status (case/control) in a linear 
regression model for VEP amplitude and binary logistic regression models for P1 
and P2 responses. Drug-exposed infants had smaller amplitude VEPs after 
correcting for alcohol excess (bright flash amplitude p<0.001, dim flash 
amplitude p<0.001): excess alcohol exposure had no independent effect on the 
neonatal flash VEP amplitude (p=0.664). Drug-exposed infants were also less 
likely to have a bright flash P1 response (p=0.001) and less likely to have a dim 
flash P2 response (p<0.001) after correcting for excess alcohol exposure. 
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Table 4-9 Flash VEPs and drug exposure 
 
Drug exposure group 
 1 2 3 4 5 p-value 
Dim amp (µV) 14.3 8.7 10.8 9.3 12.7 0.544 
IQR (7.4-30.5) (0-16.9) (0-26.0) (0-19.4) (1.8-34.3)  
Bright amp (µV) 26.1 31.0 31.5 25.2 23.9 0.706 
IQR (18.0-45.9) (17.1-38.8) (22.0-51.3) (16.0-39.3) (16.7-46.9)  
P1 lat (ms) 130 - 140 145 127 0.858 
IQR - - (126-181) (107-188) (102-175)  
P2 lat (ms) 194 200 208 204 218 0.122 
IQR (177-207) (180-233) (194-215) (196-215) (197-241)  
N3 lat (ms) 279 319 323 269 307 0.219 
IQR (232-306) (262-324) (250-381) (237-314) (269-332)  
Data are medians. Inter-quartile ranges are given below in brackets. Kruskal-Wallis tests were 
used for comparisons between the five drug exposure groups. 
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Figure 4-11 Boxplot of VEP amplitudes and drug exposure 
Group 1: opiates alone, group 2: opiates + cannabis, group 3: opiates + benzodiazepines, 
group 4: opiates + benzodiazepines + cannabis, group 5: other drug exposure including 
stimulants. There were no differences in VEP amplitude between groups: Kruskal-Wallis 
test, p= 0.706. 
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4.4 Neonatal flicker VEPs 
Six sets of flicker data were lost due to a computer system failure and therefore 
144 sets of flicker VEPs were available for analysis (99 drug-exposed infants and 
45 comparison infants). 
4.4.1 Flicker  responses 
Responses were defined as a signal to noise ratio (SNR) > 2.8 at the stimulus 
frequency and were investigated at F1, F2 and F3 (fundamental response and 
harmonic responses). Similar to the pilot work, the largest proportion of 
responses at F1 was obtained with the 4.64 Hz stimulus for both drug-exposed 
and comparison infants (Table 4-10). The proportion of responses present 
reduced with increasing frequency of the stimulus.  
The proportion of F1 responses at each frequency was compared between drug-
exposed infants and comparison infants for both the pulse wave and sine wave 
stimuli. There was little difference between the groups although with the 5.86 
Hz sine wave stimulus more drug-exposed infants had a response than 
comparisons (62.6% cases vs 42.2% controls, p=0.021; 95% CI for difference 0.03, 
0.38) (Table 4-10). Using a Bonferroni correction to account for the number of 
statistical tests performed however, a p-value of < 0.005 would be considered 
significant. A multivariate, repeated measures logistic regression model was 
performed to test the overall difference between groups after correcting for 
wave type and frequency. Using this model a p-value of 0.345 was obtained 
suggesting there was no overall difference in the proportion of F1 responses 
between drug-exposed infants and comparisons. 
There was no difference in the proportion of F2 responses between groups at any 
of the stimulus frequencies using either sine or pulse wave (Table 4-11).  A 
multivariate, repeated measures logistic regression model was used to compare 
overall F2 responses between cases and controls and produced a p-value of 
0.653.  
As it is possible to have a harmonic response in the absence of a detectable 
fundamental response, the response status was further classified as a positive 
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response at any of F1, F2 or F3. Using this definition, the proportion of responses 
increased with over 90% of comparison infants having a detectable response with 
the 4.64 Hz sine wave stimulus (Table 4-12). Using this classification, there were 
still few differences between groups with respect to response rate. The cases 
had a higher proportion of responses with the 7.32 Hz sine stimulus compared to 
controls (66.7% vs 48.9%, p=0.044) (Table 4-12). However, a multivariate 
repeated measures, logistic regression model applied to investigate the overall 
difference between groups found no statistically significant difference between 
cases and controls (p=0.572). 
In summary, there were no significant differences in the proportion of flicker 
VEP responses between drug-exposed and comparison infants.  
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Table 4-10 Proportion of F1 responses 
 
  PULSE   SINE  
Freq (Hz) Case Control p-value Case Control p-value 
4.64 51/99 24/45 0.859 70/99 31/45 0.846 
 (51.5%) (53.3%) (-0.19, 0.16) (70.7%) (68.9%) (-0.14, 0.18) 
5.86 37/99 15/45 0.636 62/99 19/45 0.021 
 (37.4%) (33.3%) (-0.13, 0.21) (62.6%) (42.2%) (0.03, 0.38) 
7.32 37/99 13/45 0.308 53/99 20/45 0.309 
 (37.4%) (28.9%) (-0.08, 0.25) (53.5%) (44.4%) (-0.08, 0.27) 
12.7 14/99 11/45 0.158 15/99 7/45 0.950 
 (14.1%) (24.4%) (-0.25, 0.04) (15.2%) (15.6%) (-0.13, 0.12) 
18.55 14/99 10/45 0.256 17/99 5/45 0.315 
 (14.1%) (22.2%) (-0.22, 0.06) (17.2%) (11.1%) (-0.06, 0.18) 
Data are the number of significant F1 responses as defined by SNR > 2.8. The percentage 
response is given in brackets below. Statistical analysis was done using Z tests for 2-proportions. 
The 95% confidence interval for the difference is given in brackets below the p-value. A 
multivariate, repeated measures, logistic regression model was applied to test the overall 
difference between cases and controls and found no significant difference between groups 
(p=0.345). 
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Table 4-11 Proportion of F2 responses 
 
  PULSE   SINE  
Freq (Hz) Cases Controls p-value Cases Controls p-value 
4.64 34/99 16/45 0.888 61/99 31/45 0.390 
 (34.3%) (35.6%) (-0.18, 0.16) (61.6%) (68.9%) (-0.24, 0.09) 
5.86 24/99 6/45 0.101 43/99 18/45 0.698 
 (24.2%) (13.3%) (-0.02, 0.24) (43.4%) (40.0%) (-0.14, 0.21) 
7.32 15/99 8/45 0.697 18/99 6/45 0.447 
 (15.2%) (17.8%) (-0.16, 0.11) (18.2%) (13.3%) (-0.08, 0.17) 
12.7 12/99 4/45 0.547 7/99 3/45 0.929 
 (12.1%) (8.9%) (-0.07, 0.14) (7.1%) (6.7%) (-0.08, 0.09) 
18.55 15/99 5/45 0.494 7/99 5/45 0.450 
 (15.2%) (11.1%) (-0.08, 0.16) (7.1%) (11.1%) (-0.15, 0.06) 
Data are the number of significant F2 responses as defined by SNR > 2.8. The percentage 
response is given in brackets below. Statistical analysis was done using Z tests for 2-proportions. 
The 95% confidence interval for the difference is given in brackets below the p-value. A 
multivariate, repeated measures, logistic regression model was applied to test the overall 
difference between cases and controls and found no significant difference between groups 
(p=0.653). 
 
 
 
 
Chapter 4  153 
Table 4-12 Proportion of F1, F2 or F3 responses 
 
  PULSE   SINE  
Freq (Hz) Cases Controls p-value Cases Controls p-value 
4.64 73/99 36/45 0.399 86/99 42/45 0.199 
 (73.7%) (80%) (-0.21, 0.08) (86.9%) (93.3%) (-0.16, 0.03) 
5.86 62/99 24/46 0.296 81/99 32/45 0.169 
 (62.6%) (53.3%) (-0.08, 0.27) (81.8%) (71.1%) (-0.05, 0.26) 
7.32 55/99 22/45 0.457 66/99 22/45 0.044 
 (55.6%) (48.9%) (-0.11, 0.24) (66.7%) (48.9%) (0.005, 0.35) 
12.7 34/99 17/45 0.692 28/99 12/45 0.840 
 (34.3%) (37.8%) (-0.20, 0.14) (28.3%) (26.7%) (-0.14, 0.17) 
18.55 31/99 18/45 0.316 28/99 14/45 0.732 
 (31.3%) (40.0%) (-0.26, 0.08) (28.3%) (31.1%) (-0.19, 0.13) 
Data are the number of significant responses at F1, F2 or F3 (as defined by SNR > 2.8). The 
percentage response is given in brackets below. Statistical analysis was done using Z tests for 2-
proportions. The 95% confidence interval for the difference is given in brackets below the p-value. 
A multivariate, repeated measures, logistic regression model was applied to test the overall 
difference between cases and controls and found no significant difference between groups 
(p=0.572). 
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4.4.2 Flicker amplitudes 
Flicker VEP F1 amplitudes were investigated between drug-exposed and 
comparison infants. An Anderson-Darling test for normality demonstrated that 
flicker VEP amplitude data were not normally distributed and data were 
therefore described as medians and inter-quartile ranges. 
Table 4-13 shows the median flicker VEP amplitudes for all infants. The drug-
exposed infants had larger median amplitude responses at all frequencies 
tested, which was statistically significant at 4.64 Hz sine, 5.86 Hz sine, 7.32 Hz 
sine, 12.7 Hz pulse and 18.55 Hz sine. The maximum amplitude difference 
between groups was 0.7 µV. The optimal stimulus frequency was 4.64 Hz for 
both cases and controls. A multivariate, repeated measures analysis of variance 
model was performed to test the overall difference between groups after 
correcting for the stimulus frequency and wave form. Due to the skewed 
distribution of the flicker amplitude data, the data was logarithm transformed 
for this statistical model. This produced a p-value of <0.001 suggesting that the 
cases had overall significantly larger amplitude flicker responses compared to 
controls.  
Flicker F2 amplitudes were also compared between groups (Table 4-14). Again 
there was a trend for the drug-exposed infants to have larger amplitude flicker 
responses but using a multivariate, repeated measures analysis of variance 
model, there was no statistically significant overall difference between groups 
(p=0.090).  
In summary, the proportion of flicker responses did not differ between drug-
exposed infants and comparison infants, and the optimum stimulus frequency 
was identical for both groups (4.64 Hz). The drug-exposed infants had increased 
amplitude F1 responses at all frequencies which reached statistical significance. 
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Table 4-13 F1 amplitude 
 
  PULSE   SINE  
Freq (Hz) Cases Controls p-value Cases Controls p-value 
4.64 2.46 2.16 0.313 3.28 2.5 0.049 
 (1.56-3.26) (1.39-3.08) (-0.21, 0.68) (2.23-5.06) (1.71-4.01) (0.001,1.21) 
5.86 1.45 1.26 0.111 2.09 1.57 0.005 
 (1.15-1.89) (0.62-2.20) (-0.06,0.54) (1.42-2.99) (1.18-2.14) (0.17, 0,87) 
7.32 1.54 1.20 0.176 1.84 1.43 0.016 
 (0.89-2.14) (0.81-1.87) (-0.09,0.46) (1.27-2.41) (0.94-2.01) (0.06,0.62) 
12.7 0.86 0.71 0.028 0.74 0.72 0.734 
 (0.62-1.18) (0.45-0.97) (0.02,0.32) (0.54-1.02) (0.53-1.09) (-0.10,0.15) 
18.55 0.61 0.54 0.526 0.59 0.47 0.029 
 (0.39-0.84) (0.41-0.79) (-0.07,0.15) (0.42-0.90) (0.35-0.73) (0.01,0.22) 
Data are medians with inter-quartile ranges given below in brackets. Mann-Whitney tests were 
used for statistical analysis. The 95% confidence interval for difference is given below the p-value 
in brackets. A multivariate, repeated measures analysis of variance model was applied to test the 
overall difference between cases and controls and found the cases to have significantly larger 
amplitude F1 flicker amplitudes (p<0.001). 
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Table 4-14 F2 amplitude 
 
  PULSE   SINE  
Freq (Hz) Cases Controls p-value Cases Controls p-value 
4.64 0.72 0.69 0.990 1.32 1.19 0.786 
 (0.39-1.06) (0.38-1.15) (-0.16,0.17) (0.82-1.95) (0.84-1.97) (-0.25,0.31) 
5.86 0.57 0.49 0.022 0.80 0.65 0.098 
 (0.37-0.86) (0.27-0.49) (0.02,0.25) (0.49-1.13) (0.42-1.00) (-0.23,0.27) 
7.32 0.36 0.39 0.983 0.46 0.43 0.904 
 (0.27-0.57) (0.20-0.61) (-0.09,0.08) (0.24-0.66) (0.23-0.69) (-0.08,0.09) 
12.7 0.24 0.23 0.786 0.22 0.20 0.359 
 (0.15-0.33) (0.15-0.36) (-0.06,0.04) (0.13-0.38) (0.13-0.34) (-0.03,0.07) 
18.55 0.19 0.14 0.084 0.18 0.15 0.313 
 (0.11-0.26) (0.10-0.24) (-0.006,0.07) (0.11-0.26) (0.10-0.24) (-0.02,0.06) 
Data are medians with inter-quartile ranges given below in brackets. Mann-Whitney tests were 
used for statistical analysis. The 95% confidence interval for difference is given below the p-value 
in brackets. A multivariate, repeated measures analysis of variance model was applied to test the 
overall difference between cases and controls and found no significant difference between groups 
(p=0.090). 
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4.4.3 Neonatal flicker VEPs and NAS 
The flicker F1 amplitude was compared between infants who developed NAS 
(defined as requiring pharmacological treatment) and infants who did not 
develop NAS. 
There was little difference in the flicker F1 amplitude between groups (Table 4-
15). As there were few other differences in the flicker VEP between cases and 
controls, further investigative statistics relating to the development of NAS were 
not undertaken. 
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Table 4-15 Flicker amplitudes and NAS 
 
  PULSE   SINE  
Freq (Hz) No NAS NAS p-value No NAS NAS p-value 
4.64 2.41 2.45 0.369 3.36 3.13 0.761 
 (1.75-3.3) (1.47-3.1) (-0.31,0.77) (1.98-4.67) (2.23-5.15) (-0.91,0.69) 
5.86 1.59 1.36 0.049 2.25 1.99 0.214 
 (1.23-2.16) (1.13-1.65) (0.007,0.48) (1.58-3.03) (1.39-2.99) (-0.17,0.75) 
7.32 1.56 1.57 0.621 1.72 1.76 0.401 
 (0.82-2.16) (0.97-2.01) (-0.41,0.29) (1.28-2.23) (1.21-2.66) (-0.49,0.20) 
12.7 0.83 0.94 0.117 0.73 0.75 0.722 
 (0.49-1.17) (0.71-1.22) (-0.32,0.04) (0.53-1.01) (0.54-1.03) (-0.17,0.12) 
18.55 0.52 0.67 0.270 0.55 0.62 0.148 
 (0.37-0.83) (0.40-0.85) (-0.23,0.07) (0.37-0.77) (0.48-0.91) (-0.20,0.04) 
Data are medians with inter-quartile ranges given below in brackets. Mann-Whitney tests were 
used for statistical analysis. The 95% confidence interval for difference is given below the p-value 
in brackets
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5 Chapter 5 Results: Follow up data 
One hundred and seven infants were reviewed at six months: 81 of 102 (79%) 
drug-exposed infants and 26 of 50 (52%) comparison infants recruited. Overall 
study retention was 70%. Reasons for non attendance (45 infants) included: 
parent/carer uncontactable (25 infants: 56%), did not attend a pre-arranged 
appointment on two or more occasions (11 infants: 24%), geographically unable 
to attend (three infants: 7%) and declined follow up participation (six infants: 
13%). All infants attending for follow up completed both clinical visual and 
developmental assessment.   
5.1 Growth parameters and general health 
Median age at six month assessment was 27 weeks (IQR 26-28) for both groups 
(no significant difference; Mann-Whitney test p=0.231). There were no 
significant differences between groups in terms of weight or OFC at six month 
follow up: mean weight cases 7.52 kg (SD 1.05)  vs mean weight controls 7.94 kg 
(SD 1.09) , 2-sample t test p=0.110; mean OFC cases 43.26 cm (SD 1.54) vs mean 
OFC controls 43.83 cm (SD 1.88), 2-sample t test p=0.146. 
In addition, in view of the relatively high drop-out rate of comparison infants, 
the demographic characteristics of comparison infants who were followed up 
were compared to those of comparison infants who were not followed up. There 
were no significant differences in birth weight (2 sample t-test p=0.445), OFC (2 
sample t-test p=0.712, gestation (Mann-Whitney test p=0.984), 5-minute Apgar 
score (Mann-Whitney test p=0.263) or DEPCAT score (Mann-Whitney test 
p=0.258) between groups. 
Fourteen of the drug-exposed cohort had been admitted to hospital following 
discharge (17%). Reasons for admission were: bronchiolitis (five infants), gastro-
oesophageal reflux disease (two infants), non-specific viral illness (two infants), 
hernia repair (three infants), urinary tract infection (one infant) and pyloric 
stenosis (one infant). Three of the comparison infants (12%) had been admitted 
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to hospital: two with a non-specific viral illness and one with viral meningitis. All 
infants had been commenced on a weaning diet when seen for follow up and no 
infants were breast fed at six months of age. All infants were on term 
commercial formula milk. 
All comparison infants were in the care of their parents. Sixty-one drug exposed 
infants were in the care of their parents, 14 infants were in foster care (17%) 
and six infants were accommodated with a family member (7%).  Overall 24% of 
the drug exposed cohort was accommodated at six months of age. 
5.2 Infant Pattern VEPs 
Pattern onset VEPs were recorded in 105/107 infants at the six month 
assessment (79 cases, 26 controls). One infant did not undergo testing due to a 
computer system failure and one infant was too unsettled for recording.  
Ninety two infants underwent 120 minute check size VEP recording (67 cases, 25 
controls), 103 infants underwent 60 minute check size recording (77 cases, 26 
controls) and 94 infants underwent 15 minute check size recording (70 cases, 24 
controls). 40 infants underwent 60 minute pattern reversal VEP recording (26 
cases, 14 controls). 
5.2.1 Pattern VEP responses 
Comparison infants 
All comparison infants tested had reproducible VEP responses at all three check 
sizes: 25/25 responses at 120 minute check size, 26/26 responses at 60 minute 
check size, 24/24 responses at 15 minute check size.  
Drug- exposed infants 
All cases tested (67/67) had responses present at the large (120 minute) check 
size. Three drug-exposed infants had an absent VEP response at the medium (60 
minute) check size and only 51/70 drug-exposed infants had a response at the 
small (15 minute) check size. Compared to controls, drug-exposed infants were 
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significantly less likely to have a pattern VEP response present at the small 
check size; Fisher‟s exact test p=0.003. 
5.2.2 Pattern VEP latencies 
VEP latency data were of a skewed distribution and were therefore described as 
medians and inter-quartile ranges. Statistical tests were done using Mann-
Whitney tests.  
Amplitudes and latencies were compared between drug-exposed infants and 
comparisons for the C2 peak response (C2a) at each check size. The cases had 
significantly delayed latencies at the 120 minute and 15 minute check sizes 
(Table 5-1, Figure 5-1). At the 60 minute check size the cases had delayed 
latency C2 responses but this did not quite reach statistical significance using a 
non-parametric test (p=0.063 with Mann-Whitney test).  When 60 minute C2 
latency data were logarithm transformed to a normal distribution and tested 
with a 2-sample t test, the p-value was 0.050. C1 latency data did not differ 
significantly between groups although the numbers of C1 responses were low. 
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Table 5-1 Pattern VEP latencies 
 
       Check size C2 latency (ms) p-value 
 Cases Controls  
120 minute 115.0 99.0 0.019 
 (94-136) (93-142)  
60 minute 110.0 106.0 
 
0.063 
 (0.050*) 
 (96-126) (94-112)  
15 minute 122.0 108.0 0.028 
 (109-130) (92-125)  
Data are medians with inter-quartile ranges given in brackets below. Statistical tests were done 
using Mann-Whitney tests and (*) 2-sample t test for logarithm transformed 60 minute data. 
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Figure 5-1 Boxplot of pattern VEP latency 
The drug exposed infants had delayed latency C2 peak responses at the large (120 minute) 
check size: median latency 115 ms cases vs 99 ms controls; Mann-Whitney test p=0.019. 
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5.2.3 Pattern VEP amplitudes 
Pattern VEP amplitude data were of a skewed distribution and were therefore 
described as medians and inter-quartile ranges. The drug-exposed infants had 
significantly reduced amplitude responses at the 60 minute check size and a 
trend to reduced amplitude responses at the other check sizes (Table 5-2, Figure 
5-2). 
 
 
Table 5-2 Pattern VEP amplitudes 
 
Check size C2 amplitude (μV) p-value 
 Cases Controls  
120 minute 24.0 26.0 0.091 
 (15-33) (17-43)  
60 minute 25.0 34.0 0.005 
 (19-34) (28-39)  
15 minute 13.0 17.0 0.191 
 (10-20) (10-25)  
Data are medians with inter-quartile ranges given in brackets below. Statistical tests were done 
with Mann-Whitney tests. 
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Figure 5-2 Boxplot of pattern VEP amplitude 
The drug exposed infants had smaller amplitude responses at the medium (60 minute) 
check size; median amplitude 25 µV cases vs 34 µV controls; Mann-Whitney test p=0.005. 
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The comparison infant pattern VEPs were used to define limits of normality to 
enable drug-exposed infant pattern VEPs to be classified as normal or abnormal. 
An absent VEP response at any check size was classified as abnormal. The upper 
limit values for VEP latency and lower limit values for VEP amplitude were used 
as cut off values for normality and are demonstrated below:  
 
Check size Latency upper limit  
 (ms) 
 
Amplitude lower limit   
(μV) 
120 minute 
 
 142  8 
60 minute 
 
 127  12 
15minute 
 
 157  2 
 
 
Using these definitions 34/79 (43%) drug-exposed infants had an abnormal 
pattern VEP: cases 34/79 abnormal pattern VEPs vs controls 0/26 abnormal 
pattern VEPs; Fisher‟s exact test p<0.001. 
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5.2.4 Pattern VEPs and NAS 
C2 amplitudes and latencies were compared between drug exposed infants who 
developed NAS (defined as requiring pharmacological treatment) and those who 
did not. There were no significant differences or trends in the VEP parameters 
between groups, suggesting that NAS and/or its pharmacological treatment does 
not account for the changes demonstrated in visual electrophysiology (Table 5-
3). 
 
Table 5-3 Pattern VEP parameters and NAS 
 
 NAS No NAS p-value 
120 minute    
C2 latency (ms) 105.0 126.0 0.525 
 (92.0-139.0) (100.3-135.7)  
C2 amplitude (μV) 20.0 25.0 0.095 
 (14.0-28.0) (18.5-35.5)  
    
60 minute    
C2 latency (ms) 106.0 118.0 0.410 
 (95.0-125.0) (98.0-127.0)  
C2 amplitude (μV) 26.0 23.0 0.392 
 (20.0-37.0) (17.0-31.0)  
    
15 minute    
C2 latency (ms) 122.5 118.0 0.412 
 (116.0-130.5) (98.5-130.5)  
C2 amplitude (μV) 13.5 13.0 0.199 
 (10.0-23.3) (8.0-17.5)  
 
Data are medians with inter-quartile ranges given below in brackets. Statistical tests were done 
using Mann-Whitney tests. 
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5.2.5 Pattern VEPs and drug exposure 
Pattern VEP parameters were compared between infants in the five different 
drug exposure groups. There were no significant differences between groups 
suggesting the effect shown was secondary to opiate exposure and not other 
substances of misuse (Table 5-4). 
 
Table 5-4 Pattern VEP parameters and drug exposure 
 
VEP 
parameter 
Drug exposure group 
 1 2 3 4 5 p-value 
120 minute       
C2 lat (ms) 115.0 132.5 132.0 101.0 113.5 0.356 
 (97-135) (105-146) (97-142) (91-131) (92-138)  
C2 amp (µV) 26.5 18.0 24.0 20.0 22.5 0.330 
 (24-35) (12-30) (14-32) (14-28) (17-39)  
       
60 minute       
C2 lat (ms) 104.5 119.5 98.0 110.5 114.5 0.613 
 (97-127) (104-134) (94-123) (97-125) (94-130)  
C2 amp (µV) 22.0 31.5 25.0 22.0 28.5 0.340 
 (18-28) (20-37) (19-45) (15-32) (20-35)  
       
15 minute       
C2 lat (ms) 123.0 121.0 122.0 118.0 126.0 0.787 
 (88-132) (103-162) (111-124) (116-131) (115-131)  
C2 amp (µV) 15.0 9.5 12.0 13.0 14.5 0.429 
 (11-20) (8-19) (7-13) (9-19) (10-22)  
Data are medians with inter-quartile ranges given in brackets below. Statistics were done using 
Kruskall-Wallis tests. C2 lat: latency, C2 amp: amplitude. 
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5.2.6 Pattern reversal VEPs 
Forty infants underwent pattern reversal VEP recording (26 cases and 14 
controls). All comparison infants had a pattern reversal response present 
(14/14). Four drug-exposed infants had an absent response; two of these infants 
had nystagmus present. These two infants had recordable 60 min pattern onset 
VEPs supporting the evidence that pattern onset VEPs are more reliable in 
infants with nystagmus compared to pattern reversal (106). 
There was a trend to delayed VEP latencies in the drug-exposed group but this 
was not significant: median P100 latency cases (n=22) 113 ms vs median latency 
controls (n=14) 107 ms; Mann-Whitney test p = 0.167 and median N75 latency 
cases (n=13) 76 ms vs median latency controls (n=7) 73 ms; Mann-Whitney test p 
= 0.381. 
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5.3 Visual outcomes 
All infants underwent a clinical visual assessment. A fail was defined as the 
presence of strabismus, nystagmus, delayed visual maturation, reduced visual 
acuity or a refractive error which was confirmed by ophthalmology on 
cycloplegic refraction and required correction with glasses. Visual acuity (VA) 
from the comparison group was used to define normal acuity for this age group: 
the poorest VA amongst the control infants was 6/48 (one infant), and so this 
was defined as the limit of normality. Thus reduced VA was poorer than 6/48. A 
borderline assessment was defined as 1) minor visual abnormalities, 2) refractive 
error which was not confirmed by ophthalmology due to failure to attend 
following referral, or 3) moderate refractive error confirmed by ophthalmology, 
but not prescribed glasses and remaining under follow up. 
Overall 40% of drug-exposed infants failed the visual test battery (32 infants). A 
further nine infants (11%) were described as borderline: these were infants with 
possible refractive errors not assessed by ophthalmology (two infants), moderate 
refractive errors not prescribed glasses (three infants), exophoria (two infants), 
anisocoria (one infant) and absent blink response (one infant).  2/26 (8%) of the 
comparison group failed the visual assessment: one  infant had an intermittent 
strabismus (esotropia) and one had a refractive error (myopia). Significantly 
more drug-exposed infants failed the visual test battery than comparison 
infants: 32/81 cases failed vs 2/26 controls failed; Fisher‟s exact test p=0.003.  
Clinical visual outcomes are summarised as follows: 
 Abnormal vision Normal vision 
Methadone exposed 32 49 
Non-exposed 2 24 
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The relative risk of an abnormal visual assessment was: 
RR= 32/(32+49) /  2/(2+24)  = 5.1. 
Therefore infants exposed to methadone in utero were five times more likely to 
have an abnormal visual assessment than matched infants not exposed to 
methadone.  
The attributable risk percent was also calculated to estimate the proportion of 
disease amongst the exposed group which was attributable to methadone 
exposure. 
% AR = incidence in exposed group-incidence in non exposed group/ incidence in 
exposed group x 100 = 80%. 
Therefore 80% of the visual abnormalities demonstrated in the drug-exposed 
group were attributable to methadone exposure. A population attributable risk 
percent was not calculated as it is unlikely the comparison group recruited for 
this study were representative of the general population. 
Nystagmus was present in nine of the drug-exposed cohort (11%). No control 
infant demonstrated nystagmus. The nystagmus was horizontal in all cases and 
varied in being manifest (four infants), latent (three infants) and manifest latent 
(one infant). Of the nine infants with nystagmus, six had been treated for NAS in 
the neonatal period (66%) and eight (89%) were known to have been exposed to 
benzodiazepines in addition to opiates in utero. There was no significant 
difference in the incidence of NAS between infants with nystagmus and without 
nystagmus: 6/9 (66%) infants with nystagmus vs 35/72 (49%) infants without 
nystagmus; Fisher‟s exact test p=0.347. There was also no significant difference 
in the incidence of benzodiazepine exposure between infants with nystagmus 
and without nystagmus: 8/9 (89%) infants with nystagmus vs 49/72 (68%) infants 
without nystagmus; Fisher‟s exact test p=0.268. 
Strabismus was detected in 20 drug-exposed infants (25%). 12 infants had an 
exotropia and eight infants had an esotropia.  
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Reduced VA (defined as VA poorer than 6/48) was detected in 18 drug-exposed 
infants (22%). The reduced acuity was associated with other ophthalmic 
abnormalities in 11 of these infants. Delayed visual maturation was diagnosed in 
infants who had reduced VA or visual inattentiveness, but who subsequently 
showed catch up in visual development: 11 infants (14%) demonstrated DVM. 
Forty nine drug exposed infants were seen by ophthalmology in addition to 
having a six month study assessment. Age at ophthalmology assessment varied 
from eight months to 14 months. Discrepancies between study visual assessment 
and ophthalmology assessment were: five infants had a strabismus noted at the 
study assessment and no strabismus when seen by ophthalmology; four infants 
had strabismus noted by ophthalmology which had not been present when seen 
for the study assessment.  
Visual outcomes were compared between infants who had NAS in the neonatal 
period (defined as requiring pharmacological treatment) and infants who did not 
have NAS. There was no significant association between six month visual 
outcome and NAS: Chi 2 test; p=0.239. 
          NAS No NAS 
Pass       21 28 
Fail       20 12 
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Visual outcomes were also compared between infants in the five different drug 
exposure groups. There was no significant association between six month visual 
outcome and drug exposure group: Chi 2 test; p=0.528. 
 Gp 1 Gp 2 Gp 3 Gp 4 Gp 5 
Pass 9 9 6 14 11 
Fail 3 3 5 11 10 
 
Binary logistic regression was performed to account for the potential 
confounding effect of excess alcohol exposure on six month visual outcome. 
Excess alcohol was defined as significantly elevated FAEEs on meconium analysis 
as described in the methods section. After correcting for excess alcohol 
exposure, drug-exposed infants were significantly less likely to pass the six 
month visual assessment (p=0.007). There was also no significant difference in 
the proportion of infants failing the six month visual assessment between infants 
exposed to excess alcohol in utero and those not exposed: Chi 2 = 0.035; 
p=0.852. There was no independent effect of in utero alcohol exposure on visual 
outcome (p=0.790). 
Visual outcomes were compared between infants exposed to high dose 
methadone (>50mg) and those exposed to lower dose methadone (≤50mg) to 
assess for a dose-response relationship. Although a greater proportion of infants 
exposed to the higher dose failed the visual assessment compared to the lower 
dose (65% versus 44%), this did not quite reach statistical significance: Chi-
squared test p=0.055. 
In summary, drug-exposed infants were at significantly greater risk of visual 
abnormalities at six months of age than non drug-exposed matched infants after 
correcting for excess alcohol exposure in utero. There was no significant 
association between six month visual outcome and NAS or drug exposure group 
suggesting that all drug exposed infants were at risk. 
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5.4 Developmental outcomes 
All infants underwent a full Griffiths developmental assessment. A fail was 
defined as a GQ < 85: all of these infants were referred for further assessment to 
either hospital or community follow up clinics. All comparison infants passed the 
developmental assessment; in contrast eight drug-exposed infants failed (26/26 
controls pass vs 73/81 cases pass; Z test for 2-proportions, p=0.003). 
The GQ and sub-quotient scores were not normally distributed; data were 
therefore described as medians and comparisons done with Mann-Whitney tests. 
Developmental outcomes for each sub-quotient and overall GQ scores are shown 
in Table 5-5. The drug-exposed infants had significantly reduced development 
quotients for all sub scales and reduced GQ scores compared to comparison 
infants (Figure 5-3). Two drug exposed infants had abnormalities of tone: one 
infant had generalised hypotonia and one had unequal tone of the upper limbs. 
Potential confounders for developmental outcome were maternal smoking, 
antidepressant use and excess alcohol intake during pregnancy. A linear 
regression model was used to assess if these factors confounded the 
developmental outcome as follows: 
Regression equation 
GQ = 106 - 8.06 Status no - 2.18 Smoker + 0.05 Antidepressant - 1.17 Alcohol 
 
 
Predictor                               Coef  SE          Coef              T              P 
Constant                              105.873            1.791          59.10        0.000 
Status                                    -8.056            2.024          -3.98         0.000 
Smoker                                  -2.184            2.283          -0.96         0.341 
Antidepressant                        0.052            2.600           0.02         0.984 
Alcohol                                  -1.165            1.722          -0.68         0.500 
 
Therefore, the drug-exposed infants had significantly poorer developmental GQ 
scores after correcting for maternal smoking status, antidepressant use and 
excessive alcohol intake during pregnancy. Adjusted p-values after correcting for 
maternal smoking status, antidepressant use and excessive alcohol intake in 
pregnancy are shown in Table 5-5. 
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Of the eight drug-exposed infants who failed the developmental assessment, six 
infants (75%) had concurrent significant visual problems which included reduced 
visual acuity in all cases. Four of the eight infants who failed the developmental 
assessment had abnormal pattern VEPs (absent response to 60 minute check size 
in three, delayed response to 15 minute check size in one). 
Infants who failed the visual assessment performed poorer on their 
developmental scales than infants who passed the visual assessment: median GQ 
infants who failed = 95 vs median GQ infants who passed = 100; Mann-Whitney 
test p <0.001. A linear regression model was used to assess the independent 
effect of visual impairment on developmental outcome (outcome variable: GQ 
score, predictor variables: group, smoking status, alcohol excess status, visual 
impairment). Using this model, visual impairment was found to be independently 
associated with lower developmental scores (p<0.001). 
Developmental sub-quotients and GQ scores were compared between drug-
exposed infants who received pharmacological treatment for NAS and those who 
did not. Infants treated for NAS performed significantly poorer in their 
locomotor, personal-social and language subscales, as well as having a 
significantly reduced overall GQ score (Table 5-6). 
Developmental outcomes were also compared between infants who were 
accommodated (n=20) and infants who were in the care of their biological 
parents (n=61). Accommodated infants performed poorer on their developmental 
scales than infants not accommodated: median GQ accommodated infants = 92 
vs median GQ not accommodated = 97; Mann-Whitney test p = 0.003. However, 
infants who were accommodated were more likely to have been treated for NAS 
in the newborn period (accommodated infants 70% NAS vs non accommodated 
43%; Chi 2 test p = 0.039) and were more likely to have been exposed to 
benzodiazepines and stimulants in utero (accommodated infants 90% poly-drug 
exposure vs non accommodated 63%; Chi 2 test p = 0.015). 
 
 
Chapter 5  176 
Table 5-5 Developmental outcome of cases and controls 
 
Development 
Cases 
(n=81) 
Controls 
(n=26) 
p-
value 
 
Adjusted p-
value 
  
Locomotor 
102 
(93-107) 
111 
(101-111) 
<0.001  0.006   
Personal-social 
94 
(88-96) 
99 
(94-103) 
<0.001  0.001   
Language-
hearing 
105 
(105-109) 
109 
(105-109) 
<0.001  0.007   
Eye-hand 
94 
(86-99) 
104 
(99-104) 
<0.001  0.001   
Performance 
96 
(86-100) 
101 
(101-111) 
<0.001  0.002   
GQ 
97 
(93-100) 
105 
(101-108) 
<0.001  <0.001   
Data are medians (inter-quartile ranges). Statistical analysis was done using Mann-Whitney tests. 
Adjusted p-values are after correcting for maternal smoking status, antidepressant use and excess 
alcohol consumption in pregnancy using linear regression models. 
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Table 5-6 Developmental outcome and NAS 
 
Development NAS (n=40) No NAS (n=41) p-value 
Locomotor 98 (87-102) 102 (94-107) 0.012 
Personal-social 89 (84-94) 94 (89-99) 0.016 
Language-hearing 105 (100-105) 105 (105-109) 0.011 
Eye-hand 94 (84-99) 94 (90-99) 0.137 
Performance 96 (86-100) 96 (91-101) 0.329 
GQ 95 (91-99) 99 (94-102) 0.008 
Data are medians (inter-quartile ranges). Statistical analysis was done using Mann-Whitney tests. 
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Figure 5-3 Boxplot of Griffiths GQ scores 
Drug-exposed infants had significantly reduced overall neurodevelopment scores compared 
to control infants: Mann-Whitney test p<0.001. Six of the eight infants who failed the 
developmental assessment (GQ < 85) had coexisting visual impairment. 
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5.4.1 Development and drug exposure group 
Developmental quotients were compared between infants in the five different 
drug exposure groups. There were significant differences between groups with 
infants exposed to increasing in utero poly drug exposure having lower 
development quotients (Table 5-7, Figure 5-4). 
An association was sought between the dose of prescribed maternal methadone 
prior to delivery and six month neurodevelopmental outcomes. The median 
methadone dose did not differ between infants who passed and failed the 
developmental assessment: median dose of infants who failed = 52.5 vs median 
dose of infants who passed = 50.0; Mann-Whitney test p = 0.923. In addition 
there was no correlation between prescribed maternal methadone dose and 
Griffiths GQ score: Pearson‟s correlation p = 0.175. 
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Table 5-7 Developmental outcome and drug exposure 
 
Development Drug exposure group 
 1  2 3 4 5 p-value 
Locomotor 104.5 102.0 102.0 98.0 93.0 0.020 
 (98-118) (95-107) (98-107) (93-102) (84-102)  
Personal-
social 
96.5 94.0 94.0 89.0 89.0 0.062 
 (94-103) (90-98) (89-94) (84-94) (84-97)  
Language 107.0 109.0 105.0 105.0 105.0 0.115 
 (101-109) (105-109) (105-109) (105-105) (98-105)  
Eye-hand 94.0 99.0 94.0 94.0 94.0 0.039 
 (94-99) (94-104) (89-99) (82-99) (84-97)  
Performance 96.0 96.0 96.0 96.0 91.0 0.092 
 (91-101) (91-101) (91-101) (86-96) (82-96)  
GQ 100 99.5 99.0 95.0 93.0 0.002 
 (97-103) (98-103) (94-100) (93-97) (89-98)  
 
Data are medians with inter-quartile ranges given in brackets below. Statistical tests were done 
using Kruskal-Wallis tests. 
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Figure 5-4 Boxplot of development scores and drug exposure  
There were significant differences between groups with infants exposed to increasing poly 
drug misuse having lower scores (Kruskal-Wallis test; p=0.002). 
 
 
In summary, at six months of age drug-exposed infants had lower 
neurodevelopmental scores compared to comparison infants matched for 
gestation, birth weight and socio-economic group even after correcting for 
maternal smoking status, antidepressant use and excess alcohol intake during 
pregnancy. Infants who were treated for NAS performed poorer than infants not 
treated for NAS and infants exposed to poly drug misuse in utero performed 
poorer than infants exposed to opiates alone. 
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5.5 Neonatal VEPs and outcomes 
5.5.1 Neonatal flash VEPs and visual outcome  
Seventy nine drug-exposed infants underwent both neonatal flash VEP recording 
and six month clinical visual assessment. Neonatal flash VEPs were compared 
between infants who passed and failed the clinical visual assessment at six 
months of age. For the purpose of analysis infants in the borderline category 
were defined as normal. There were no differences in morphology (Chi 2 test; 
p=0.329), presence of P1 components (Chi 2 test; p=0.596) or presence of P2 
components (Chi 2 test; p=0.466) between groups. Median VEP amplitude did not 
differ between groups with either the bright flash (pass 29 µV vs fail 22.4 µV; 
Mann-Whitney test p=0.159) or the dim flash (pass 11 µV vs fail 9.6 µv; Mann-
Whitney test p=0.927). Similarly, median P1 and P2 latencies did not differ 
between groups: P1 latency pass 130 ms vs fail 149 ms, Mann-Whitney test 
p=0.751; P2 latency pass 207 ms vs fail 207 ms, Mann-Whitney test p=0.547. 
The association between the neonatal flash VEP and six month clinical visual 
outcome is shown in Table 5-8. Neonatal flash VEPs were classified as normal / 
abnormal as previously described (Chapter 4.3.3). The sensitivity of an abnormal 
neonatal VEP at detecting an abnormal visual outcome was 60% (18/ 18+12). 
Specificity was 51% (25/ 24+25). Positive and negative predictive values of the 
neonatal flash VEP were 43% and 68% respectively. 
Table 5-8 Neonatal flash VEPs and visual outcome 
 
 
Visual outcome 
Abnormal (Fail) Normal (Pass) 
Neonatal flash VEP 
Abnormal 18 24 
Normal 12 25 
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5.5.2 Neonatal flash VEPs and developmental outcome  
Seventy nine drug-exposed infants underwent both neonatal flash VEP recording 
and developmental assessment at six months of age. An abnormal developmental 
assessment was defined as a GQ score < 85. Flash VEPs were defined as normal / 
abnormal as previously described (Chapter 4.3.3). The relationship between the 
neonatal VEP and subsequent developmental outcome is shown in Table 5-9. An 
abnormal neonatal flash VEP had a high sensitivity (5/ (5+1) = 83%) but low 
specificity (36/ (36+37) = 49%) for predicting developmental outcome. The 
predictive value for abnormal developmental outcome of an abnormal neonatal 
flash VEP (positive predictive value) was 12% (5/ 37+5) and the  predictive value 
for normal developmental outcome of a normal neonatal flash VEP was 97% (36/ 
36+1). 
 
Table 5-9 Neonatal flash VEPs and developmental outcome 
 
 
Developmental outcome 
Abnormal (Fail) Normal (Pass) 
Neonatal flash VEP 
Abnormal 5 37 
Normal 1 36 
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5.5.3 Neonatal flash VEPs and six month pattern VEPs 
Seventy seven drug-exposed infants underwent both neonatal flash VEP 
recording and six month pattern VEP recording. Flash and pattern VEPs were 
designated as normal / abnormal as previously described. Table 5-10 
demonstrates the association between the newborn flash VEP and six month 
pattern follow up VEP. There was little correlation between the newborn flash 
VEP and the six month pattern VEP: the sensitivity and specificity of an 
abnormal neonatal flash VEP at predicting an abnormal pattern VEP at 6 months 
were 39% and 39% respectively (positive predictive value = 33% and negative 
predictive value = 46%). 
Table 5-10 Neonatal flash VEPs and infant pattern VEPs 
 
 
Six month pattern VEP 
Normal Abnormal 
Neonatal flash VEP 
Normal 17 20 
Abnormal 27 13 
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5.6 Summary of six month assessment 
At six months of age methadone-exposed infants were more likely to have visual 
abnormalities than comparison infants, even after correcting for excess in utero 
alcohol exposure (40% vs 8%; adjusted p=0.007). The attributable risk was 80% 
suggesting that 80% of visual abnormalities seen in the drug-exposed cohort were 
attributable to methadone exposure. Abnormalities in the methadone-exposed 
cohort included nystagmus (11%), strabismus (25%) and reduced VA (22%).  
Electrophysiological abnormalities persisted at six months of age: methadone- 
exposed infants had smaller amplitude pattern VEPs (25 μV vs 34 μV; p=0.005) 
with delayed peak latencies (115ms vs 99ms; p=0.019) and fewer responses at 
the small check size (p=0.003), compared to controls. 
Methadone-exposed infants had significantly lower neurodevelopmental scores 
compared to comparison infants (GQ 97 for cases vs 105 for controls; p<0.001), 
even after correcting for maternal smoking, antidepressant treatment and 
excess alcohol consumption during pregnancy. Infants exposed to poly-drug 
misuse and treated for NAS in the newborn period performed particularly poorly 
on their neurodevelopmental scores. Visual impairment was independently 
associated with poor neurodevelopmental outcome. 
The neonatal VEP had a low positive predictive value for six month visual and 
neurodevelopmental outcome and would therefore seem to be of limited value 
in predicting which infants warrant follow-up assessment. 
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6 Chapter 6 Discussion 
This study was prompted by awareness that a growing number of patients 
referred to the local paediatric ophthalmology and visual electrophysiology 
departments with visual problems had a history of methadone exposure, and by 
increasing evidence of opiate related visual problems, as outlined in Chapter 1. 
Substitute methadone is the currently recommended treatment for pregnant 
opiate-dependent women, with advantages for mother and baby, including 
stabilisation of maternal lifestyle and reduced incidence of IUGR (5,129). The 
disadvantages of methadone use during pregnancy include an increased 
incidence of NAS and possible detrimental effects on infant visual and 
neurological development. The latter are variably reported in the literature, and 
have not been properly quantified to date. This study sought to explore the 
effects of in utero methadone exposure upon early infant visual development 
and also to assess the use of the VEP in predicting infant outcomes including NAS 
and subsequent visual and neurological development. 
6.1 Subject demographic characteristics 
Mothers: 
Women who misuse drugs in pregnancy commonly suffer other consequences of 
social deprivation such as physical and mental ill health and poor nutritional 
status. The vast majority of drug-misusing mothers in this study were from the 
lower socioeconomic groups (median DEPCAT 7). They did however have a 
normal BMI (median 23), and this did not differ significantly from that of the 
comparison mothers. Cigarette smoking was more common in the drug-misusing 
population than the population as a whole: 95% of drug-misusing mothers in the 
study cohort smoked compared to 60% of the comparison mothers. It is 
recognised that self reporting significantly underestimates the number of 
pregnant smokers and therefore the incidence of smoking in both groups may 
have been higher than reported (130). Mental health problems requiring 
pharmacological treatment were present in 14% of drug-misusing mothers – this 
is comparable to the 12% described in a large local cohort of drug-misusing 
mothers by Dryden et al (8). 
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Infants:  
It is well recognised that infants of drug-misusing mothers are more likely to be 
born prematurely and to suffer IUGR compared to infants of non-drug-misusing 
mothers (10,11). It was therefore very important to match drug exposed infants 
with comparison infants for gestation and birth weight, and this objective was 
achieved.  As anticipated, the mean birth weight of the drug-exposed cohort was 
below the 50th centile (2892 grams; 25th centile). Despite matching for birth 
weight, the drug-exposed infants had significantly smaller head sizes compared 
to comparisons. This effect appeared to be due to the higher proportion of 
smoking mothers in the drug-exposed group: after correcting for smoking status 
there was no longer any significant difference in head sizes. This finding is in 
contrast to those of Shipton et al who found significantly smaller head 
circumferences in a much larger cohort of methadone exposed infants compared 
to gestation and social deprivation matched non-methadone exposed infants of 
smoking mothers (131). Breast feeding rates were similarly poor in both groups, 
denying infants the many advantages of breast feeding. 
Drug exposure: 
In common with other authors, and consistent with the pilot data, a high 
incidence of poly-drug misuse was found in the study cohort (8,32,122). The 
most commonly misused substances were illicit opiates and benzodiazepines. 
Exposure to poly pharmacy makes interpretation of study results complicated 
and necessitated the recruitment of a large number of infants. The sample size 
calculation estimated that 100 infants would require to be recruited to provide a 
cohort of 20 infants exposed to methadone alone, but in reality only nine infants 
in the drug-exposed cohort were exposed to methadone alone. It is likely that 
the comprehensive collection of toxicology samples, including infant meconium, 
provided more accurate information than was available in the pilot study. The 
vast majority of women on the methadone programme continued to use illicit 
opiates during pregnancy and it should be noted that that there is evidence that 
the beneficial effects of substitute methadone on infant birth weight are lost 
with concurrent illicit opiate use (14). Identifying the substances used by the 
mother is crucial if appropriate recommendations are to be made about 
substitute treatment.  
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Alcohol exposure: 
Meconium analysis was undertaken to assess for excess alcohol consumption in 
pregnancy. Overall 41% of the drug-exposed cohort and 23% of comparisons 
tested had elevated FAEEs on meconium analysis suggestive of heavy alcohol 
intake during pregnancy although no infant had a clinical diagnosis of fetal 
alcohol syndrome. Regression models were used to correct for the potential 
confounding effect of excess alcohol exposure on both visual and developmental 
outcomes: this has not previously been documented in the published literature. 
Neonatal abstinence syndrome: 
Forty eight percent of the drug-exposed cohort received treatment for NAS; 
which is comparable with the 40-80% reported in other studies and consistent 
with previous local audit (4,8). First line treatment was oral morphine solution 
and second line treatment was phenobarbital (30), similar to practice in other 
units in the UK (132). Predictably infants requiring treatment for NAS had a 
significantly longer hospital stay than infants not treated, but even untreated 
infants stayed in hospital three times longer than comparisons. These data 
underline the significant resources which these infants utilise within the health 
care setting. 
6.2 Neonatal visual electrophysiology 
6.2.1 Neonatal VEPs 
In the neonatal period, there were significant differences between the flash 
VEPs of drug-exposed infants and those of matched comparison infants. The 
most common flash VEP abnormalities detected in the drug-exposed cohort were 
reduced amplitudes, immature waveforms and an absence of P1 components. In 
comparison the control infants‟ VEPs were of larger amplitude and of mature 
waveform with a greater proportion of both P1 and P2 components. Infants 
exposed to methadone in utero were over five times more likely to have an 
abnormal neonatal VEP than non-exposed infants (relative risk of 5.6).The pilot 
study finding of delayed VEP latencies in drug-exposed infants was not replicated 
Chapter 6  189 
in the larger study: this may reflect better matching of gestational age between 
cases and controls.  
Prenatal substance misuse appears to result in an immaturity in the evolution of 
normal cortical visual pathways: this electrophysiological finding accords with 
the clinical finding of delayed visual maturation described in Pilot Study 4 and by 
other authors (64,125). All drug exposed infants‟ neonatal VEPs were recorded 
prior to commencement of oral morphine or phenobarbital treatment, so this 
was not a confounding factor. 
There was no relationship between the neonatal VEP and the onset or severity of 
NAS, suggesting that the electrophysiological abnormalities described in 
association with maternal drug misuse were not reflective of the temporary 
cortical upset caused by neonatal withdrawal. This is an important negative 
finding, as infants with no NAS who tend to be discharged early from hospital 
with no follow up demonstrate the same abnormalities in their neonatal visual 
electrophysiology as those infants kept under close follow up.  
Similarly, there were no differences in VEPs between infants in different sub-
groups of illicit drug exposure. Regression analysis was used to investigate 
further the independent effects of different drugs of misuse on the newborn VEP 
and suggested that the differences in flash VEPs demonstrated between drug-
exposed and comparison infants were associated with in utero methadone 
exposure and not the other drugs of misuse. It is possible that the other drugs of 
misuse may have had an independent effect on the newborn infant VEP but the 
sub-groups were too small to provide sufficient power to detect a difference. It 
is also possible that any differences were masked by the effect of methadone 
exposure. As all the study infants had been exposed to methadone in utero we 
were unable to determine the effects of other illicit drug use alone on the infant 
VEP. 
A change in the flash luminance resulted in significant differences in flash VEPs 
with a brighter light stimulus producing larger amplitude responses with reduced 
latencies and more mature waveform morphology. This highlights the 
importance of standardising flash stimuli for research trials. Data are not 
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comparable between laboratories unless equipment has been calibrated to 
exactly the same standards.  
In contrast to the flash VEP, there were only minor differences in flicker VEPs 
between drug-exposed and comparison infants.  The flicker VEP is a novel 
technique and little normative data are available for the newborn period. 
Studies suggest that the optimal flicker frequency increases with increasing 
postnatal age and maturity; however the significance of the flicker VEP 
amplitude is not yet understood. It is therefore not possible to explain the 
differences demonstrated in the flicker VEP amplitude, which although of 
statistical significance, may not be of clinical significance. 
6.2.2 Proposed mechanism for alteration in VEPs 
The VEP is a cortically generated visual response and therefore any adverse 
effect of opiates or other drugs of misuse on either the eye or brain may result 
in an alteration of visual electrophysiology. 
There is evidence from animal studies that methadone accumulates in the eye in 
the developing fetus. Pertschuk et al (1977) used an immunofluorescence 
technique to compare the eyes of adult rats exposed to methadone with 
neonatal rats that had been exposed to methadone in utero. 32% of the neonatal 
rats who had been exposed to methadone prenatally demonstrated positive 
immunofluorescence localised to the retina; by contrast no adult rats showed 
evidence of methadone staining in the eye (133). Similarly, Davis et al (1979) 
found that postnatal methadone administration to both rats and frogs led to an 
accumulation of methadone and its metabolites in the eye tissue at a 
concentration 100 times greater than that in the blood (134). 
Immunofluorescence studies have also demonstrated neuronal staining for 
methadone in the brain tissue of methadone addicts who had died of an 
overdose and in rats administered methadone (135,136). In both studies, 
methadone-staining was seen in the hypothalamus, thalamus, hippocampus, 
amygdale, cerebellum and brain stem. 
Methadone exposure also leads to an alteration of neurotransmitters within the 
brain. Guo et al (1990) investigated the effect of prenatal methadone exposure 
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on acetylcholine levels in the brains of neonatal rat pups and found reduced 
acetylcholine content in the striatum (137). Robinson et al (1996) demonstrated 
increased acetylcholine turnover in rat pups exposed to methadone in utero 
compared to controls (138) and choline acetyltransferase expression (the 
synthesising enzyme for acetylcholine) was reduced in the brains of rat pups 
exposed to methadone in utero compared to controls (139). The combined or 
individual effects of reduced acetylcholine content, increased turnover and 
reduced choline acetyltransferase activity may lead to a depletion of 
acetylcholine in the brain with a resultant alteration in visual electrophysiology. 
In a follow-on study Wu et al (2001) found methadone exposed rat pups to have 
a 40-50% reduction in neurotrophic nerve growth factor compared to controls, 
suggesting a mechanism for the alteration in cholinergic neurons shown in other 
studies (140).  
Methadone and morphine exposure have an adverse effect on opiate receptor 
binding in animal models (141,142): prenatal exposure to methadone resulted in 
reduced µ-opioid binding affinity in the neonatal rat pup (141) and prenatal 
morphine administration significantly altered regional development of opiate 
receptors in the brains of the rat pups (142). Perinatal morphine administration 
also causes a reduction in neuronal packing density in the somatosensory cortex 
and preoptic area of the hypothalamus with morphine-induced reduction of 
basilar dendritic growth in cortical pyramidal neurones (143).  
Although no similar studies exist in human neonates exposed to methadone in 
utero, any combination of the mechanisms described above could lead to an 
alteration in visual electrophysiology in the human newborn infant. 
6.3 Six month follow up 
6.3.1 Growth parameters 
There were no significant differences in weight or head circumference between 
drug-exposed and comparison infants when seen for assessment at six months of 
age, reflecting normal postnatal growth. Importantly, drug exposed infants had 
demonstrated catch up head growth. A previous study also documented catch up 
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weight and head growth by 18 months of age in children who had been exposed 
to opiates in utero (38): that study found that children did not demonstrate 
catch up in longitudinal growth; length was not recorded as part of the current 
study protocol. 
6.3.2 VEPs 
Six month follow-up demonstrated that VEP abnormalities persisted beyond the 
neonatal period, with drug-exposed infants having smaller amplitude pattern 
responses with delayed latencies. Drug-exposed infants also had significantly 
fewer VEP responses to the small check size in keeping with the clinical picture 
of reduced visual acuity and delayed visual maturation. 
The fact that VEP abnormalities persisted to six months of age suggests that the 
effect is not due to residual circulating opiate and is consistent with a 
permanent teratogenic effect of prenatal drug exposure on the developing visual 
system.  By six months of age no infants were on treatment for or had symptoms 
of NAS. 
6.3.3 Visual outcome 
A significant proportion (40%) of the drug-exposed cohort failed the clinical 
visual assessment at six months of age, even after correcting for excess alcohol 
exposure in utero. Infants exposed to methadone in utero were over five times 
more likely to have a clinical visual abnormality at six months of age than non-
exposed infants (relative risk of 5.1). There was no association between visual 
outcome and either NAS or drug exposure group, suggesting that all infants born 
to mothers on the methadone programme during pregnancy are at risk of visual 
problems, regardless of maternal illicit drug use. 
Nystagmus 
The overall incidence of nystagmus in infants who had been exposed to 
methadone in utero was 11%. By comparison, Lloyd et al (2006) found an 
incidence of nystagmus of 5% in a population of opiate exposed infants (4). 
Infantile nystagmus is extremely rare in the general population: the 
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Leicestershire nystagmus survey found an incidence of 0.24% (24 cases per 
10,000 population) (144). The incidence of nystagmus in infants who had been 
exposed to methadone in utero was therefore 50 fold that of the general 
population.  
Pilot Study 4 found that significantly more infants who had a history of NAS 
demonstrated nystagmus compared to those without a history of NAS (92% versus 
38%, p=0.017) (125); this finding was not replicated in the main study (p=0.482), 
possibly due to the smaller number of infants in the main study with nystagmus 
(n=9). 
It has been proposed that infantile nystagmus may be caused by visual 
deprivation, resulting in oculomotor development outpacing sensory 
development (145). A developmental model of infantile nystagmus suggests that 
it develops as a response to reduced contrast sensitivity in an early “critical 
period”. An alternative explanation may be abnormal µ-opioid receptor binding 
in the cerebellum of the developing brain (64).  Animal studies and post-mortem 
human studies have demonstrated neuronal staining for methadone in the 
cerebellum (135,136). Administration of opioids to healthy human subjects leads 
to a temporary disruption of ocular fixation, resulting in nystagmus, possibly due 
to an effect on opioid receptors within the cerebellum (146). 
Strabismus 
Disruption of coordinated binocular vision early in life leads to strabismus and 
varying degrees of amblyopia, with the extent of impairment dependent on the 
time of onset, duration and type of visual deprivation (147). Twenty-five percent 
of the methadone-exposed cohort had strabismus, which is in close agreement 
with findings reported elsewhere (61,62). This is much higher than in a similarly-
aged general population: screening of 38,000 infants showed a prevalence of 
strabismus of 1.3% (71). The proportion of children in the main study with 
strabismus who had NAS or not did not differ: 13/41 versus 7/40, Fisher‟s exact 
test, p=0.138, supporting the finding by Gill that strabismus does not appear to 
be related directly with NAS (61).  
Delayed visual maturation 
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DVM was diagnosed in 14% of infants exposed to methadone in utero. DVM is 
generally a retrospective diagnosis made in infants who show delayed visual 
development for their postnatal age but then demonstrate catch up. Since the 
follow up assessment did not take place until six months of age, it is possible 
that some cases of DVM could have been missed. Both the clinical diagnosis of 
DVM and immature VEP morphology demonstrated in the neonatal period suggest 
that prenatal exposure to methadone and other drugs of misuse causes a delay in 
the development of normal visual processing during the fetal and/or early 
neonatal period. 
Fundal findings 
Only two children in the retrospective case series (Pilot study 4) demonstrated 
fundal abnormalities. Since dilating eye drops were not used in the six month 
follow-up visual assessment, only infants who were seen by colleagues in 
ophthalmology had dilated fundoscopy undertaken, of whom only one had an 
abnormal examination documented (hyperplastic optic nerves). This is very 
much in contrast to the ophthalmic manifestations of fetal alcohol syndrome, 
where over half of children demonstrate optic nerve hypoplasia. 
Cerebral visual impairment 
CVI was diagnosed in 25% of children in the retrospective case-series. CVI causes 
problems with processing of complex visual scenes and visually guided movement 
(72-74). This results in children having difficulties in picking out objects from a 
visually crowded scene, recognising faces and emotions, reading and copying, 
and difficulty with steps, curbs and floor boundaries. These difficulties can 
affect performance and behaviour and could be one mechanism for the reported 
developmental delay and behavioural problems recognised in these children. 
This was the first time that CVI had been reported in association with prenatal 
opiate exposure and is likely to be an underestimate as CVI is commonly 
diagnosed around school entry age (125). The cohort of infants in the main study 
was too young at the six month follow-up to assess for CVI, highlighting the 
importance of longer term follow up of this cohort. 
Effects of different drugs of misuse 
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Mulvihill et al (2007) suggested that infants exposed to a combination of opiates 
and benzodiazepines may be at higher risk for visual abnormalities (64). They 
proposed that concurrent use of benzodiazepines may prevent the up regulation 
of µ-opioid receptors in the brain where opiates commonly bind. In this study 
89% of infants who developed nystagmus were know to have been exposed to 
benzodiazepines in addition to opiates in utero, this was higher than the 
proportion of infants exposed to benzodiazepines in utero who did not develop 
nystagmus (89% vs 68%), but the difference was not significant (p=0.268). 
6.3.4 Neurodevelopmental outcome 
Infants exposed to methadone in utero demonstrated reduced 
neurodevelopment quotients compared to control infants matched for birth 
weight, gestation and socio-economic group, even after correcting for maternal 
smoking, antidepressant use and excess alcohol consumption during pregnancy. 
This was a global delay with significant differences between all developmental 
sub groups. Neurodevelopmental delay has been widely reported in the 
literature in association with maternal opiate misuse and may be secondary to 
many different factors. 
Social circumstances: Neurodevelopmental outcome in these infants may be 
confounded by social circumstances. Factors associated with drug misuse such as 
smoking, alcohol misuse, poor nutrition, housing and education all have 
potential adverse effects on infant development. To try to correct for these 
factors the controls were matched to cases for socioeconomic group and 
regression models used to correct for the potential confounding effects of 
maternal smoking, maternal antidepressant use and excess alcohol use in 
pregnancy. We cannot however rule out a specific impact of parental addictive 
behaviour on the neurodevelopmental outcome of these children. By six months 
of age 76% of drug-exposed infants were in the care of their biological parents 
and 24% were accommodated (17% in foster care and 7% accommodated with a 
family member). No infant had been adopted. Interestingly, infants who were 
accommodated performed poorer on their neurodevelopmental scores than 
infants living with their biological parents: these infants were, however, more 
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likely to have been treated for NAS in the newborn period and to have been 
exposed to poly-drug misuse including benzodiazepines and stimulants in utero. 
Visual problems: Visual impairment may cause delay of developmental 
milestones, particularly eye-hand co-ordination, and correction of visual 
abnormalities may lead to a subsequent improvement in development. Visual 
impairment was found to be an independent predictor of poor 
neurodevelopmental outcome and will therefore have contributed to reduced 
neurodevelopmental scores in these infants. 
Direct effect of drug exposure: Post mortem studies in narcotic addicts who died 
from a methadone overdose show uptake of methadone in the hypothalamic 
nuclei, sensory-motor cortex, cerebellum, hippocampus and thalamic nuclei 
(135). There may therefore be a direct effect of prenatal exposure to 
methadone on the developing brain which contributes to the 
neurodevelopmental problems seen.  
6.3.5 Proposed overall aetiology 
The nature of the abnormalities described in this study (abnormal VEPs at birth 
and six months of age, reduced visual acuity, DVM, nystagmus, strabismus, and 
neurodevelopmental delay) suggests a detrimental effect of in utero drug 
exposure on the brain rather than an effect on the eye per se. Although ERGs 
were not recorded as part of the main study protocol, the majority of children in 
Pilot Study 4 had normal ERGs, suggesting that retinal function in these children 
is likely to be normal. A general toxic effect of methadone and other drugs of 
misuse on the brain could result in acetylcholine and neurotrophic nerve growth 
factor depletion and cause the VEP abnormalities demonstrated with associated 
poor vision from birth. Since good vision is required to develop binocularity and 
regulate gaze stabilising mechanisms, poor vision from birth could explain the 
clinical visual abnormalities described at follow up. This mechanism is well 
demonstrated in animal studies: newborn monkeys with normal vision develop 
nystagmus and strabismus after a period of forced blindness secondary to having 
their eye lids sutured closed for a period of time. Similarly in kitten models, 
binocular visual deprivation via surgical or optical strabismus resulted in a severe 
loss of cortical binocularity (148,149). 
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6.4 Study strengths 
Pilot study and sample size calculation: 
A major strength of this study was the undertaking of appropriate pilot work. A 
preliminary pilot study demonstrated the feasibility of measuring flash VEPs in 
newborn infants exposed to methadone in utero (122). This pilot work 
demonstrated the poly-drug exposure of these infants and provided data to 
inform the sample size calculation for the study. The pilot work undertaken to 
inform the follow-up phase of the study (Pilot study 4) ensured that the visual 
assessment protocol used was appropriate for the population under investigation 
(125). The large sample size of 100 infants for the main study allowed the 
assessment of individual drugs on the outcome measures and in particular 
allowed analysis of a subgroup of infants exposed to opiate alone. 
Data collection and drug exposure:  
Another strength of the study was the prospective nature of data collection and 
the comprehensive pattern of drug exposure obtained from maternal interview, 
maternal notes and toxicology samples. This is especially relevant for the follow-
up phase of the study as the vast majority of studies investigating longer term 
outcomes in infants exposed to drug misuse in utero rely on retrospective 
collection of drug-exposure data.  
Recruitment rate:  
The high recruitment rate of 98% ensured that the study population was 
representative of the general drug-misusing population as a whole. 
Control population: 
To try to correct for potential confounders, the comparison infants were 
matched to the drug-exposed infants for birth weight, gestation and socio-
economic group. To ensure that the comparison population was not exposed to 
excess alcohol in utero, meconium samples were collected for FAEE analysis.  
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Blinding:  
Where possible, assessments were undertaken blinded to exposure status. As the 
chief study researcher it was not possible for the author to be blinded to the 
infant‟s exposure status but repeat VEP analysis (both flash and pattern VEPs) 
was undertaken by a second individual who was blinded to the infant‟s exposure 
status. Any discrepancy in opinion was referred to a third party who was also 
blinded. This should have ensured there was no bias in interpretation of the VEP 
results. Six month visual follow-up was undertaken in conjunction with an 
optician who was blinded to the infant‟s exposure status, thereby reducing bias 
for the visual follow up. 
6.5 Study limitations 
Confounders: 
Children who have been exposed to methadone in utero are also commonly 
exposed to other adverse consequences associated with maternal drug misuse, 
such as maternal physical and mental ill health, poor nutritional status, smoking 
and alcohol consumption (1,6). Despite matching successfully for DEPCAT scores 
and using regression models to correct for maternal smoking and excess alcohol 
intake it is possible that there remain differences other than pre-natal drug 
exposure which could account for the differences seen between groups.  
Blinding: 
The Griffiths neurodevelopmental assessment was undertaken by the author 
alone and it was not possible for her to be blinded to the infant‟s exposure 
status as she was responsible for recruitment, data collection and follow-up 
organisation. It is therefore possible there could have been some bias in 
interpretation of the developmental assessment. To minimise this, a well 
validated developmental scale for the assessment was used. 
Follow-up: 
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Retaining subjects from poor and disadvantaged backgrounds to follow-up 
studies is recognised to be challenging due to their chaotic lifestyles and 
frequent change of address. A 40% drop-out rate was predicted for the follow-up 
phase of the study to allow for this: actual drop-out rate was 21% in the cases 
and 48% in the controls, overall 30%. This compared favourably with other 
studies: Hunt et al (2008) had a drop out rate of 50% in their study of 133 opiate-
exposed infants (38). Every effort was made to optimise study retention 
including telephone calls to parents, reminder letters sent in the post, reminder 
telephone calls regarding visits and taxi transportation to the study hospital. A 
high loss to follow-up may introduce bias as the results of those infants lost to 
follow-up may significantly alter the final results: in this case it is proposed that 
infants whose family life is so chaotic that they are uncontactable for follow up 
are unlikely to perform better than infants who attend for follow up.   
Timing of follow-up: 
Six months was chosen for the follow up visit as the majority of visual problems 
could be diagnosed by this age and it was early enough to allow intervention if 
required in children with problems such as significant refractive errors. The six 
month appointment also allowed completion of follow up within the two year 
time duration of the study. The retrospective case series identified a subgroup 
of children with CVI which is usually not diagnosed until childhood (72,73) and so 
the proportion of children with visual problems may be higher if these children 
were to be followed up for a longer period of time.  
Six months of age is generally recognised as being too young to make an 
accurate assessment of neurodevelopmental outcome. Full assessment of 
neurodevelopment should ideally be made at approximately two years of age 
and in the pre-school year. It is possible that some children may develop 
neurodevelopmental problems not apparent at six months of age and in addition 
six months of age is too young to assess for behavioural problems which have 
been reported to be more common in drug-exposed children. It is therefore 
likely that the six month follow-up under represents the full scale of visual, 
developmental and behavioural problems affecting children of drug-misusing 
mothers. 
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As the study progressed it became apparent that it would be useful to follow-up 
this cohort of infants for longer term assessment and an Ethics Committee 
amendment was made to collect consent for future follow-up at the time of 
initial consent. 
Drug-exposure status: 
Maternal history is often unreliable as a method of detecting prenatal drug 
exposure. This study used a prospective five-point technique to determine drug 
exposure in the study infants (maternal case notes, maternal interview, 
maternal urine toxicology, infant urine toxicology, infant meconium toxicology). 
This provided a comprehensive assessment of drug exposure and compares 
favourably with other studies. There are however no toxicology samples which 
can be obtained from an infant which reflect first trimester drug exposure, and 
drug-misusing women often present late for obstetric care due to chaotic 
lifestyle and a reluctance to have involvement with social services. It is 
therefore possible that an infant could have been exposed to an illicit drug 
which was not detected, particularly in the first trimester of pregnancy. 
6.6 Clinical recommendations 
Infants who have been exposed to methadone in utero should be referred for a 
programme of visual assessment. Referral should be made from the neonatal 
unit to the local ophthalmology service. 
Neonatologists and paediatricians should be made aware of the risks of visual 
problems in infants exposed to methadone in utero and should enquire about 
and screen for these opportunistically when seeing children in clinic. 
Dissemination of the results of this study has been undertaken via presentation 
of the findings at national meetings and publication in peer-reviewed journals. A 
Press Release was circulated secondary to one of the publications and this has 
generated more widespread media attention (Appendix 9). 
Infants and children with proven ophthalmologic abnormalities should be 
referred for visual electrophysiology. There does not appear to be a role for VEP 
testing in the newborn period to help predict visual or developmental outcome. 
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All children who have been exposed to methadone in utero with developmental 
delay should be referred to ophthalmology, and assessment should include a 
structured questionnaire to assess for CVI. 
6.7 Future research and controversies 
The cohort of infants recruited for this study has prospectively collected data 
including neonatal and maternal demographics and drug exposure status and so 
would therefore be ideally suited to longer-term visual and developmental 
follow-up.  
Longer term visual follow up should include assessment for CVI. Developmental 
assessment should also be undertaken to determine how many children with 
developmental delay have associated CVI. Future research should also address 
whether a developmental programme could improve outcome in children with 
developmental delay and CVI. Longer term follow up would also allow an 
assessment of how accommodation status impacts on the child‟s 
neurodevelopmental and behavioural outcomes. 
Methadone is widely prescribed to pregnant opiate-dependent women. Use of 
methadone in pregnancy conveys various advantages to mother and infant 
including stabilisation of maternal lifestyle and reduced incidence of both 
preterm delivery and IUGR (5,10,11). However infants born to methadone-
maintained mothers have a significant incidence of NAS and longer term adverse 
visual outcomes. Provision of optimal health care is always a balance of the risks 
and benefits of any therapy but we also have a duty to “first do no harm”. 
Prescription of a substance that has been shown to have potential long-term 
teratogenic effects on the developing fetus must be critically reviewed. 
Further study should therefore investigate alternatives to methadone treatment 
for pregnant opiate-dependent women. Acute detoxification may be unsafe in 
pregnancy and relapse rates are high. Buprenorphine is a synthetic opiate which 
is used worldwide for opiate dependence with theoretical advantages over 
methadone in the treatment of opiate addiction in pregnancy due to reduced 
placental transfer (150). Limited published data on the use of buprenorphine in 
pregnancy suggest a good safety profile, a trend towards a shorter hospital stay 
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and reduced incidence of NAS for the newborn infant as well as potential 
advantage in terms of infant neural development (121,151). Future studies 
should investigate the role of buprenorphine versus methadone on both short 
and longer term infant outcomes. 
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7 Chapter 7 Appendices 
7.1 Appendix 1: Parent information sheet 
Visual and brain function in infants born to drug-using mothers 
Parental information sheet: Version 4 (Sept 2008) 
You are being invited to allow your baby to take part in a research study.  Before 
you decide, it is important for you to understand why the research is being done 
and what it will involve. Please read the following information carefully and 
discuss it with others if you wish. Ask us if anything is unclear or if you would 
like more information. Take time to decide whether or not you wish your baby to 
take part. 
What is the purpose of the study? 
Methadone is given to pregnant mums to help to stabilise their drug habit and 
improve their health in pregnancy.  The benefit of taking methadone in 
pregnancy is that the baby is less likely to be born prematurely; the downside is 
that he/she may develop withdrawal symptoms after birth.  At present we 
cannot tell which babies will get withdrawals, which is why we are planning this 
study. We believe that measuring vision and brain-wave activity (using tests 
which will not hurt the baby) will help to explain why some babies develop 
withdrawal symptoms, and may tell in advance which babies will be affected. 
This might help us to care better for babies in the future. Because drugs in 
pregnancy may affect babies‟ longer term vision and development, we would 
like to follow up your baby when he/she is 6 months old to check his/her vision 
and development. 
Why has my baby been chosen? 
We are asking all pregnant mums who are receiving methadone treatment 
and/or using other drugs in pregnancy and whose babies are born no more than 
four weeks early if their baby can take part in this study.   
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Does my baby need to take part? 
No. It is entirely up to you.  If you do decide that your baby can take part you 
will be given this information sheet to keep and be asked to sign a consent form.  
You will be free to withdraw from the study at any time and you won‟t have to 
give a reason.  If you decide not to take part or to withdraw, this will not affect 
the standard of care that your baby will receive. 
What will happen to my baby and myself if he/she takes part? 
While your baby is less than four days old, we will record their VEP (visual 
evoked potential) and their EEG (electroencephalogram). Small pads with leads 
will be placed on their head using paste which is like Vaseline. More pads on 
their chest will measure their heart rate and breathing. We will record the EEG, 
which is brain wave activity, for about an hour and video your baby so we know 
when he/she is asleep or awake. We will then record more brain wave activity 
while showing your baby flashes of light (the VEP). The tests are completely 
painless. No needles are involved. It will take about 1½ hours and you will be 
welcome to stay with your baby. 
From your baby: we will collect samples of urine and meconium (faeces) during 
the first few days after he/she is born. The baby‟s urine sample will be collected 
from a small bag stuck onto his/her bottom which is painless. The meconium will 
be collected directly from the nappy. 
From you: we will collect a urine sample when you come into hospital in labour 
and a blood sample from the placenta (afterbirth) afterwards. We know that lots 
of mums take extra drugs in pregnancy besides the methadone; the results of 
these tests will be kept confidential and will not be given to anyone else: they 
will not affect the care that you receive. 
These tests will help us to know which drugs are in your system and whether 
they reached your baby. 
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We will make an appointment to follow up your baby at 6 months of age to 
check their vision and development. This will usually be done at the Princess 
Royal Maternity but if you are unable to attend we will ask your permission to 
come and visit you. Follow up will involve a repeat VEP test and we will also 
check how well your baby sees. If there are any concerns about your baby‟s 
vision or development he/she will be referred to one of the specialists at 
Yorkhill Hospital.  
What are the possible risks of taking part? 
There are no risks to either yourself or your baby from taking part in this study. 
What are the possible benefits of taking part in this study? 
There is not expected to be any direct benefit to either yourself or your baby 
from taking part in this study.  There is a possibility that we may identify a 
problem with your baby‟s vision or development which would not otherwise have 
been detected until later, in which case we will refer you to a specialist. Taking 
part in the study may help future babies if the results allow us to improve the 
way we look after pregnant drug using mums and their babies. 
Suggestions and complaints 
If taking part in this research project harms your baby, there are no special 
compensation arrangements.  If your baby is harmed due to someone‟s 
negligence, then you may have grounds for a legal action but you may have to 
pay for it.  Regardless of this, if you wish to complain about any aspect of the 
way you have been treated during the course of this study, the normal National 
Health Service complaints mechanism may be available to you.  You can put any 
complaint in writing to Mrs. Anne Snape, Patient Liaison Manager, North Glasgow 
University Hospitals Division, 84 Castle Street, Glasgow G4 0SF (telephone 0141 
211 5112). If you have any suggestions to make regarding the study, please 
contact Dr. Helen Mactier (telephone 0141 211 5304). 
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Will my baby‟s taking part in this study be kept confidential? 
Unless you have any objections, we will inform your GP that your baby has taken 
part in this study. Otherwise, all information collected about your baby during 
the course of this research will be kept strictly confidential.   
What will happen to the results of the research study? 
Information gathered from this study will be analysed and the results submitted 
for publication in a medical journal.  Information may also be presented at 
scientific meetings.  Your baby will not be identified in any presentation or 
written document. 
Who is funding this research? 
The equipment required to record the VEP has been purchased for the Princess 
Royal Maternity by the Glasgow Royal Infirmary Appeals Trust.  None of the 
persons involved receives any money when a baby joins the study. 
Who has reviewed this study? 
This study has been approved by the Glasgow Royal Infirmary Ethics Committee. 
Contact for further information 
Dr Helen Mactier, Consultant Neonatal Paediatrician, can be contacted on 0141 
211 5304 or via Glasgow Royal Infirmary switchboard (0141 211 4000).  If you 
have any questions or concerns - please simply ask the midwife who is looking 
after your baby.  Her name will be on a card on your baby‟s incubator. 
Thank you for taking time to consider this research study. 
Dr Helen Mactier and Dr Laura McGlone 
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7.2 Appendix 2: Letter to G.P. 
Neonatal Unit, 
Princess Royal Maternity, 
8-16 Alexandra Parade, Glasgow. 
 
Visual and brain function in infants born to drug-using mothers. 
GP information Sheet Version 1, June 2008 
Dear Dr. 
Please be advised that your patient (name)…………………………………………….. 
Date of birth………………………………………….. 
Hospital number……………………………………… 
Address…………………………………………………………………………………. 
Is participating in the above study. This is a study of visual and cortical function 
in newborn infants exposed to methadone +/- other drugs in pregnancy.  The 
infant underwent EEG and VEP recordings during the first week of life, and will 
be recalled for visual function testing at the age of 6 months. 
If you have any queries, please contact Dr. Helen Mactier, Consultant 
Neonatologist at Princess Royal Maternity (telephone 0141 211 5249/5304) who 
will be happy to discuss them with you. 
Yours faithfully, 
 
Dr. Helen Mactier 
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7.3 Appendix 3: PRM neonatal abstinence syndrome 
guidelines 
Introduction to the NAS policy 
Neonatal Abstinence Syndrome (NAS) is a constellation of symptoms occurring in 
a baby as a result of withdrawal from physically addictive substances taken by 
the mother. These substances include methadone, benzodiazepines, opiates, 
cocaine and amphetamines as well as caffeine, nicotine and some antidepressant 
agents. The majority of infants with NAS in Glasgow will be withdrawing from 
opiates or opioids ± benzodiazepines. Almost all drug misusing mothers smoke in 
pregnancy; it is not known how much nicotine withdrawal contributes to 
symptoms.  
Diagnosing NAS 
Signs and symptoms of NAS include excessive irritability, in-coordinate sucking, 
vomiting, diarrhoea and poor weight gain. Rarely, convulsions may occur. The 
diagnosis of severity of NAS (and the need for pharmaceutical treatment) is 
largely subjective, but various scoring systems have been used in an attempt to 
standardise treatment. The scoring system currently used in Glasgow is the 
modified Lipsitz tool. The aim of treatment is to control symptoms to allow oral 
feeding, tolerable irritability and adequate weight gain. NAS is the likely 
diagnosis in an infant who demonstrates the signs and symptoms listed above 
and whose mother was known to have used addictive substances in pregnancy. 
Other common causes of excessive irritability can generally be excluded by 
careful history taking, clinical examination and measurement of blood sugar, 
calcium and magnesium. 
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Lipsitz Score Tool  
Signs 0 1 2 3 
Tremors (muscle 
activity of limbs) 
Normal Minimally 
increased when 
hungry or 
disturbed 
Moderate or 
marked increase 
when undisturbed; 
subside when fed 
or held snugly 
Marked increase 
or continuous 
even when 
undisturbed, 
progressing to 
seizure-like 
movements  
Irritability 
(excessive crying) 
None Slightly 
increased 
Moderate to 
severe when 
disturbed or 
hungry 
Marked even 
when 
undisturbed 
Reflexes Normal Increased Markedly 
increased 
  
Stools Normal Explosive, but 
normal 
frequency 
Explosive, more 
than 8 per day 
  
Muscle tone Normal Increased Rigidity   
Skin abrasions No Redness of knees 
and elbows 
Breaking of skin   
Respiratory rate 
/ minute 
< 55 55-75 76-95   
Repetitive 
sneezing 
No Yes     
Repetitive 
yawning 
No Yes     
Vomiting No Yes     
Fever No Yes     
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Management of NAS  
Simple measures to control symptoms of NAS include swaddling, the use of 
dummies and prolonged nursing. The pharmaceutical treatment of choice is the 
substance from which the infant is withdrawing.  
Treatment should be started if the Lipsitz score > 5 on two occasions 12 hours 
apart despite efforts to console the infant by nursing/carrying.   Treatment may 
also be required if the symptoms are sufficient to cause poor feeding/ongoing 
weight loss after 5 days. 
Pharmaceutical treatment: 
This will depend upon the mother‟s drug use during pregnancy. Mothers will fall 
into 3 groups:  
A. Opiate/opioid use only  
B. Opiate/opioid plus benzodiazepine  
C. Non-opiate/opioid drugs only 
Groups A and B (Opiate/Opioid users) 
Initial therapy - oral morphine solution 60micrograms/kg four hourly. 
Escalating treatment - if symptoms are not controlled within 24 hours  
 Increase oral morphine daily by 10micrograms/kg per dose to a maximum of 
80micrograms/kg/dose.  
 If symptoms are not controlled after 48 hours on the maximum dose of oral 
morphine add phenobarbital (dose as below).  
Group C. (Non- Opiate/Opioid users)   
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Initial therapy - Start oral phenobarbital – loading dose 15mg/kg, followed by 
maintenance dose 8mg/kg once daily. 
Weaning treatment: This should be commenced when the symptoms of NAS are 
adequately controlled.  This may be defined as a Lipsitz score of < 5 on at least 
one occasion in the past 24 hours.  Also the symptoms may be considered 
controlled if the infant is able to be consoled if nursed and they are sleeping for 
periods of at least two hours between feeds.  This latter approach is helpful if a 
baby is being weaned in the community without Lipsitz scoring.   
Babies on Oral Morphine only  
Each day, wean the oral morphine by 10micrograms/kg per dose. If symptoms 
worsen (Scores >5) during the weaning process, review the maternal drug history 
and consider addition of oral Phenobarbital rather than stopping or reversing the 
weaning of the morphine therapy.  The aim is to reduce and stop the morphine 
therapy within the 1st 10 days of life as a delay beyond this time will necessitate 
a potentially avoidable admission to the SCBU.  
 
Babies on Oral Morphine and Phenobarbital 
Each day, if scores remain < 5, wean the oral morphine by 10micrograms/kg per 
dose. Oral Morphine should be weaned completely before reducing the 
Phenobarbital therapy.  Once the morphine has been discontinued the 
Phenobarbital may be weaned in hospital or, if the there are no other reasons 
for the baby to remain in hospital, as an out-patient.  
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7.4 Appendix 4: Standard Operating Procedure for 
recording VEPs 
Check eligibility of infant: 
> 36 weeks gestation 
no congenital ocular abnormality 
no signs of neonatal encephalopathy 
infant clinically well 
signed informed consent obtained 
Infant care management: 
Check infant‟s feeding schedule: VEP should be commenced shortly after 
completion of a feed. VEPs will be recorded in the consulting room in the Special 
Care Baby Unit (SCBU) in Princess Royal Maternity.  Discuss planned recording 
session with SCBU staff and ensure that room is vacant.  Affix “do not disturb” 
notice to consulting room door. 
Invite parents to attend during the recording session. Avoid visiting period unless 
by discussion with mother (no visitors expected). Ensure that postnatal ward or 
SCBU midwifery staff (as applicable) are aware of the procedure. 
Transport infant to SCBU consulting room in a cot. Take a bottle of infant 
formula unless mother is breast feeding. Ensure nappy clean and infant 
reasonably content. Offer additional feed if required. 
Infants will be either placed supine in a cot or held by the parent or researcher 
during the recording. 
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Preparation of infant: 
Examine electrodes for evidence of silver chloride coating and absence of visible 
scratches. Test electrodes by connecting together with conducting paste and 
performing impedance test. 
Place scalp electrodes: The scalp electrodes will be placed relative to bony 
landmarks, in proportion to the size of the head, according to the international 
10/20 system 1, 2 (Figure 1): The recording electrode will be positioned at a 
distance of 10% of the total nasion-inion distance above the inion in the midline 
(Oz position). The reference electrode will be positioned at a distance of 30% of 
the total nasion-inion distance above the nasion in the midline (Fz position). The 
ground electrode will be positioned on the mastoid bone below the ear. 
Measure nasion-inion distance with a disposable measuring tape and note correct 
position for electrodes. Cleanse skin at electrode sites gently with a clean cotton 
bud and exfoliating paste.  Apply conducting paste to electrodes and fix to the 
scalp with medical adhesive tape. 
Scalp-electrode impedance will be measured prior to each recording and should 
be approximately equal with target levels of below 5 kOhms. If the impedance is 
greater than 10 kOhms, the electrodes will be repositioned and/or scalp gently 
recleaned. Overhead room lights should be switched off and the room 
illuminated by the wall-mounted angle poise lamp, turned towards the wall. The 
X-ray viewing box should be switched off. 
VEP recording: 
Switch on Espion® recording system and check that hand-held flash is plugged in 
and operating. Enter patient details including name, date of birth and hospital 
number.  
The hand-held integrating sphere will be presented to the infant‟s eyes in the 
midline held against the infant‟s forehead. VIDI protocol Version 1.0 will be run 
which will deliver standard flash, bright flash and pulse wave and sine wave 
flicker. The protocol will be run twice to ensure reproducibility.  
Chapter 7  214 
Documentation: 
Awake/sleep state and degree of eye opening will be documented for each step 
of recording. Record relevant maternal and infant data on the case report form 
/ database. 
Completion of procedure: 
Once recording has been completed the adhesive tape will be gently removed by 
the application of warm water and the electrodes removed from the scalp. 
Residual conducting paste will be removed with warm water. The recording 
session will be summarised with parents/carers. The infant will then be returned 
to the postnatal ward or SCBU. 
Electrodes will be cleaned after each recording by soaking in cold water and 
gently rubbing off residual conducting paste.  Electrodes will be sterilised after 
use by soaking in Milton® solution for 15 minutes. Electrodes will be soaked 
overnight in Milton® solution on a weekly basis to ensure re-chlorination. 
VEPs will be stored in a password locked computer and data regularly backed up 
after each recording. The Espion recording system will be kept in a locked room 
within the PRM. 
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Figure 1: 
 
 
 
 
References: 
1. Harding G, Odom J, Spileers W, Spekreijse H. Standard for visual evoked 
potentials 1995. Vision Research. 1996; 36(21): 3567-72. 
2. Odom J, Bach M, Barber C et al. Visual evoked potentials standard. 
Documenta Ophthalmologica. 2004; 108: 115-123. 
 
Chapter 7  216 
7.5 Appendix 5: Letter to parent 
Neonatal Unit, 
Level 4, 
Princess Royal Maternity, 
8-16 Alexandra Parade, 
Glasgow. 
Date: ……………………. 
Dear 
Thank you for agreeing to bring ……………………………..  for a vision and 
development check as discussed on the telephone. 
We look forward to seeing you on 
………………………………………………………………………………………………. 
Please come to the Neonatal Unit on Level 4 of the Princess Royal Maternity. 
We will arrange a taxi to pick you up and take you home again as discussed on 
the telephone. 
Kind regards 
 
Dr Laura McGlone 
Neonatal Specialist Registrar 
Tel: 0141 211 5388 
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7.6 Appendix 6: Standard Operating Procedure for visual 
assessment  
Parents will be invited to attend the Princess Royal Maternity for assessment. 
Assessments will be undertaken as close to six months (26 weeks) corrected 
gestational age as possible. Two professionals will be involved in assessment 
(research fellow and optician). 
Tests will be carried out in a well lit room with the infant sitting on the 
parent/carers knee and will be timed to co-ordinate with the infant‟s feeding 
regime.  
Eleven tests will be carried out in total subject to the child‟s co-operation. Each 
test has pass/fail criteria. 
Symmetrical corneal reflexes: * 
Lighted pen torch held 30cm from child‟s eyes. Attention gained on testers face. 
Corneal reflections should be symmetrical. Fail if constant asymmetry. 
Pupil response:  
Dim room. Cover each eye in turn and observe pupil constriction in response to a 
lighted pen torch. Allow 5 sec for response. Fail if no response. 
Lateral tracking: * 
Present a small toy in the centre of the field of vision 20-30 cm from the child‟s 
nose. Move toy at 10cm / second laterally to one side and note angle at which 
child stops tracking object. Repeat on other side. Can be repeated up to 3 
times. Pass = 1/1 or 2/3 positive responses tracking to >20 degrees. Note type of 
eye movements and presence of NYSTAGMUS. 
In addition, cover each eye in turn and observe for LATENT NYSTAGMUS. 
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Lateral field testing:  
Tester kneels 60 cm in front of child so at same height as child. Use small high 
contrast toy on a stick. Move object from peripheral field inward, along an arc, 
towards the midline at a rate of 5 cm/sec and distance of 25cm from child‟s 
face. Note the angle from midline at which child looks to object. Repeat 2-3 
times. Fail if complete absence of response either side. 
Convergence to approaching object:  
Present small toy 30cms from child‟s eyes. Bring toy towards nose at 2-5 cm/sec 
and watch for eyes converging. Fail if persistent lack of convergence. 
Visual following of falling toy:  
Attract attention to a large, colourful toy held by tester 60-90 cm away with 
outstretched arm. Observe whether child makes eye or head movement to 
ground as toy falls or immediately after toy has fallen. Can repeat up to 3 times. 
Pass is response on 1/1 or 2/3. 
Batting/reaching:  
A large colourful toy is held at arms length from child. Observe for attempts to 
bat / reach for toy. Fail is no attempt to obtain toy. 
Acuity cards: * 
Use Cardiff Acuity Test cards with pattern on one side and luminance matched 
grey field on other side. Present card 50cms from child‟s eyes. For each acuity 
level shuffle three cards then present card at child‟s eye level with the centre of 
the card at the tester‟s eye level. Observe infants‟ eye movements to estimate 
the position (top/bottom) of the pattern. If two correct estimates are made 
proceed to the next acuity level. The end point is taken as the highest level at 
which 2/3 cards are scored correctly and the equivalent Snellen acuity recorded.  
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Screening retinoscopy: * 
Non-dilated retinoscopy is performed to screen for media opacities and gross 
refractive errors. 
View retinoscopy reflexes in slightly dimmed room and note whether there are 
clear retinal reflexes in each eye (Fail = evidence of media opacity). 
With the infant fixating the retinoscope, compare the speed of the reflexes 
between the eyes and between perpendicular meridians in each eye. Expected 
result is quick „with‟ reflexes in all meridians showing a small lag of 
accommodation.  
Engage the infant‟s interest in a fixation target (toy on stick). Move the target in 
front of the retinoscope towards the child‟s face and observe the reflexes using 
a retinoscopy working distance in the range of 50-67 cm. (Accommodation should 
neutralise and then reverse the reflexes ‟against‟ movement.). Pass =Neutral 
achieved with the target 10-20 cm in front of the retinoscope and equal between 
the eyes (no significant anisometropia) and between perpendicular meridians in 
each eye (no significant astigmatism). 
Diffuse light reaction:  
Sit child in darkened room. Shine a light source on the wall within child‟s field of 
vision. Observe for head turn / eye movements towards light (5-10 sec for 
response). Repeat with light source on other side. 
Defensive blink:  
Tester sits facing child. Attract attention with wriggling fingers which are 
withdrawn until level with testers shoulder. Then move hand with fingers 
extended and palm forward rapidly (10cm/sec) towards child to 10cm from nose. 
Observe for rapid eyelid blink response. Can repeat up to 3 times. Pass is 
response on 1/1 or 2/3. 
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Tests highlighted with a * are to screen for the most commonly identified 
abnormalities detected in this population and should be prioritised if the infant 
has a limited attention span. 
A fail in any test will result in prompt referral for formal ophthalmology 
assessment. 
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7.7 Appendix 7: Standard Operating Procedure for 
neurodevelopmental assessment. 
Parents will be invited to attend the Princess Royal Maternity for assessment. 
Assessments will be undertaken as close to six months (26 weeks) corrected 
gestational age as possible. Two professionals will be involved in assessment 
(research fellow and optician). 
Assessment will include: 
Measurement of O.F.C.: Measured 3 times with a disposable tape measure, 
largest diameter recorded and plotted on appropriate growth chart. 
Assess muscle tone and posture: Tone normal, hypotonic or hypertonic. Posture 
normal or abnormal. 
Developmental assessment will be carried out using the Griffiths Mental 
Development Scales (Birth to 2 years) using the appropriate manual and 
recording sheets.  
Locomotor development: 
Examination prone (lifts chin, head, shoulders) 
Examination supine (lifts head, shoulders, anticipates pull to sit) 
Rolling (side to back, side to side, back to stomach) 
Sitting with support (back firm, slight support, alone) 
Crawling reaction (draws up knees, pivoting, tries to crawl, progress forwards or 
backwards) 
Stepping reaction (dancing, one foot in front of other) 
Playing with toes 
Personal-social: 
Smiles 
Chapter 7  222 
Vocalises when talked to 
Expresses emotions (2+) 
Turns to person talking 
Looks at mirror image 
Spoon (holds, manipulates in play) 
Awareness of strangers 
Hearing/language: 
Startles / listens to bell 
Searches for sounds with head movements 
Turns head deliberately to bell 
Listens to tuning fork 
Listens to conversations 
Number of different sounds 
Babble (two syllables) 
Eye/hand: 
Follows moving bell-ring (horizontally, vertically, in a circle) 
Reaction to Ring (grasps, reaches for, grasps when dangling, secures when 
dangling, secures by string, dangles by string) 
Looks for fallen object 
Strikes objects together 
Forefinger and thumb partially specialized 
Performance: 
Hand (to mouth, plays with fingers) 
Reaction to Rod (holds, resists withdrawal) 
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Reaction to Cube (grasps, takes from table, holds two, manipulates, passes hand 
to hand, drops one cube for third) 
Tissue paper (pulls, reaches for, plays with) 
Lifts cup inverted over toy 
 
A sub-quotient score will be calculated for each of the developmental sub-
scales. A total general quotient score (G.Q.) will also be calculated using the 
Griffiths manual. Infants with abnormalities or developmental delay will be 
referred via the paediatric consultant to the appropriate hospital clinic 
(neonatal OPC, developmental clinic or neurology OPC). After completion of the 
Griffiths assessment all test material will be cleaned by wiping with sterilising 
alcohol wipes. 
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7.8 Appendix 8: Letter to ophthalmology 
Neonatal Unit, 
Princess Royal Maternity, 
8-16 Alexandra Parade,  
Glasgow. 
Date: …………… 
Dear Jane, 
The following baby was exposed to methadone in utero and was recruited to the 
VIDI study. 
Name: 
D.O.B.: 
Address: 
Tel. no: 
Findings at the 6 month vision screening assessment were:  
 
I would be grateful if you could arrange out-patient clinic follow-up for them. 
Kind regards 
 
Dr Laura McGlone 
Neonatal Specialist Registrar 
Chapter 7  225 
7.9 Appendix 9: Press release and media clip 
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7.10 Appendix 10: Further reflections on methodology 
and future research 
This was a cohort study as the exposure status was known definitively at the 
time of study recruitment. In the neonatal part of the study, infants who had 
already been exposed in utero to methadone were recruited and investigated for 
abnormalities of the VEP in the newborn period. These infants‟ demonstrated 
VEP abnormalities which were present at the time of study recruitment and a 
matched non-exposed group were recruited for comparison purposes. 
In the follow-up study, the same cohort of methadone exposed and non-exposed 
infants were followed up prospectively to assess for clinical visual and 
developmental abnormalities. Therefore at the time of study recruitment the 
infants had a defined exposure status but were free of disease. 
Validity of neonatal results: 
The validity of the neonatal results can be considered under the headings of 
chance, bias and confounding. Chance was minimised by the large sample size 
recruited and the high significance level of the p-values obtained (p<0.001 for 
VEP amplitude and morphology).   
Bias was minimised by the high recruitment rate of study participants, 
recruitment within a single hospital and matching of drug-exposed and 
comparison infants. In addition bias was further minimised as infants had an 
exposure status defined prior to study recruitment. 
Confounding was minimised by the matching of drug-exposed and comparison 
infants. In addition, we explored for potential confounders and undertook 
regression analysis to correct for the effect of confounders on study outcomes. 
Validity of follow-up results: 
Bias was minimised in the follow-up study as exposure status was defined both 
prior to study recruitment and to occurrence of the disease, suggesting a 
temporal sequence between exposure and the disease. There was minimal error 
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in classification of exposure status (misclassification) as a result of the extensive 
toxicology undertaken in addition to history. The bias of non participation was 
minimised by the high recruitment rate of both drug-exposed and comparison 
infants. The bias of loss to follow-up is often a factor in prospective cohort 
studies and was minimised by the high retention rate of drug-exposed infants. 
Although there was a higher loss of comparison infants, there were no significant 
differences in demographic characteristics between comparison infants followed 
up and those not followed up, suggesting the groups were similar. In addition, 
published data suggest the incidence of visual abnormalities described in our 
comparison population to be representative of the larger population. 
Confounding was minimised by matching of drug exposed and comparison infants 
and by restriction of study participants (to exclude the confounding effects of 
prematurity, congenital anomalies and illness). In addition, regression analysis 
allowed correction of other identified potential confounders. 
Judgement of cause-effect relationship: 
The above discussion highlights that it is unlikely that chance, bias and 
confounding are responsible for the statistical associations demonstrated in this 
study. We propose a cause-effect relationship between in utero methadone 
exposure and infant visual abnormalities. This is supported by the strength of 
association between methadone exposure and both abnormal VEPs and visual 
impairment: the relative risk of over five for both of these outcomes and 
attributable risk percent of over 80% makes it unlikely that another unidentified 
factor could account for the findings. The cause-effect relationship is also 
biologically credible: several animal studies have demonstrated a detrimental 
effect of prenatal methadone exposure on cerebral neurotransmitters and nerve 
growth factor which could have an adverse effect on early visual processing – it 
is entirely likely this effect also applies to human newborns. These findings are 
also consistent with other published studies in the literature, using alternative 
methodology in different geographic settings and populations‟, contributing to 
the growing body of evidence that prenatal methadone exposure is harmful to 
the developing fetus. In addition, the time sequence of the association supports 
a cause-effect relationship: in utero exposure definitively predated the onset of 
symptoms. Finally, there is evidence of a dose-response relationship as more 
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infants exposed to high dose methadone failed the clinical visual assessment 
than infants exposed to low dose; although this did not quite reach statistical 
significance. Assuming this causal effect of methadone exposure, over 80% of 
VEP abnormalities and clinical visual abnormalities could be attributed to 
methadone and therefore be eliminated if infants were not prenatally exposed. 
Outline of future trial: 
As our study has suggested a causal relationship between in utero methadone 
exposure and infant visual impairment, future studies should investigate 
alternatives to substitute methadone during pregnancy. Although 80% of the 
difference in outcome seems to be related to methadone exposure, it is possible 
some other unidentified confounders related to the lifestyle of drug misusing 
mothers could be partly responsible. This could be addressed by conducting a 
randomised, controlled trial programme to compare substitute buprenorphine 
treatment during pregnancy with substitute methadone. The primary outcome of 
this trial programme should be the incidence of clinical visual impairment and it 
should be powered to detect a reduction in the incidence of clinical visual 
abnormalities at six months of age in the buprenorphine-exposed group. A 
secondary outcome should be VEP abnormalities at six months of age. This trial 
programme would involve recruitment and randomisation in early pregnancy of 
opiate dependant women. Although the main outcome would be infant visual 
impairment, comparisons would also be made of pregnancy outcomes, neonatal 
outcomes (including birth weight, OFC, gestational age and development of NAS) 
and longer term developmental outcomes. Assessors should be blinded to the in 
utero drug exposure group. Such a study should ideally involve follow-up until 
school age to assess the natural history of visual and developmental 
abnormalities and assessment of CVI. A study of this nature would involve 
collaboration between obstetricians, neonatologists, ophthalmologists and 
developmental paediatricians. It would involve detailed data collection during 
pregnancy relating to smoking, alcohol use and additional illicit drug use and 
utilise urine and meconium toxicology collection to facilitate this. 
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